**PŘÍRODOVĚDECKÁ FAKULTA UNIVERSITY KARLOVY**

DOKTORSKÁ DISERTAČNÍ PRÁCE

NOVÉ KOMPONENTY SIGNÁLNÍ DRÁHY WNT

Tomáš Valenta

ŠKOLITEL: RNDr. Vladimír Kořínek CSc.

Laboratoř buněčné a vývojové biologie
ÚMG AV ČR

Praha, 2007

OBSAH

SEZNAM ZKRATEK

AC	Anchor Cell
APC	Adenomatous Polyposis Coli
AR	Androgen Receptor
Bcl-2, -9	B-cell lymphoma 2, -9
Brg-1	Brahma related gene 1
BTB/POZ	Broad-complex, Tramtrack, Bric à brac/Poxvirus, and Zinc finger
β-TrCP	β−Transducing repeat Containing Protein
CBP	CREB Binding Protein
Cdc 73	Cell division cycle 73
CK1α, γ	Casein Kinase 1α, γ
CK2	Casein Kinase 2
CRD	Cystein Rich Domain
CtBP	C-terminal Binding Protein
DISC	Death-Inducing Signaling Complex
DIX	Dishevelled-Axin
Dlp	Dally like protein
DR4, 5	Death Receptor 4, 5
Dsh	Dishevelled
DTC	Distal Tip Cell
Dvl	Dishevelled
ERK1	Extracellular signal Regulated Kinase
evi	evenness interupted
FAP	Familiar Adenomatous Polyposis
Fz	Frizzled
GBP/Frat	GSK-Binding Protein/Frequently rearranged in advanced T-cell lymphomas
Grg	Groucho related gene
GSK3β	Glycogen Synthase Kinase 3β
HDAC	Histon Deacetylase
Hh	Hedgehog
HIC1	Hypermethylated In Cancer 1
HMG	High Mobility Group
HMT	Histon Methyl Transferase
HSPG	Heparan Sulphate Proteoglycans
ICAT	Inhibitor of β-catenin and Tcf
int-1	integrated-1
LEF-1	Lymphoid Enhancer Factor 1
LRH-1	Liver Receptor Homolog 1
LRP	Low Density Lipoprotein Related Prorein
LSD1	Lysin Specific Demethylase 1
MEK1	Mitogen-activated protein kinase kinase 1
MLL	Mixed Lineage Leukemia

MMTV	Mouse Mammary Tumor Virus
NAD	Nicotin Amide Dinucleotid
NHR-25	Nuclear Hormone Receptor 25
NLK	NEMO-Like Kinase
NLS	Nucler Localising Signal
nNOS	neuronal Nitric Oxidide Synthetase
PAF-1	Polymerase Associated factor 1
PAK-1	p21 Activated Kinase 1
PIASz	Protein Inhibitor of Activated STAT y
PDZ	PDS-95, Dlg-A, ZO-1
PP2A	Protein Phosphatase 2A
Ryk	Related to Y (tyrosin) kinase
SET	Su(var)3-9, Enhancer of zeste, Trithorax
SF-1	Steroidogenic Factor 1
sFRP	soluble Frizzled Related Protein
SGP	Somatic Gonad Precursor
SIRT1	Sirtuin 1
SUMO	Small Ubiquitin Modifier
SWI/SNF	Switch/Sucrose Non Fermenting
SYS	Symetrical Sisters
TBP	TATA-box Binding Protein
TCF-1, -3, -4	T-Cell Factor 1, -3, -4
TLE	Transducin-Like Enhancer
TRAIL	Tumor necrosis factor- Related Apoptosis-Inducing Ligand
TNF	Tumor Necrosis Factor
vps-35	vacuolar protein sorting 35
wg	wingless
WIF	Wnt Inhibitory Factor
wls	wntless

1 ÚVOD

Buněčné signalizační kaskády představují klíčový molekulární mechanismus, který koordinuje veškeré životní procesy v buňkách, a tím i v celém organismu. Aktivita signálních kaskád je nezbytná pro regulaci buněčného růstu, diferenciaci buněk či jejich řízené odumíraní, a to jak v průběhu embryogeneze, tak v dospělém organismu. Signální dráhy zprostředkovávají odpověď buněk na okolní podněty, jsou nezbytné pro mezibuněčnou komunikaci a bez synchronizované aktivity složité signalizační mašinérie si nelze představit masivní buněčnou expanzi spojenou s tvorbou tkání během vývoje každého jedince. Jednou z těchto signalizačních kaskád je vysoce evolučně konzervovaná signalizační dráha Wnt. Předkládaná práce ve stručnosti uvádí do problematiky molekulárních mechanismů signalizace Wnt. Experimentální část byla zaměřena zejména na signalizaci Wnt v buněčném jádře a vztah mezi signalizací Wnt a jinými buněčnými regulačními drahami.

Základem této práce je soubor čtyř publikací, jejichž hlavním spojujícím motivem je studium komponent a mechanismů, které ovlivňující signalizaci Wnt.

1. **Valenta, T.**, Lukas, J. and Korinek, V. (2003) HMG box transcription factor TCF-4's interaction with CtBP1 controls the expression of the Wnt target Axin2/Conductin in human embryonic kidney cells. *Nucleic Acids Res*, **31**, 2369-2380.

2. **Valenta, T.**, Lukas, J., Doubravska, L., Fafilek, B. and Korinek, V. (2006) HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nuclear bodies. *Embo J*, **25**, 2326-2337.

3. Asahina, M., **Valenta, T.**, Silhankova, M., Korinek, V. and Jindra, M. (2006) Crosstalk between a nuclear receptor and beta-catenin signaling decides cell fates in the C. elegans somatic gonad. *Dev Cell*, **11**, 203-211.

4. Doubravska, L., Simova S., Cermak, L., **Valenta T.**, Korinek V., Andera L. (2006) Wnt signaling suppresses TRAIL-induced apoptosis of human pre-B cells (impact of beta catenin stabilization and MEK1/ERK activation). *Apoptosis*. submitted

Cílem uvedených prací bylo rozšíření našich poznatků o regulačních mechanismech signalizace Wnt, a to zejména na úrovni buněčného jádra. Hlavní důraz byl kladen na interakční partnery, kteří mají potenciál inhibovat signalizaci Wnt. Opomenuto nezůstalo ani studium vzájemné interference mezi signalizací Wnt a jinými signálními kaskádami.

2   LITERÁRNÍ PŘEHLED

Signální dráha iniciovaná sekretovanými ligandy Wnt patří mezi významné regulátory buněčné proliferace a diferenciace, a to jak v průběhu embryogeneze, tak v dospělém živočišném organizmu. Nepostradatelnost signalizace Wnt při regulaci buněčných procesů dokládá vysoká evoluční konzervovanost základních mechanismů této signalizace i jednotlivých proteinů, které se signalizace účastní[1, 2].

Příslušnost k rodině proteinů Wnt je určená spíše jejich strukturními, než funkčními vlastnostmi. Není proto překvapivé, že zahájení signalizace vazbou ligandu Wnt na receptor (respektive receptorový komplex) může iniciovat několik, do jisté míry nezávislých procesů. Jedním z nich je signální dráha Wnt/β-katenin, označovaná též jako kanonická signalizace Wnt. V případě kanonické signalizace dochází po interakci ligandu Wnt s receptorovým komplexem ke stabilizaci klíčového proteinu, β-kateninu, jeho kumulaci v cytoplazmě a následné translokaci do buněčného jádra. V jádře se β-katenin váže na transkripční faktory Lef/Tcf a zahajuje tak transkripci specifických genů [3].

Alternativu ke kanonické signalizaci Wnt představuje několik signálních drah, které jsou souhrnně známé jako nekanonická signalizace Wnt. Jedná se nejméně o tři rozdílné mechanismy, u kterých se na přenosu signálu významnou měrou podílejí proteiny známé z jiných signalizačních drah. Přestože se nekanonické signalizační dráhy významně účastní regulace řady vývojových procesů během embryogeneze (neurulace), nejsou zdaleka tak charakterizovány jako kanonická dráha [4, 5]. Protože další část předkládané práce je zaměřena především na studium procesů v rámci signalizace Wnt/β-katenin, lze případné zájemce o detaily týkajících se ostatních typů signalizace Wnt odkázat na příslušnou literaturu [6, 7]. Průběžně aktualizované informace zaměřené na signalizaci Wnt lze rovněž nalézt na internetové stránce ''The Wnt homepage''

(http://www.stanford.edu/~rnusse/wntwindow.html).

2.1 Mechanismy kanonické signalizace Wnt (Wnt/β-katenin)

Kanonickou signalizaci Wnt (či jinak též signalizaci Wnt/β-katenin) lze právem označit za jeden z rozhodujících signalizačních mechanismů ovlivňujících osud buňky (anglicky cell fate decision) u mnohobuněčných živočichů. Komponenty této signalizace se uplatňují při regulaci mnoha procesů u tak evolučně vzdálených organizmů jako jsou žahavci (*Cnidaria*), hlístice *Caenorhabditis elegans*, octomilka (*Drosophila melanogaster*) a obratlovci včetně savců [8, 9]. Signalizace Wnt/β-katenin hraje nezastupitelnou roli během řady dějů v průběhu embryonálního vývoje. U octomilky je kanonická signalizace nezbytná mimo jiné pro ustavení polarity tělních segmentů nebo pro synaptogenezi během larválního vývoje [1, 10]. V případě obratlovců je zodpovědná například za určení tělní polarity v průběhu gastrulace, či kontrolu tělní segmentace [11, 12]. V dospělém organismu je aktivita kanonické dráhy nezbytná pro udržení samoobnovujícího potenciálu kmenových buněk v řadě tkání [13-15]. Svou roli uplatňuje rovněž při některých regeneračních procesech. Nefyziologická aktivace signalizace Wnt je často spojena s nekontrolovaným růstem buněk, nádorovou transformací a vznikem nádorů [13, 14, 16, 17]

Jak již bylo výše zmíněno, klíčovou událostí v rámci přenosu signálu je v případě kanonické Wnt-signalizace stabilizace proteinu β-katenin v cytoplazmě cílové buňky. V situaci, kdy buňky nejsou stimulovány prostřednictvím ligandu Wnt, je většina β-kateninu lokalizována jako součást mezibuněčných spojů a β-katenin tak prakticky neuplatňuje svoji signalizační funkci, neboť hladina volného β-kateninu v cytoplazmě je posttranslačně udržována na nízké úrovni [18, 19]. Na udržení nízké hladiny cytoplazmatického β-kateninu se podílí multiproteinový degradační komplex, jehož součástí je strukturní protein Axin, nádorový supresor APC, proteinkinázy CK1α, GSK3β [20-24]. V nestimulovaných buňkách je β-katenin prostřednictvím těchto proteinkináz fosforylován. Fosforylovaný β-katenin je následně modifikován ubikvitinem, a poté degradován v proteazomu[25-27].

Vazba ligandu Wnt na receptorový komplex složený z receptoru Frizzled a koreceptoru LRP vede k interakci proteinu Dishevelled s intracelulární částí receptoru Frizled [28-31]. Dishevelled se tímto krokem aktivuje a zahajuje dosud ne zcela přesně popsaný proces vedoucí zablokování aktivity degradačního komplexu. Výsledkem zmíněného procesu je pokles fosforylace β-kateninu a následné zastavení jeho degradace [32, 33]. Současně

dochází k vazbě Axinu na koreceptor LRP, což přispívá k rozpadu degradačního komplexu[34]. Výsledkem obou jmenovaných procesů je stabilizace cytoplazmatického β-kateninu, růst jeho koncentrace a jeho následná translokace do jádra. V buněčném jádře se β-katenin váže s transkripčními faktory z rodiny Lef/Tcf. Tyto transkripční faktory nemají samy o sobě schopnost zahájit transkripci a fungují tak jako transkripční represory. Avšak právě tvorba heterokomplexů s β-kateninem jim umožňuje iniciovat transkripci řady Wnt-specifických genů[35-37]. Mezi cílové geny signalizace Wnt patří mimo jiné geny pro významné regulační proteiny ovlivňující buněčný cyklus a buněčnou proliferaci [38-41].

Je ovšem potřeba zdůraznit, že kanonická signalizace Wnt je mnohem více komplexním procesem než představuje výše uvedené schéma základní kaskády dějů, ke kterým v buňce dochází po stimulaci ligandem Wnt. Ve skutečnosti je dráha Wnt také velmi regulovaným procesem, a to na všech úrovních – extracelulární, cytoplazmatické i jaderné. V rámci kanonické kaskády se významně uplatňuje řada proteinů, které tuto signalizaci usměrňují či přímo blokují.

Obrázek 1. **Zjednodušené schéma kanonické signalizace Wnt**
(A) V případě, že ligand Wnt není přítomen, dochází ke konstitutivní degradaci β-kateninu, klíčového modulátoru signální dráhy Wnt, degradačním komplexem složeným z proteinů Axin, APC a kináz GSK3β a CK1α. β-katenin je tímto komplexem fosforylován a následně degradován v proteasomu.
(B) Vazba ligandu Wnt na membránový receptorový komplex Fz/LRP způsobí aktivaci vnitrobuněčného proteinu Dvl a inaktivaci degradačního komplexu vyvázáním molekuly Axinu na intracelulární část receptoru LRP. Dochází k akumulaci β-kateninu, který vstupuje do jádra a spolu s proteiny Lef/Tcf zahajuje transkripci cílových genů.
(upraveno podle reference [13])

2.1.1 Extracelulární a membránové komponenty kanonické signalizace Wnt

2.1.1.1 Ligandy Wnt

Název jak pro tyto proteiny, tak pro celou signální dráhu, v níž proteiny Wnt stojí na počátku jako ligandy zahajující signalizaci, vznikl již počátkem devadesátých let jako složenina z názvů pro dva původně nezávisle popsané geny, a to *wingless* a *int-1*. Gen *wigless (wg)* byl identifikován jako jeden z důležitých faktorů ovlivňujících polaritu tělních článků (segment polarity gene) u octomilky. Zatímco v případě normálních jedinců se u larvy octomilky střídají v epidermis ventrální kutikuly nahé a dentikulární segmenty, tak v případě mutantů *wingless* jsou všechny segmenty dentikulární. Některé z alelických forem tohoto genu se mohou projevit u mutantních jedinců bezkřídlým fenotypem [42, 43]. Druhý z genů byl popsán při studiu nádorů v epitelu mléčné žlázy u myši. V řadě těchto nádorů vyvolaných retrovirem MMTV (Mouse Mammary Tumor Virus) je často jako důsledek integrace proviru nefyziologicky aktivována transkripce přilehlého lokusu, který kóduje sekretovaný protein nazvaný Int-1 (název podle preferovaného místa integrace) [44-46]. Pozdější práce potvrdily homologii obou genů, čímž byl rovněž popsán první gen rodiny Wnt, a to v tomto případě gen *wnt*1 [47].

V současné době je známo u obratlovců okolo dvaceti genů kódujících proteiny Wnt (člověk a myš jich mají 19, *Xenopus sp.* 16, *Gallus sp.* 11, *Danio sp.* 12), které můžeme rozdělit podle aminokyselinové sekvence do dvanácti nezávislých podskupin, z nichž má pouze šest své orthologní partnery u modelových bezobratlých (*Drosophila melanogaster* a *Caenorhabditis elegans*). Překvapivá je však skutečnost, že u primitivních mnohobuněčných živočichů můžeme nalézt spektrum genů *wnt* velmi podobné obratlovcům. Jako příklad lze uvézt zástupce žahavců - mořskou sasanku rodu *Nematostella,* která ve svém genomu obsahuje dvanáct genů *wnt*, které nalézají své orthologní partnery u jedenácti z celkových dvanácti podskupin *wnt*-genů obratlovců. Recentní práce naznačují přítomnost genů w*nt* již v genomu živočišných hub (*Porifera*) [48]. Je tedy pravděpodobné, že relativně vysoká komplexita genů *wnt* je evolučně velmi stará. Zatímco u vývojové linie vedoucí k obratlovcům zůstala tato genetická komplexita zachována, v případě prvoústých živočichů došlo k její významné redukci. U rostlin a jednobuněčných organismů nebyla dosud exprese *wnt*-genů spolehlivě prokázána. Na základě fylogenetické analýzy můžeme tedy proteiny Wnt považovat za signální molekuly

specifické pro *Metazoa*, které se podílejí na kontrole organizace tělního plánu již více než 650 milionů let [8, 49, 50]

2.1.1.2   Biogeneze ligandů Wnt

Proteiny Wnt jdou hydrofobní, na cystein bohaté sekretované molekuly, které mohou působit na cílové buňky v blízkosti i ve větší vzdálenosti od místa sekrece (tzv. short-range nebo long-range signaling) [49, 51-53]. Přes svoji omezenou solubilitu působí podobně jako koncetranční morfogeny a významně tak ovlivňují vznikající tkáňovou polaritu v průběhu embryogeneze. Pro aktivitu ligandů Wnt je velmi důležitý způsob jejich biogeneze, v rámci níž hrají velkou roli proteinové modifikace. Proteiny Wnt jsou, tak jako ostatní sekretované molekuly, syntetizovány s N-koncovým signálním peptidem, který určuje lokalizaci nascentního Wnt-polypeptidu do endoplazmatického retikula, kde je poté signální peptid odštěpen působením peptidázy. V endoplazmatickém retikulu jsou proteiny Wnt modifikovány acylací. V tomto procesu hraje klíčovou roli protein porcupine. Porcupine je v membráně endoplazmatického retikula vázaná acyltransferáza, která je zodpovědná za kovalentní připojení palmitátu na konzervovaný cystein (případně více cysteinů) v N-koncové části Wnt-proteinu. Některé mutace v sekvenci proteinu porcupine způsobují poruchy v sekreci proteinů Wnt, což vede k jejich hromadění v cytoplazmě buněk. Modifikace palmitátem nejen zvyšuje hydrofobicitu proteinů Wnt, ale je rovněž nezbytná pro jejich další biogenezi, sekreci a správnou signalizační aktivitu. [54-56]. Další významnou modifikací proteinů Wnt, která následuje po acylaci, je N-glykosilace na asparaginech. Sekreční dráha Wnt-proteinů dále pokračuje v Golgiho komplexu, kde se uplatňuje role nedávno popsaného proteinu wntless (wls) nezávisle též popsaného jako Evi (Evenness interrupted). Wls/evi je membránový protein lokalizovaný do membrán Golgiho komplexu, který interaguje s proteiny Wnt. Je-li exprese Wls/evi experimentálně snížena prostřednictvím interferujících molekul RNA nebo pokud je jeho aktivita ovlivněna mutací, dochází k poruše v sekreci proteinů Wnt a k jejich akumulaci v buňkách, které tyto ligandy produkují. Ačkoliv přesná úloha proteinu wls/evi není dosud známá, je pravděpodobné, že tento protein specificky usměrňuje sekreci vznikajicích ligandů. Wls/evi by rovněž mohl ovlivňovat tvorbu exportních váčků (exocytic vesicles), prostřednictvím kterých jsou proteiny Wnt transportovány ven z buňky   [57, 58].

Pozoruhodná je skutečnost, že pravděpodobně již na úrovni těchto váčků dochází k rozdělení proteinů Wnt na ty, které budou působit v blízkosti místa sekrece (short range signaling) a na ligandy, jejichž aktivita se uplatní ve větší vzdálenosti od místa sekrece (long range signaling). Pro morfogenní aktivitu na větší vzdálenosti je nezastupitelná role tzv. retromerového komplexu, což je konzervovaný multiproteinový komplex, který se uplatňuje při vnitrobuněčném proteinového transportu včetně transcytózy a transportu proteinů mezi endozómy a Golgiho komplexem. Mutace ovlivňující aktivitu retromerového komplexu, nebo nefyziologicky způsobená inaktivace komponent tohoto komplexu (například proteinu vps-35) ruší schopnost ligandů Wnt působit na větší vzdálenosti, a to jak v případě *C.elegans*, tak u obratlovců. Aktivita retromerového komplexu je nutná pouze u buněk produkujících ligandy Wnt, v nichž je retromerový komplex důležitý pro sekreci aktivních proteinů Wnt [59, 60].

Nedávno byl u octomilky popsán pod názvem Sprinter další transmembránový protein důležitý pro maturaci proteinů Wnt. Tento evolučně konzervovaný protein je lokalizován v plazmatické membráně, jeho inaktivace vede k zablokování sekrece ligandů Wg (ortholog Wnt1 u octomilky) a k hromadění Wg v produkujících buňkách. Tento fenotyp je tak velmi podobný situaci u Wls/evi [61].

Důsledkem proteinových modifikací v průběhu sekrece je skutečnost, že proteiny Wnt jsou sekretovány jako vysoce hydrofobní molekuly, což výrazně omezuje jejich solubilitu a schopnost volně difundovat k cílovým buňkám. Tyto proteiny se tak prakticky nevyskytují mimo buňku jako volné molekuly. Modifikace palmitátem navíc zvyšuje jejich schopnost vázat se do membránových struktur [56]. Jednou z membránových struktur důležitých pro transport ligandů Wnt mezi buňkami jsou lipoproteinové útvary označované jako argosómy. Původní představy, že argosomy jsou jakési exocytarní váčky, které se tvoří z buněčné membrány v průběhu sekrece proteinů Wnt, byly recentně výrazně modifikovány. Argosomy (u octomilky známé též pod názvem lipoforiny) vznikají pravděpodobně až mimo buňku jako jednovrstevné fosfolipidové membránové váčky obsahující cholesterol a trigliceridy. Významnými komponenty argosómů jsou také apolipoproteiny, které zde fungují jako důležité strukturní proteiny. Ligandy Wnt jsou v argosomech lokalizovány právě prostřednictvím palmitátového zbytku. Nefyziologická inaktivace některých komponent argosómů silně omezuje transport ligandů Wnt k cílovým buňkám. Zablokování tvorby argosomů rovněž výrazně mění podobu gradientu proteinů Wnt (pravděpodobně nejen) u octomilky, čímž se rovněž mění charakter exprese (expression pattern) některých cílových genů [62-64].

Při transportu a tvorbě gradientu proteinů Wnt se také uplatňují některé složky extracelulární matrix. Heparan-sulfátové proteoglykany (HSPG) byly popsány jako jedna z komponent extracelulární matrix, která je schopna vázat proteiny Wnt. HSPG jsou rovněž schopny na sebe navázat lipoproteinové partikule, tedy pravděpodobně i argosómy. Dosud není přesně známo, zda jsou proteiny Wnt asociovány s HSPG přímo, či právě prostřednictvím argosómů. Genetické studie u octomilky prokázaly nezastupitelnost HSPG pro správnou tvorbu morfogenního gradientu proteinů Wnt. Absence proteoglykanů Dally nebo Dlp, či mutace v enzymech nezbytných pro biogenezi HSPG, vedou u octomilky k fenotypu, který připomíná mutanty octomilek bez funkčního proteinu Wg (ortholog lidkého proteinu Wnt1). Recentní práce naznačují možnost, že se Dally a Dlp podílejí také na transportu ligandů Wnt. HPGS tedy mohou tvořit jakousi síť nutnou nejen pro distribuci proteinů Wnt, ale i pro formování jejich funkčního gradientu [65-68]. Aktivita proteoglykanů Dally a Dlp jako spolutvůrců gradientu Wnt může být dále modulována. Sekretovaný enzym Notum je schopen modifikovat podobu sacharidových řetězců u Dally a Dlp, čímž významně formuje charakter gradientu Wnt. Za normálních okolností koreluje u octomilky exprese *notum* s expresí *wnt*. Zvýšená hladina proteinu Notum vede k u octomilky k potlačení   fyziologické aktivity proteinů Wnt, snížená exprese nebo některé mutace působí opačně   [69, 70]. Přes menší množství dat lze konstatovat, že rovněž u obratlovců mohou HSPG výrazně modulovat signální dráhu Wnt [71-73].

Pozoruhodná je skutečnost, že se základní principy biogeneze, transportu a tvorby morfogenního gradientu proteinů Wnt uplatňují nejen v případě této signální dráhy. Sekreční mechanismus proteinů Wnt je velmi podobný biogenezi jiných významných signálních molekul – Hedgehog. Rovněž pro správnou funkci ligandů Hh je nutná modifikace palmitátem, při jejich transportu se uplatňují argosomy jejich gradient může být modifikován prostřednictvím HSPG. [63, 74, 75]

2.1.1.3 Receptorový komplex

Ligand Wnt se na cílových buňkách váže se specifickými receptory, respektive s receptorovým komplexem, a spouští tak samotnou signalizaci. Právě složení receptorového komplexu rozhoduje o tom, zda bude po vazbě ligandu zahájena kanonická

nebo nekanonická forma signalizace Wnt. Jeden typ ligandu Wnt může iniciovat jak signalizaci závisející na β-kateninu, tak signalizaci na β-kateninu nezávislou, jak dokazují experimenty s využitím purifikovaného proteinu Wnt5a, který byl dříve považován za klasický případ iniciátora nekanonické signalizace [6, 76, 77]. Skutečnost, že v průběhu vývojových procesů stojí některé ligandy Wnt spíše na začátku kanonické, respektive nekanonické, signalizace bude tedy pravděpodobně určena rozdílným zastoupením komponent receptorových komplexů, či různou četností konkrétních forem těchto komplexů v cílových buňkách. Určitou roli může rovněž mít rozdílná afinita konkrétních typů ligandů Wnt ke konkrétním receptorům. Pro přesnější popis interakcí mezi ligandy Wnt a jejich receptory je potřeba získat více detailnějších experimentálních dat.

Genetická a biochemická data podporují hypotézu, že primárním receptorem pro ligandy Wnt je recetor Frizzled (Fz), přičemž se tento receptor uplatňuje v kanonické signalizaci Wnt i v jejích nekanonických formách. Receptory Frizzled patří do skupiny receptorů asociovaných s G-proteiny (G-Protein Coupled Receptors) a s ostatními zástupci tohoto typu receptorů sdílí několik charakteristických strukturních znaků. V případě receptorů Frizzled můžeme rozeznat tři základní strukturně-funkční oblasti. Glykosilovaná N-koncová část receptoru je extracelulární a obsahuje ve své aminokyselinové sekvenci charakteristickou doménu bohatou na cystein (CRD). Ta je schopna s vysokou afinitou vázat ligandy Wnt. Střední část receptoru Frizzled obsahuje ve své proteinové sekvenci sedm hydrofobních α–helixů, které sedmkrát procházejí cytoplazmatickou membránou a jsou tak rozhodující pro membránovou lokalizaci receptoru. C-konec receptoru je orientován cytoplazmaticky, je mimo jiné asociován s heterotrimerními G-proteiny a zprostředkuje přenos signálu k dalším komponentám signalizace Wnt [28, 78, 79]. Genetická komplexita genů *wnt* má svůj protějšek v počtu genů pro receptory Frizzled. Savčí genom obsahuje přibližně deset genů *frizzled*, genom octomilky čtyři geny. Přestože postrádáme detailnější biochemická data, zdá se, že jednotlivé receptory Frizzled se chovají poněkud "promiskuitně", tedy že jeden konkrétní receptor Fz může vázat více různých typů ligandů Wnt a naopak. [28, 30, 79, 80]. Například u octomilky, kde je ovšem redundance jak v případě ligandů Wnt, tak receptorů Fz nižší, interagují s jedním typem ligandu Wnt (konkrétně s Wg) dva ze čtyř možných Fz receptorů (Fz1 a Fz2). Aby došlo k zablokování signalizace iniciované Wg musí být oba receptory mutovány nebo inaktivovány, přičemž výsledný fenotyp je totožný s fenotypem *wg* mutantů [80].

Receptor Frizzled ovšem není schopen aktivovat kanonickou signalizaci sám. Pro její zahájení je nutná kooperace s koreceptorem LRP (Low density liporotein Related Protein).

V případě obratlovců známe dva členy proteinů LRP, a to LRP5 a LRP6. U octomilky existuje jeden zástupce Arrow [81]. Koreceptory LRP jsou transmembránové proteiny s jednou transmembránovou doménou, jejich extracelulární část je poměrně velká a je schopna vázat ligandy Wnt, avšak s výrazně nižší afinitou než CRD doména receptorů Fz. Cytoplazmatická doména proteinů LRP je relativně krátká, má ale nezastupitelnou roli při procesech vedoucích ke stabilizaci β-kateninu, jak bude popsáno později. Nezbytnost této domény pro aktivaci signalizace dokládají experimenty založené na expresi mutantních forem LRP5 a LRP6 postrádajících intracelulární doménu. Tyto formy LRP se chovají jako tzv. dominantně negativní, to znamená, že zcela blokují kanonickou signalizaci [31, 81, 82].

2.1.1.4 Extracelulární inhibitory a aktivátory signalizace Wnt

Signální dráha Wnt může být inhibována již na extracelulární úrovni, a to nejen prostou regulací exprese receptorových proteinů Fz a LRP, ale také prostřednictvím specifických antagonistických molekul. Takovými molekulami jsou například solubilní proteiny sFRP (soluble Frizzled Related Proteins). Podobně jako receptory Frizzled obsahují proteiny sFRP ve své sekvenci doménu CRD. Prostřednictvím této domény sFRP váží ligandy Wnt a brání tak jejich asociaci s membránovými recepory Fz a LRP. Proteiny sFRP tedy působí jako inhibiční receptory. Proteiny sFRP jsou specifické pro obratlovce, kde mají důležitou roli při modulaci signalizace Wnt v průběhu embryogeneze [83, 84].

Jiným typem solubilních antagonistů jsou proteiny Dickkopf. Tyto molekuly jsou schopny se přímo vázat na receptory LRP. Proteiny Dickkopf rovněž interagují s jiným membránovým proteinem Kremen a ve spolupráci s ním iniciují internalizaci receptorů LRP, a tak výrazně limitují aktivitu signalizace Wnt. Zajímavé je, že proteiny Dickkopf se vyskytují pouze u obratlovců a primitivních bezobratlých (*Cnidaria*), u pokročilejších forem bezobratlých nebyly dosud nalezeny. [85, 86].

Svojí vazbou na receptor LRP blokuje signalizaci Wnt také sekretovaný protein Wise [87, 88].

Protein WIF (Wnt Inhibitory Factor) je solubilním antagonistou, který funguje podobně jako sFRP. WIF je schopen vázat ligandy Wnt na svoji specifickou doménu, která je ovšem odlišná od domény CRD, a působí tak jako inhibiční solubilní receptor. Strukturně

podobnou Wnt-vázající doménu jako WIF obsahují ve své extracelulární části receptorové tyrosin kinázové ze skupiny Ryk (Related to tyrosine kinase). Některé práce naznačují, že by kináza Ryk mohla fungovat v případě savčích buněk jako alternativní (ko-)receptor signalizace Wnt/β-katenin. Ovšem tato hypotéza je pro omezené množství dat stále otevřená [89, 90].

Existuje několik proteinů odlišných od ligandů Wnt, které jsou schopny aktivovat receptorový komplex Fz/LRP. Jedním z nich je na cystein bohatý protein Norrin, který je schopen se vázat na některé receptory Frizzled, mediovat asociaci Frizzled/LRP a zahájit tak kanonickou signalizaci Wnt [91]. Jinými agonistickými molekulami jsou R-spondiny. R-spondiny jsou schopny působit synergicky s ligandy Wnt. V některých případech působí samy o sobě jako aktivátory cílových genů pro Wnt, a zahajují signalizaci podobným způsobem tedy vazbou na receptory Frizzled a LRP [92-94].

2.1.2 Cytoplazmatické komponenty kanonické Wnt-signalizace

2.1.2.1 β-katenin a jeho degradační komplex

Klíčovou molekulou v rámci kanonické signalizace Wnt je β-katenin. β-katenin má v buňkách dvě základní funkce. Jako strukturním protein je součástí mezibuněčných adhezivních spojení (adherent junctions). β-katenin je základním vazebným partnerem pro cytoplazmatické části různých kadherinů, jako například pro membránově vázaný E-kadherin a podílí se tak na tvorbě základní kostry adhezivních spojů. Prostřednictvím modulace své vazby na α-katenin, může β-katenin významně ovlivňovat podobu aktinového cytoskeletu. [95-98]. Neméně významná je signalizační funkce β-kateninu, která byla poprvé popsána při genetických studiích na octomilce. Jedinci s mutací v genu *armadillo* (muší ortholog obratlovčího genu pro *β-katenin*) nevykazovali žádné významnější poruchy v mezibuněčné adhezi, přesto však umírali v průběhu vývoje na defekty, které se fenotypově shodovaly s poruchami způsobenými mutantním genem *wingless* [99, 100]. Signalizační role β-kateninu/armadilla jako aktivátoru transkripce v rámci signalizace Wnt byla později potvrzena nejen u octomilky, ale i u obratlovců [36, 101].

Charakteristická struktura β-kateninu je tvořena N-terminální regulační oblastí, centrální částí, která obsahuje 12 tzv. armadillo-repetic (Armadillo repeats). Většina níže popisovaných interakcí β-kateninu s ostatními proteiny (včetně E-kadherinu, APC a transkripčních faktorů Lef/Tcf) je lokalizována právě do této oblasti, a navíc jsou některé z těchto interakcí vzájemně exkluzivní. C-terminální část β-kateninu obsahuje silnou transaktivační doménu [102]. Signalizační a strukturní aktivita jsou na sobě nezávislé a od sebe oddělitelné, respektive se alespoň částečně vzájemně vylučují. Existují mutantní formy proteinu Armadillo, které mají vliv pouze na adhezivní funkci tohoto proteinu a neovlivňují funkci signalizační, respektive *vice versa* [103, 104]. Přirozeně došlo k oddělení adhezivní a signalizační funkce v případě *Caenorhabditis elegans*, který má několik různých β-kateninů, z nichž se jeden (HMP-2) uplatňuje pouze jako součást adhezivních spojů, zatímco ostatní (WRM-1, BAR-1, SYS-1) fungují v rámci signalizace Wnt [105-107].

V situaci, kdy buňky nejsou stimulovány prostřednictvím ligandu Wnt, je většina β-kateninu lokalizována jako součást adherentních spojů (v heterokomplexech s α-kateninem a E-kadherinem). β-katenin tak prakticky neuplatňuje svoji signalizační funkci, neboť hladina volného monomerního β-kateninu v cytoplazmě je posttranslačně udržována na nízké úrovni [18, 19]. Na udržení nízké hladiny cytoplazmatického β-kateninu se podílí multiproteinový degradační komplex, jehož součástí je strukturní protein Axin, tumor supresor APC, proteinkinázy z rodiny kasein kináz (CK1α −δ, −ε), a proteinkináza GSK3β (nebo GSK3α) [20-24]. V nestimulovaných buňkách je β-katenin fosforylován nejprve prostřednictvím kasein kinázy (nejčastěji CK1α) na N-koncovém serinu 45, poté následuje rozhodující fosforylace pomocí kinázy GSK3β (Glycogen synthase kinase 3β) na N-koncových serinech 33 a 37 a na threoninu 41[108, 109]. Dvoukroková fosforylace β-kateninu je signálem pro jeho ubikvitinaci, na které se podílí ubikvitin ligáza β-TrCP (β-Transducing repeat Containing Protein). Takto označený β-katenin je následně degradován v proteazomu [25-27].

Přestože rozhodujícím signálem pro degradaci β-kateninu je jeho fosforylace prostřednictvím proteinkináz, strukturní funkce Axinu a APC je esenciální pro správný průběh celého procesu. Axin je schopen interagovat nejen se všemi ostatními členy β-katenin-degradačního komplexu, ale prostřednictvím tzv. DIX domény s proteinem Dishevelled [33, 110]. Relativní exprese *axinu* v buňkách je obvykle nízká. Axin je tedy

pravděpodobně rozhodujícím limitním faktorem, který ovlivňuje rychlou agregaci nebo naopak destabilizaci degradačnho komplexu [20, 21]. Axin sám o sobě může být fosforylován prostřednictvím asociovaných kináz, tato fosforylace je nezbytná pro interakci Axinu s β-kateninem [111, 112]. V savčích buňkách byly nalezeny dva geny pro axinové proteiny, a to *axin1/axil* a *axin2/konduktin*. Zatímco *axin1* je exprimován konstitutivně, transkripce genu *axin2* je přímo stimulována signalizací Wnt, což je typický příklad negativní zpětné vazby v rámci signalizace Wnt. V situacích *in vivo* jsou přitom oba proteiny funkčně ekvivalentní [113].

Další strukturní protein β-katenin-degradačního komplexu je nádorový supresor APC (Adenomatous Polyposis Coli). Gen pro *apc*, který kóduje obrovitý protein (u člověka 2843 aminokyselin) je často mutován ve většině tzv. sporadických tumorů tlustého střeva, germinální mutace jedné alely genu *apc* se vyskytuje u pacientů s tzv. rodinnou polypózou tlustého střeva (FAP, Familiar Adenomatous Polyposis) [114, 115]. APC je dynamický adaptorový protein, který zprostředkovává interakce s jinými regulátory signalizace Wnt nejen v cytoplazmě, ale i v buněčném jádře. Strukturně je APC tvořen několika funkčními motivy. Obsahuje deset opakujících se 15-20 aminokyselinových motivů, které váží β-katenin. Mezi těmito repeticemi jsou střídavě lokalizována tři místa interagující s Axinem. Na molekule β-kateninu je vazebné místo pro APC lokalizováno do takřka stejných armadillo-repetic jako vazebné místo pro E-cadherin. β-katenin se tak nemůže současně vázat na molekuly degradačního komplexu a komponenty mezibuněčných spojů [116]. Rovněž APC může být fosforylován, a tato fosforylace umožňuje uvolnění ubikvitinem modifikovaného β-kateninu z degradačního komplexu. Jak nefosforylovaný β-katenin, tak nefosforylovaný APC se váží na Axin, dochází k dvoukrokové fosforylaci β-kateninu, a zároveň CK1α fosforyluje APC. Fosforylace zvyšuje afinitu APC k β-kateninu, a současně vede k uvolnění Axinu z degradačního komplexu. Axin pak může okamžitě vázat další volný β-katenin. Jednou z důležitých rolí pro APC by tedy mohlo být uvolnění fosforylovaného β-kateninu z degradačního komplexu [20, 21, 117, 118]. Defekty ve funkci APC lze u někteří nádorových buněčných linií alespoň částečně kompenzovat zvýšenou expresí genu pro *axin* [21].

Na stabilitu cytoplazmatického β-kateninu mohou mít vliv také proteinfosfatázy, působící antagonisticky proti aktivitě kináz CK1α a GSK3β. Je známo, že se fosfatáza PP2A podílí na zvýšení hladiny cytoplazmatického β-kateninu po stimulaci Wnt. Fosfatáza PP2A má navíc schopnost se vázat na Axin a APC. Přestože nejsou přesně

známy mechanismy regulující aktivitu PP2A je možné, že fosforylační status β-kateninu je za určitých okolností výsledkem protichůdných aktivit kinázy GSK3β a fosfatázy PP2A [119-121].

2.1.2.2 Stabilizace β-kateninu jako rozhodující událost kanonické signalizace Wnt

Kanonická signalizace Wnt je zahájena, jak bylo výše uvedeno vazbou ligandu Wnt na receptor Frizzled a koreceptor LRP. Experimenty založené na transfekcích různých forem chimérních receptorů Frizzled a LRP naznačují, že ligandy Wnt by mohly účinkovat jako jakýsi svorník přibližující k sobě oba tyto receptory. Ačkoli přímý experimentální důkaz chybí, zdá se, že blízká asociace obou receptorů je nezbytným krokem, jenž iniciuje kanonickou dráhu [122, 123]. Vzájemné přiblížení obou receptorů však není dostačující podmínkou. Pro iniciaci signalizace je nutná endocytóza receptorového komplexu. Pokud dojde k blokaci endocytózy, je rovněž zablokována signalizace Wnt v cílových buňkách [124, 125]. Prakticky okamžitě po vazbě ligandu Wnt na receptorový komplex následuje několik dějů, jejichž výsledkem je destabilizace β-katenin-degradačního komplexu. Vazba ligandu Wnt vede během několika minut k fosforylaci intracelulární části koreceptoru LRP, která obsahuje pět charakteristických fosforylačních motivů PPP(S/T)P, jež jsou fosforylovány prostřednictvím kinázy GSK3β. Současně dochází k fosforylaci sousedních motivů kinázou CK1γ. Tato členka rodiny kasein kináz je zvláštní tím, že je díky palmitylaci asociována s plazmatickou membránou. Pro aktivaci signalizace Wnt je nutná fosforylace oběma kinázami. Na takto fosforylovaný protein LRP se váže s vysokou afinitou Axin, což je jednou z příčin destabilizace β-katenin-degradačního komplexu. Jak je patrné, v tomto případě se CK1γ a GSK3β uplatňují nikoliv jako blokátory signalizace Wnt, ale přesně naopak. Velmi důležitou roli zde hraje membránová lokalizace uvedených kináz [82, 108, 126].

Další děje vedoucí k blokaci aktivity β-katenin-degradačního komplexu, jsou (současně s předchozími) iniciovány prostřednictvím receptoru Frizzled (Fz). Receptor Frizzled aktivuje po vazbě ligandu Wnt fosforylaci proteinu Dishevelled. Dishevelled je stěžejní modulátor jak kanonické signalizace Wnt, tak jejích nekanonických forem. Savčí genom obsahuje tři geny pro *Dishevelled* (*Dvl-1,-2,-3*) u octomilky je gen jeden (*Dsh*). Fosforylovaný Dvl se stává aktivním a prostřednictvím své PDZ domény se váže na

receptor Fz. Aktivní, a zároveň prostřednictvím receptoru Fz s membránou asociovaný Dvl, působí jako adaptorový protein, který váže další komponenty. Dvl prostřednictvím své DIX (Dishevelled-Axin) domény váže Axin, je také schopen vázat CK1, a tak přispívá k blokaci β-katenin-degradačního komplexu. Dvl rovněž asociuje s vnitrobuněčným inhibitorem kinázy GSK3β, proteinem GBP/Frat [33, 110, 127]. Zatím není přesně známo jakým mechanismem je Dvl aktivován. Epistatická analýza u octomilky naznačuje, že by určitou roli mohly hrát G-proteiny asociované s receptorem Fz [128]. Roli G-proteinů v kanonické signalizaci Wnt potvrzují i experimenty provedené na buněčných liniích. Zvýšená exprese nebo konstitutivní aktivita proteinu $G_{\alpha 0}$ vede k aktivaci transkripce cílových genů signalizace Wnt [129]. Jako možné kinázy aktivující Dvl byly dále popsány CK1ε a kináza Par-1 [130-132].

Výsledkem výše popsaných procesů je zablokování degradace β-kateninu a růst koncentrace volného monomerního β-kateninu. Následuje jeho translokace do buněčného jádra, kde β-katenin asociuje s transkripčními faktory Lef/Tcf. [36, 101, 133].

V řadě laboratoří bylo dokumentováno, že pokud je proces degradace β-kateninu narušen mutací, dochází k nefyziologické aktivaci signální dráhy Wnt. Mimořádně důležité je, že tato aberantní signalizace velmi často vede ke vzniku nádorů v různých typech tkání [13, 134]. K relativně nejlépe prozkoumaným nádorovým onemocněním souvisejícím s patologicky zvýšenou transkripční aktivitou β-kateninu jsou již zmíněné dědičné nebo sporadické nádory tlustého střeva, které jsou iniciovány mutacemi v nádorovém supresoru APC [37]. Mutace blokující aktivitu jiné komponenty degradačního komplexu, Axinu1, byly popsány v mnoha typech karcinomů jater [135, 136]. Některé melanomy, nádory vaječníků a také malé procento nádorů střeva obsahuje specifické mutantní formy β-kateninu. Jedná se většinou o mutace v N-koncových serinech nebo threoninech, díky nimž takto mutovaný protein vykazuje vysokou stabilitu, hromadí se v jádře buňky a spouští tak transkripci závislou na faktorech Lef/Tcf. V těchto případech pak β-katenin působí jako konstitutivně aktivní onkogen. [137, 138].

2.1.3 Nukleární komponenty kanonické signalizace Wnt

2.1.3.1 Jaderný import β-kateninu

Mechanismus jakým se nefosforylovaný β-katenin dostává z cytoplazmy do buněčného jádra není dosud přesně objasněn. K problematice importu β-kateninu do buněčného jádra a na druhé straně rovněž i k jeho exportu zpět do cytoplazmy existuje řada vzájemně si odporujících prací. Zdá se pravděpodobné, že jaderný import β-kateninu je nezávislý na mechanismu, který vyžaduje transportní systém NLS-importin/karyopterin. β-katenin sám o sobě vykazuje jistou podobnost s karyopteriny a pravděpodobně je schopen přímo interagovat s komponenty jaderných pórů. Pro tuto interakci a rovněž pro jaderný import je důležitá přítomnost posledních tří armadillo-repetic a C-konce β-kateninu [139-142]. β-katenin může být rovněž exportován ven z jádra, a to způsobem závislým na vlastní „exportní" doméně [143].

V momentě, kdy je β-katenin v jádře, může být jeho jaderná lokalizace fixována prostřednictvím některých proteinů, se kterými β-katenin interaguje. Jedním z nich je Pygopus a dalšími jsou transkripční faktory Lef/Tcf. Existuje ovšem také celá řada proteinů, jež mají schopnost zadržovat β-katenin, a to buď v jádře nebo naopak v cytoplazmě. Mezi tyto tzv. retenční proteiny patří především Axin a APC, které se mohou mimo cytoplazmu nacházet poměrně často rovněž v buněčném jádře, obzvláště v situaci, kdy je β-katenin-degradační komplex neaktivní [116, 144-146]. Na to, v jakém buněčném kompartmentu dojde k retenci β-kateninu pomocí těchto proteinů, má největší vliv jejich lokální koncentrační gradient (jádro/cytoplazma) [142].

2.1.3.2 Transkripční faktory Lef/Tcf

Jak již bylo zmíněno β-katenin má na svém C-konci transaktivační doménu, postrádá ale doménu DNA-vazebnou, která by β-kateninu umožnila iniciovat transkripci specifických cílových genů. Proto se β-katenin váže s transkripčními faktory Lef/Tcf, které β-katenin lokalizují k příslušným cílovým promotorům.

Zatímco genomy bezobratlých kódují vždy jeden transkripční faktor *Lef/Tcf* (*POP-1*v případě *Caenorhabditis elegans*, *Pangolin* u octomilky), genom obratlovců obsahuje čtyři geny: *Lef-1* (Lymphoid enhancer factor), *Tcf-1, Tcf-3, Tcf-4* (T-cell factor-1, -3, -4) [147]. Přestože se u savců dramaticky liší exprese jednotlivých typů Lef/Tcf během embryonálního vývoje i v dospělosti, jejich biochemická aktivita je vysoce podobná. Tato skutečnost je podepřena poznatky získanými u myší při inaktivaci jednotlivých transkripčních faktorů Lef/Tcf pomocí homologní rekombinace (tzv. knock out). Ze získaných výsledků výplývá, že například transkripční faktory TCF-1 a LEF-1 jsou částečně redundantní a mohou vzájemně kompenzovat ztrátu své funkce [148]. Oba tyto faktory jsou významné pro růst a diferenciaci hematopoietických buněk (TCF-1 hlavně pro T-lymfocyty, LEF-1 pro B-lymfocyty) [149-151]. TCF-4 je nezbytný pro obnovu epitelu střevních buněk, kde je exprimován v epiteliálních kmenových buňkách střevních krypt. Z jiných typů tkání je možné zmínit epitel mléčné žlázy, kde je TCF-4 rovněž významně exprimován. [152, 153]. TCF-3 je důležitým regulátorem polarity tělní osy během embryonálního vývoje [154, 155].

Všechny transkripční faktory Lef/Tcf sdílí několik základních společných charakteristických rysů. V promotorové oblasti cílových genů se váží prostřednictvím své DNA vazebné domény označované jako HMG-box na vysoce konzervovaný sekvenční motiv A/T A/T CAAA(G) [133, 156]. HMG-box se váže do malého žlábku v rámci DNA-šroubovice. Transkripční faktory Lef/Tcf nemají žádnou transaktivační doménu, nejsou tedy samy o sobě schopny iniciovat transkripci. Transkripci zahajují pouze ve formě komplexu s β-kateninem, přičemž se β-katenin váže svojí centrální částí (přibližně armadillo-repetice 3 až 10) na N-koncovou oblast faktorů Lef/Tcf. Další charakteristickou vlastností je jejich poměrně vysoká míra alternativního sestřihu pre-mRNA na 3'- konci, a to obzvláště v případě obratlovců [157, 158] .

2.1.3.3   Transkripce mediovaná β-kateninem a její modulace

V situaci, kdy není aktivována signalizace Wnt, a tudíž nedochází k vazbě β-kateninu na Lef/Tcf, fungují tyto transkripční faktory spíše jako transkripční represory. Proteiny Lef/Tcf tvoří represivní komplex s proteiny Groucho/Grg/TLE. Tyto proteiny se váží na N-koncovou oblast Lef/Tcf, přibližně do stejných míst jako β-katenin. Groucho/Grg/TLE

patří mezi transkripční korepresory, které jsou schopny interagovat s chromatinen prostřednictvím asociovaných histon deacetyláz (HDAC1, HDAC3). Histon-deacetylázy remodelují strukturu chromatinu do velmi kompaktní podoby, a tím jej mění do transkripčně inaktivního stavu [159-161].

V případě, že došlo k aktivaci signalizace Wnt, β-katenin je translokován do jádra, kde vytlačuje proteiny Groucho/Grg/TLE z jejich vazby na transkripčních faktorech Lef/Tcf. β-katenin se sám na tyto transkripční faktory váže a mění je tak z represorů v transkripční aktivátory. Vazba β-kateninu je spojena s rozsáhlou remodelací chromatinu a jeho přeměnou do transkripčně aktivního stavu. C-konec β-kateninu je asociován s řadou chromatin remodelujících proteinů. Váží se na něj mimo jiné histon acetyláza CBP/p300 a protein Brg-1 spolu s dalšími kompomponentami chromatin remodelujícího komplexu SWI/SNF. [162-165]. Velmi významná je schopnost β-kateninu rekrutovat k místům transkripce komponenty trithoraxového HMT (histone methyl transferase) komplexu, a to konkrétně proteiny MLL1/MLL2 (mixed lineage-leukemia), které patří ke skupině SET-1 methyltransferáz. Proteiny ze skupiny SET-1 jsou schopny zprostředkovat trimethylaci histonu H3 na jeho čtvrtém lysinu (H3K4Me3). Tato chromatinová modifikace je typická pro otevřenou chromatinovou strukturu, a takový chromatin je transkripčně vysoce aktivní [166]. β-katenin také přivádí k místu transkripce obecné transkripční faktory jako například TBP [167]. Navíc β-katenin prostřednictvím proteinu Parafibromin/Hyrax (jeho kvasinkový homolog je znám jako Cdc73), který je integrální součástí aktivačního komplexu Paf-1, interaguje s proteiny iniciačního a elongačního komplexu RNA-polymerázy II [168]. Na C-konec β-kateninu se rovněž váží komponenty mediátorového systému (MED 12), který byl původně popsán u kvasinek jako komplex, který propojuje aktivitu transkripčních regulátorů s obecnými transkričními faktory a s RNA-polymerázou II [169-171]. Transkripční faktory Lef/Tcf jsou tedy spíše než klasickými transkripčními faktory jakýmisi spojovníky, které přivádějí transkripční aktivátory nebo represory k cílovým místům [172].

Proteinový komplex Tcf/β-katenin (nebo Lef/β-katenin) je pravděpodobně plně transkripčně kompetentní již sám o sobě, ale v buněčném jádře existuje celá řada proteinů, které jsou schopny ovlivňovat jím mediovanou transkripci. Tyto proteiny asociují buď s β-kateninem nebo s Lef/Tcf, a svojí aktivitou mohou úroveň transkripce zesilovat nebo reprimovat. Klasickým příkladem transkripčních aktivátorů je dvojice proteinů Legless (lidský ortholog je znám jako Bcl9) a Pygopus. Tato proteinová dvojice byla popsána

poprvé u octomilky při genetické analýze zaměřené na hledání modulátorů signalizace Wnt. Fenotyp octomilek s inanktivovaným genem *legless* nebo *pygopus* velmi připomíná některé z mutantních fenotypů *wingless*. Protein Legless se váže na první čtyři armadillo-repetice β-kateninu, na Legless se připojuje protein Pygopus. Oba proteiny významně ovlivňují schopnost β-kateninu aktivovat transkripci. Pygopus je schopen zesilovat β-kateninem mediovanou transkripci, zároveň je proteinem určujícím lokalizaci proteinu Legless. Molekulární mechanismus jakým Legless a Pygopus realizují svoji aktivitu není dosud známý, určitou roli by mohla hrát jejich interakce s dalšími modulátory transkripce, nebo přímá aktivační úloha některé z funkčních domén těchto proteinů [173-176]. Inhibičně působí proteiny Chibby a ICAT (Inhibitor of β-catenin and Tcf). Malý jaderný protein Chibby se specificky váže na β-katenin a brání jeho vazbě s transkripčními faktory Lef/Tcf [177]. ICAT funguje obdobným způsobem, ale navíc brání interakci β-kateninu s některými chromatin-remodelačními proteiny (CBP/p300) [178].

Jiným represivním mechanismem působí proteiny, které posttranslačně modifikují transkripční faktory Lef/Tcf, a tím ovlivňují jejich aktivitu. Fosforylace transkripčního faktoru TCF-4 (rovněž tak LEF-1) na serinových a threoninových zbytcích prostřednictvím kinázy NLK (NEMO-Like Kinase) snižuje schopnost komplexu TCF-4/β-katenin vázat DNA a NLK tak inhibuje kanonickou signalizaci Wnt. V případě *Caenorhabditis elegans* vede dokonce fosforylace transkripčního faktoru POP-1 kinázou LIT-1 (ortholog NLK) k jeho exportu ven z jádra prostřednictvím 14-3-3 proteinu Par-5 [179, 180]. Na druhou stranu fosforylace transkripčních faktorů Lef/Tcf nemá vždy represivní efekt. Fosforylace proteinu LEF-1 na jeho N-koncových serinech kinázou CK2, v tomto případě lokalizovanou v jádře, výrazně zvyšuje schopnost LEF-1 vázat β-katenin, a navíc brání vazbě represorů Groucho/Grg/TLE na LEF-1. CK2 tedy svým působením v tomto případě zvyšuje transkripční aktivitu [181]. Další proteinovou modifikací proteinů Lef/Tcf , jež má vliv na transkripční aktivitu je sumoylace, čili modifikace prostřednictvím SUMO (Small Ubiquitin-related Modifier). Tento typ modifikace je velmi podobný ubikvitinaci, ale enzymy, které sumoylaci katalyzují jsou substrátově specifické. Modifikace sumoylací ovlivňuje buněčnou lokalizaci, funkci a stabilitu takto modifikovaných proteinů. Sumo E3 ligázový protein PIASy (Protein Inhibitor of Activated STAT y) se podílí na sumoylaci proteinů LEF-1 a TCF-4. Zatímco v případě LEF-1 má tato modifikace represivní efekt na transkripci mediovanou β-kateninem, tak v případě TCF-4 je sumoylace stimulátorem transkripce. Sumoylace proteinů Lef/Tcf je ovšem procesem velmi dynamickým, a tyto

24

transkripční faktory mohou být opět de-sumoylovány prostřednictvím proteinu Axam [182, 183].

2.1.3.4   Deaktivace transkripce mediované β-kateninem

Pro regulaci řady buněčných procesů je velmi důležitý dynamický přechod od transkripčně aktivního k transkripčně inaktivnímu stavu a naopak. V případě transkripce mediované β-kateninem se obě situace liší, jak již bylo naznačeno, rozdílným zastoupením transkripčních aktivátorů a represorů. Zatímco transkripční faktor LEF-1 je permanentně vázaný na příslušné promotory, složení regulačních proteinů se periodicky mění. Práce Sierry a kol. naznačuje, jakým způsobem k takové změně dochází v situaci, kdy dojde k zablokovaní kanonické signalizace Wnt, a tím blokaci transkripce na předtím aktivních promotorech. Při studiu dějů na promotoru cílového genu signalizace Wnt, a sice *c-myc* , byla překvapivě demonstrována významná   jaderná aktivita proteinu APC při blokaci transkripce. Protein APC je rekrutován do místa specifického promotoru. Zde APC asociuje s proteinem LEF-1, a iniciuje výměnu transkripčních aktivátorů za represory. APC pravděpodobně vytěsňuje β-katenin z vazby na LEF-1 a zároveň s sebou rekrutuje dva důležité proteiny: ubikvitin ligázu β-TrCP a transkripční korepresor CtBP (C-terminal Binding Protein). Transkripční korepresor CtBP poté transientně interaguje s proteinovým komplexem na transkripčním faktoru LEF-1. Represivní aktivita CtBP má zřejmě rozhodující roli na blokaci transkripce. CtBP může asociovat s histon deacetylázami, a tak modifikovat chromatin v transkripčně neaktivní. Již dříve byla popsána schopnost CtBP být také v komplexu s demetylázou LSD1 (Lysin Specific Demethylase 1) a předpokládá se, že právě aktivita tohoto enzymu ruší modifikaci H3K4Me3, což opět vede k transkripční represi. Tuto hypotézu podporuje skutečnost, že asociace CtBP na LEF-1-specifický promotor koreluje s výrazným poklesem trimethylace lysinu na histonu H3. CtBP později z promotorové oblasti disociuje a je nahrazen represory Groucho/Grg/TLE [166].

2.1.3.5 Cílové geny kanonické signalizace Wnt

Výsledným efektem, všech událostí v průběhu kanonické signalizace Wnt, je transkripce specifických genů. Řada z těchto genů kóduje buněčné protoonkogeny (*c-jun*) nebo naopak nádorové supresory . Mezi cílové geny patří významné regulátory proliferace (*c-myc, cyklinD1*). Kanonická signalizace je charakteristická velkou mírou autoregulace, nepřekvapí proto, že mezi cílové geny patří také řada negativních a pozitivních regulačních proteinů, které se uplatňují v této signální dráze. Jako příklad lze uvést *Axin2*, *Frizzled, β-TrCP*. Aktivace transkripce různých cílových genů signalizace Wnt je ovšem značně závislá na buněčném typu, a tak stejný ligand Wnt může stimulovat v různých buňkách transkripci různých genů. Svou roli zde může hrát různá míra komplexity promotorových oblastí a rovněž také aktivita jiných transkripčních faktorů na promotorech integrujících signály z více různých typů signálních kaskád [38, 40, 41, 184-188].

3 VÝSLEDKY A DISKUSE

3.1 Interakce TCF-4, transkripčpního faktoru obsahujícího HMG box, s korepresorem CtBP1 kontroluje expresi cílového genu signalizace Wnt Axin2/Konduktin v lidských emryonálních ledvinných buňkách

Transkripčních faktory Lef/Tcf rozeznávají v oblasti cílového promotoru stejný vysoce konzervovaný sekvenční motiv. To samozřejmě platí také pro všechny čtyři zástupce těchto transkripčních faktorů, které se uplatňují v případě regulace transkripce u savců, včetně člověka (LEF-1, TCF-1, TCF-3, TCF-4). Jak naznačují experimenty založené na aberantní inaktivaci genů *Lef/Tcf* u myších modelů, je aktivita těchto transkripčních faktorů často redundantní a jeden transkripční faktor může alespoň částečně kompenzovat absenci jiného transkripčního faktoru, jako je to v případě LEF-1 a TCF-1 [148, 189]. Je tedy otázkou, zda jsou všechny transkripční faktory Lef/Tcf shodné, nebo jestli je jejich aktivita specificky místně a časově regulována v různých buněčných typech. Odpovědí by mohla být existence proteinů, které by specificky intreragovaly s jednotlivými proteiny Lef/Tcf, a tak by byly schopny modulovat aktivitu konkrétních transkripčních faktorů Lef/Tcf.

V této práci jsme se pokusili nalézt takové proteiny, které by specificky interagovali pouze s transkripčním faktorem TCF-4 a ovlivňovali by tak jen jeho aktivitu. Porovnání sekvencí všech lidských zástupců Lef/Tcf ukázalo největší rozdíly v C-koncové sekvenci těchto proteinů. Navíc některé práce naznačovaly, že exprese některých TCF-4-specifických genů je závislá na přítomnosti specifické C-koncové oblasti tohoto proteinu [190]. Proto byla testována právě tato oblast proteinu TCF-4. Na základě dat získaných prostřednictvím kvasinkového dvouhybridního systému byl identifikován proteinem, který specificky interaguje s C-koncem faktoru TCF-4, transkripční korepresor CtBP.

CtBP (C-terminal Binding Protein) byl původně popsán jako protein který interaguje s adenovirovým onkoproteinem E1A a významně ovlivňuje jeho aktivitu [191, 192]. Role CtBP je však v buňce velmi komplexní a CtBP moduluje transkripci mnoha důležitých proteinů, které hrají roli při regulaci buněčného cyklu nebo buněčné adhezivity [193]. CtBP je transkripční korepresor se slabou NAD/NADH dehydrogenázovou aktivitou, která má vliv na jeho represivní funkci a ovlivňuje rovněž schopnost CtBP interagovat s jinými proteiny. Represivní aktivita CtBP je zprostředkována převážně aktivitou s ním asociovaných histon deacetyláz (HDAC class I, HDAC class II). CtBP je také schopen

rekrutovat k cílovým genům komponenty chromatin remodelujícího komplexu známého jako Polycomb, který způsobuje transkripční inaktivaci chromatinu [194-196]. CtBP rovněž zabraňuje interakci chromatinu s histon methyltransferázami (CBP/p300), které pak nemohou stimulovat transkripci [197]. Genom octomilky obsahuje jeden gen pro *CtBP*. V genomu savců se vyskytují dva geny *CtBP1* a *CtBP2*, které kódují funkčně totožné a strukturně velice podobné proteiny. Protein CtBP2 se liší přítomností krátké N-terminální sekvence. Oba proteiny jsou spolu schopny dimerizovat. Je pozoruhodné, že se aberantní inaktivace genu *CtBP2* projevuje u myši fenotypem, který velmi připomíná fenotyp myší s mutacemi v komponentách signalizace Wnt [192, 198].

CtBP1 a také CtBP2 se váží na specifický krátký interakční motiv PXDLS (PLDLS, PXSLXXK). Jak ukázala analýza sekvence proteinů Lef/Tcf, tento motiv se dvakrát vyskytuje v C-koncové oblasti TCF-3 a rovněž tak TCF-4. Zdá se tedy, že proteiny CtBP by mohly být specifickými regulátory pro tyto dva reprezentanty transkripčních faktorů Lef/Tcf. Již dříve byla popsána interakce CtBP a TCF-3 *in vitro*. Relevance této interakce byla potvrzena u *Xenopus laevis*, kde je aktivita XCtBP nutná pro represivní působení XTCF-3 [199]. TCF-3 je charakteristický tím, že v buňce funguje převážně jako transkripční represor, a to nejspíše i v případě, kdy tvoří heterokomplex s β-kateninem. [155, 200, 201]. Položili jsme si tedy otázku, zda CtBP může modulovat také aktivitu TCF-4, který je ve formě heterokomplexu s β-kateninem transkripčně vysoce aktivní.

Následné experimety potvrdily schopnost CtBP1 i CtBP2 (nepublikováno) interagovat specificky s TCF-4 *in vitro* . Pro interakci je nezbytně nutná přítomnost C-konce proteinu TCF-4, který obsahuje dvě potenciální CtBP-vazebná místa. Pokud byla tato část proteinu TCF-4 odstraněna nebo vyměněna za C-konec proteinu LEF-1, který neobsahuje žádná předpokládaná CtBP-vazebná místa, pak k vazbě CtBP1 na TCF-4 nedochází.

Dále jsme sledovali vliv CtBP1 na transkripci zprostředkovanou transkripčním faktorem TCF-4. Jako základní modelový systém pro testování aktivity CtBP jsme použili buněčnou linii odvozenou z lidských embryonálních ledvin, HEK293. Tyto buňky exprimují v dostatečné míře transkripční faktor TCF-4, jak jsme potvrdili pomocí imunoblotu. Jsou-li tyto buňky stimulovány ligandem Wnt1, dochází k aktivaci transkripce z promotorů obsahujících vazebná místa pro Lef/Tcf. Intenzitu této transkripce lze kvantifikovat pomocí luciferázového reportéru pTOPFLASH, u nějž je exprese Luciferázy kontrolovaná syntetickým promotorem, který obsahuje tandem šesti optimálních Lef/Tcf-vazebných míst (kontrolní reportér pFOPFLASH má tato místa mutovaná) [37]. Pomocí zmíněných reportérů jsme prokázali, že zvýšená exprese CtBP1 v buňkách HEK 293

inhibuje transkripci iniciovanou ligandem Wnt1. Pro detailnější studium mechanismů této represe jsme připravili buňky s regulovatelnou expresí CtBP1 (293-EGFP-CtBP1), kde je možné v homogenní buněčné populaci exprimovat CtBP1 na úrovni blízké přirozené situaci v buňkách. Je-li v těchto buňkách exprimován CtBP1, dochází opět k represi transkripce u specifického reportéru. Represivní působení CtBP na transkripci Lef/Tcf-specifického promotoru je spojeno s aktivitou histon deacetyláz. Pokud byly buňky 293-EGFP-CtBP1 kultivovány s inhibitorem histon deacetyláz Trichostatinem A, zvýšená exprese CtBP1 nevede k represi transkripce iniciované ligandem Wnt1. CtBP1 je rovněž schopen reprimovat transkripci přirozených cílových genů signalizace Wnt v buňkách 293-EGFP-CtBP1. Jak jsme ukázali v případě genu *Axin2*, dochází po stimulaci ligandem Wnt1 k několikanásobnému zvýšení hladiny mRNA pro Axin2. Pokud ovšem buňky exprimují CtBP1, transkripce genu *Axin2* je výrazně reprimována.

Zjištění, že CtBP1 je schopen reprimovat transkripci indukovanou ligandem Wnt bylo později potvrzeno jinými laboratořemi. Je otázkou, zda je základem represivního působení CtBP přímá interakce s transkripčním faktorem TCF-4. Ani v naší laboratoři jsme totiž nebyli schopni prokázat přímou interakci CtBP1 s TCF-4 *in vivo*. Hamada a Bienz předpokládají, že CtBP1 interaguje s tumor supresorem APC a společně vytěsňují β-katenin z vazby na transkripčním faktoru [202]. V nedávné době byla rovněž popsána úloha CtBP při deaktivaci β-kateninem mediované transkripce. V tomto případě protein APC přivádí CtBP a β-TrCP spolu s ostatními proteiny k heterokomplexu LEF-1/β-katenin a mění jej z transkripčně aktivního v transkripčně inaktivní. CtBP je ovšem součástí represivního komplexu jen transientně [166]. V tomto případě by to mohlo být, pochopitelné, neboť se zde autoři zaměřili na transkripční faktor LEF-1, který neobsahuje CtBP-vazebný motiv. Je samozřejmě možné, že i v případě represe transkripce mediované komplexem TCF-4/β-katenin je role přímé interakce mezi TCF-4 a CtBP jen aditivní a CtBP blokuje transkripci mechanismem založeným na APC. Na druhou stranu byla prokázána přímá kolokalizace CtBP1 a TCF-4 v některých typech střevních nádorů, respektive v buňkách z nich odvozených. Navíc byla u těchto nádorů popsána mutantní forma TCF-4, která postrádá CtBP-vazebný motiv. Pokud je tato forma TCF-4 v buňkách exprimována, CtBP1 není schopen reprimovat transkripci iniciovanou signalizací Wnt. Tento výsledek by potvrzoval důležitost přímé interakce mezi CtBP a TCF-4 pro represivní aktivitu CtBP [203]. Role proteinů CtBP při regulaci signalizace Wnt může být velmi komplexní, jak ukazují studie popisující aktivitu CtBP na přirozených cílových genech

signalizace Wnt u octomilky. CtBP zde může transkripci nejen reprimovat, ale může mít také překvapivě svůj podíl při transkripční aktivaci [204].

HMG box transcription factor TCF-4's interaction with CtBP1 controls the expression of the Wnt target Axin2/Conductin in human embryonic kidney cells

Tomas Valenta, Jan Lukas and Vladimir Korinek*

Institute of Molecular Genetics Academy of Sciences of the Czech Republic, Videnska 1083, 142 20 Prague 4, Czech Republic

ABSTRACT

Members of the Tcf/Lef family of the HMG box transcription factors are nuclear effectors of the Wnt signal transduction pathway. Upon Wnt signaling, TCF/LEF proteins interact with β-catenin and activate transcription of target genes, while, in the absence of the Wnt signal, TCFs function as transcriptional repressors. All vertebrate Tcf/Lef transcription factors associate with TLE/Groucho-related co-repressors, and here we provide evidence for an interaction between the C-terminus of the TCF-4 HMG box protein and the C-terminal binding protein 1 (CtBP1) transcriptional co-repressor. Using Wnt-1-stimulated human embryonic kidney 293 cells, we show that CtBP1 represses the transcriptional activity of a Tcf/β-catenin-dependent synthetic promoter and, furthermore, decreases the expression of the endogenous Wnt target, Axin2/Conductin. The CtBP1-mediated repression was alleviated by trichostatin A treatment, indicating that the CtBP inhibitory mechanism is dependent on the activity of histone deacetylases.

INTRODUCTION

Members of the Wnt family of growth factors control numerous developmental processes and aberrant activation of Wnt genes, and Wnt signaling is also implicated in deregulated cell growth and cancer (reviewed in 1,2). Insights into the mechanisms of the Wnt signaling pathway have emerged from genetic studies in *Drosophila*, biochemical experiments in cell culture, ectopic gene expression in early *Xenopus* embryos and from target gene inactivation in mice (3). A striking characteristic of Wnt signaling is its conservation during evolution. Components of the Wnt signaling pathway have been found in such evolutionary distant species as slime mould *Dictyostelium*, diploblastic metazoan Hydra, *Caenorhabditis elegans* and in higher vertebrates, including mammals (4–6). This indicates that the Wnt signaling cascade is one of the primary regulatory mechanisms controlling cell fate decisions in multicellular organisms.

A brief outline of the canonical Wnt pathway is the following (for more detailed information, refer to the Wnt homepage at http://www.stanford.edu/~rnusse/wntwindow.html). The interaction of extracellular Wnt ligands with the Frizzled/LRP receptor complex results in increased intracellular levels of β-catenin in the target cell (7–9). In unstimulated cells, free cytoplasmic β-catenin is marked on N-terminal serine and threonine residues by phosphorylation, and then ubiquitinated and rapidly degraded by the proteasome pathway (10–13). The β-catenin degradation machinery includes casein kinase Iα (CKIα) and a multiprotein cytoplasmic complex containing serine–threonine kinase GSK-3, Axin1 (or its homolog Axin2/Conductin) and the APC tumor suppressor (14–20). When cells are stimulated by Wnt proteins, the cytoplasmic phosphoprotein Dishevelled is recruited to the plasma membrane and, by a so far unknown mechanism, inhibits the function of the GSK-3/Axin/APC complex (21,22). The unphosporylated stable β-catenin molecules accumulate in the cytoplasm and also translocate into the nucleus. Nuclear β-catenin forms heterocomplexes with TCF/LEF proteins (23–25). The TCF/β-catenin heterodimers act as bipartite transcription factors and activate the expression of the specific Wnt responsive genes (26,27). Approximately 50 Wnt targets have been identified to date, and several of these genes encode proteins related to cell cycle regulation, e.g. c-myc, Cyclin D1 and Pitx2 (28–31).

Relay and final processing of the Wnt signal in the target cell is controlled at several levels. In the extracellular space, proteins of the Dkk, WIF and SFRP families interact directly with Wnt ligands or their receptors and inhibit transmission of the signal into the cell (32–37). In the cytoplasm, LIT-1/Nemo-like kinase phosphorylates TCFs and regulates the DNA binding and subcellular distribution of TCF/LEF factors (38–40). β-Catenin activity in the nucleus may be promoted by interaction with a number of proteins including Pontin52, Brg-1, Pygopus, p300 and Lines (41–45). β-Catenin-mediated transcription is repressed by Reptin52 (a Pontin52 homolog), ICAT, XSox17α/β and XSox-3 protein (46,47). Other interacting partners modulate the function of TCF/LEF proteins.

In mammals, the Tcf/Lef family consists of four genes: *Tcf-1*, *Lef-1*, *Tcf-3* and *Tcf-4*. All TCF/LEF proteins display several common structural features (48,49). They contain a nearly identical DNA-binding domain, the HMG box, recognizing the consensus sequence A/T A/T CAAA. The

*To whom correspondence should be addressed. Tel: +4202 41062471; Fax: +4202 44472282; Email: korinek@biomed.cas.cz

extreme N-terminus harbors the β-catenin interacting domain. Although capable of binding to DNA, TCF/LEF proteins possess only limited ability to activate transcription. They might rather be viewed as nuclear vehicles targeting other auxiliary proteins to a specific set of promoters. β-Catenin possesses a strong transcription activation domain, so it is an example of an activating interacting partner. In contrast, all mammalian TCFs also associate with TLE/Groucho co-repressors and, in the absence of the Wnt signal, repress the transcription of the Tcf-dependent synthetic reporter or endogenous Tcf targets (50). TLE/Groucho proteins interact with the hypoacetylated N-terminal tail of histone H3 and also with human histone deacetylase 1 (HDAC 1) and its *Drosophila* homolog Rpd3 (51,52). This suggests that the function of TLE/Groucho is to form a specialized repressive chromatin structure that prevents the inappropriate activation of β-catenin/TCF target genes.

The participation of Wnt signaling in multiple developmental programs leads to the question of how β-catenin/TCF complexes discriminate between different subsets of all potential Wnt target genes at a given time and cellular background. Functional differences between individual TCF/LEF proteins could be one possible explanation. Although *Tcf/Lef* mRNAs are expressed in complex and often overlapping patterns during embryogenesis and in adult tissues, gene targeting experiments in mice revealed that Tcf-1, Lef-1 and Tcf-4 execute different developmental programs and their functions are only partially redundant (53–55). Additionally, several observations indicated that TCFs interact with distinct partners and show individual context-dependent DNA-binding and transactivation properties. For example, it has been reported that LEF-1 cooperates with microphthalmia-associated transcription factor (MITF) to up-regulate the dopachrome tautomerase gene promoter in melanocytes (56), and that activation of the T-cell receptor alpha enhancer by LEF-1 depends on ALY, a nuclear protein that specifically associates with LEF-1 and AML-1 (57). The activity of LEF-1 is suppressed by its association with PIASy, a nuclear matrix-associated SUMO E3 ligase, which sequesters LEF-1 into nuclear bodies (58) and, furthermore, direct interaction of LEF-1 with HDAC 1 mediates a repressive effect of LEF-1 in the absence of Wnt signaling (59). Another Tcf family member, TCF-3, interacts with casein kinase 1ε (CK1ε), and phosphorylation of TCF-3 by CK1ε stimulates its binding to β-catenin (60). In *Xenopus laevis*, XTCF-3 requires XCtBP to function as a transcriptional repressor (61). Recently, Hecht and Stemmler showed that TCF-4 and LEF-1 exhibit significant differences in regulating the promoter of two Wnt-responsive genes, *Cdx-1* and *Siamois*, in human embryonic kidney cells (62). Cdx-1 activation strictly depended on the promoter-specific transactivation domain located at the TCF-4 C-terminus. In addition, multiple isoforms are generated from *Tcf/Lef* mRNAs by way of alternative splicing or by use of dual promoters, and these isoforms display diverse functional properties (63–65). Thus, selective interaction of members of the Tcf/Lef family with various partners and their intrinsic DNA-binding properties can support the execution of different developmental programs.

To study the regulatory mechanisms of Wnt signaling, we screened for proteins interacting with human TCF-4. In this report, we show that the C-terminal binding protein 1 (CtBP1) associates with the TCF-4 C-terminus and that CtBP1 overexpression in Wnt-1-stimulated 293 cells represses transcription from the Wnt-responsive reporter and also decreases the activity of the endogenous Axin2 promoter. The CtBP1-mediated repression is alleviated by trichostatin A treatment, indicating that the CtBP inhibitory mechanism is dependent on the action of histone deacetylases.

MATERIALS AND METHODS

Plasmids

Constructs encoding proteins containing N-terminal EGFP were generated in pEGFP/C vector (BD Clontech). Myc-tagged cDNAs were prepared in pK-Myc vector. This vector was created by replacing the EGFP region in pEGFP/C with a T7 promoter and Myc tag coding sequence. Full-length cDNAs without N-terminal tags contained either natural initiator or a PCR-introduced consensus Kozak sequence. The expression plasmids for Tcf-4 were derived from human *Tcf-4E* cDNA (GenBank accession No. NM_030756) using naturally occurring restriction enzyme sites: *Sma*I (position 236 bp from ATG), *Nsi*I (995) and *Nde*I (1159). Plasmids encoding full-length or truncated forms of mCtBP1 were prepared in an analogous way using *Bgl*II, *Pvu*II, *Kpn*I and *Pst*I internal restriction enzyme sites. Detailed information about the constructs is available upon request. The mouse *Lef-1* cDNA was obtained from a mouse testis cDNA library (a gift from Stoil Dimitrov, IMG AS CR, Prague, Czech Republic). The TCF4–LEF-1 chimeric construct was generated by an exchange of the 3′ coding region in *Tcf-4* with the C-terminal coding sequence of mouse *Lef-1* using the *Apa*LI restriction enzyme site conserved in both genes. Human β-*catenin* cDNA was obtained from a bone marrow MATCHMAKER cDNA library (BD Clontech). Human *CtBP1* cDNA was amplified from the cDNA of 293 cells, mouse *CtBP2* was cloned from day-19 mouse embryo cDNA. Mouse *Wnt-1* cDNA was a gift from Marc van Dijk (University Hospital Utrecht, Utrecht, The Netherlands). For retroviral transduction, *Wnt-1* or EGFP-tagged *mCtBP1* were ligated into pLNIT (generously provided by Fred H. Gage, The Salk Institute, La Jolla, CA) or pLNCX vector (BD Clontech). Platinum Pfx DNA Polymerase (Invitrogen) was used for all PCR amplifications. PCR-derived constructs were verified by sequencing.

Yeast two-hybrid screen

A pre-transformed mouse 17-day embryo MATCHMAKER cDNA library (Clontech) was screened with the last 185 amino acids of the human TCF-4 protein fused to the GAL-4 DNA-binding domain (DBD) in pGBKT7 as bait. Positive clones were subjected to the specificity test using the GAL-4 DBD or GAL-4 DBD–lamin fusion protein as bait. Those clones that interacted specifically with the GAL-4 DBD–TCF-4 bait were sequenced.

Cell culture, transfections and retrovirus infection

Human embryonic kidney (HEK) cell lines 293, monkey kidney cells COS-7, rat fibroblast cell line Rat2, EcoPack-293 and AmphoPack-293 (Clontech) cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented

with 10% fetal bovine serum (Hyclone). Transfections were performed using the lipofectamine reagent (Invitrogen), as described by the manufacturer. For retrovirus production, ecotropic EcoPack-293 or amphotropic AmphoPack-293 packaging cells were seeded in 6-well plates 12 h prior to transfection and then transfected with 3 µg of a particular retroviral expression construct. After 24 h, the growth medium was replaced with 2 ml of fresh medium. After a further 24 h incubation, the supernatant containing non-replicating forms of the virus was harvested. Target cell lines were infected in 6-well plates with the virus supernatant in the presence of 5 µg of polybrene (Sigma) per ml. Twenty-four hours later, the medium was replaced by complete DMEM supplemented with either G418 (concentration 1 mg per ml) or hygromycin B (0.5 mg per ml; both antibiotics were purchased from Invitrogen) and doxycycline (Sigma), concentration 1 µg per ml [expression of the transduced cDNAs in pLNIT is regulated by doxycycline (66)]. After a 10 day selection, the growing (resistant) cells were washed extensively with DMEM and subsequently cultivated in fresh selective medium without doxycycline. The expression of the transferred genes was confirmed by western blot analysis.

Reporter gene assays, trichostatin A treatment and Wnt-1 stimulation experiments

For reporter gene assays, 293 cells were seeded into 24-well plates (approximately 10^5 cells per well) and transfected 2 h later with a lipofectamine mixture containing 50 ng *Renilla* pRL-SV40 plasmid (Promega) as an internal control, 400 ng luciferase reporter plasmid and up to 1 µg of the particular expression vector. The total amount of DNA was kept constant by adding empty expression vector where necessary. The firefly luciferase reporter constructs pTOPFLASH and pFOPFLASH, containing either three copies of the optimal Tcf motif GATCAAAGG or three copies of the mutant motif GGCCAAAGG, respectively, were described previously (27). The lipofectamine–DNA mixtures for reporter gene assays in 293-EGFP-CtBP1/Dox contained 50 ng *Renilla* pRL-SV40 internal control plasmid and 400 ng luciferase reporter plasmid only, i.e. no empty vector was added. COS-7 cells were seeded in 12-well plates and transfected by lipofection with 50 ng *Renilla* pRL-SV40 plasmid, 400 ng luciferase reporter plasmid and various combinations of the following plasmids (see Fig. 5A): TCF-4 expression vector (400 ng), β-catenin expression vector (800 ng) and CtBP1 expression vector (0.5–2 µg). Additional empty pK-Myc plasmid was added when necessary to make the total amount of DNA equivalent. Firefly and *Renilla* luciferase activities in cell lysates were determined 15 h post-transfection using the dual luciferase system (Promega), according to the protocol supplied by the manufacturer, and a single tube luminometer Sirius (Berthold). All reporter gene assays were done in triplicate. The reporter gene activities shown are average values, along with the standard deviations from at least three independent experiments after normalization against the *Renilla* luciferase activities. Treatments with the deacetylase inhibitor trichostatin A (Sigma) were performed using the drug at 300 nM concentration for 12 h. Wnt-1 stimulation experiments were performed as follows. 3×10^5 293 cells were seeded into 6-well plates and transfected by lipofectamine–DNA mixtures. The amounts of individual

DNAs in the mixtures were proportionally increased by a factor of three as compared to the experiments in 24-well plates. Four hours post-transfection, the cells were washed extensively with DMEM and then 1×10^5 Rat2-Wnt-1/Const cells expressing stable levels of Wnt-1 protein were plated over the target cells. Parental Rat2 cells were used as a negative control. After co-cultivation for 3–30 h, the cells were harvested together and further processed for the reporter gene assay, RNA isolation, electrophoretic-mobility shift assay (EMSA) or immunoblotting. When feeders with inducible *Wnt-1* expression (Rat2-Wnt-1/Dox) were used, the experimental procedure was modified as follows. We regularly grew the feeder cells in a complete medium supplemented with 2 ng of doxycycline per ml. This low concentration of the antibiotic was sufficient to suppress Wnt-1 production, and, additionally, Wnt-1 protein started to appear almost instantly upon the removal of doxycycline. Transfected 293 cells were covered with Rat2-Wnt-1/Dox cells and co-cultivated in medium without doxycycline. Cell cultures growing in the presence of doxycycline (5 ng per ml) were used as negative controls. The regulation of CtBP1 expression in 293-EGFP–CtBP/Dox cells was rather 'leaky', thus we cultivated these cells in higher concentrations of Dox (1 µg/ml). The full induction of the CtBP1 transgene was then achieved during 15 h growth in the absence of doxycycline.

GST interaction assays

Full-length GST–mCtBP1 and GST–mCtBP2 fusion proteins were expressed in the BL21 (DE3) strain of *Escherichia coli* using the pET-42b vector (Novagen). Full-length or truncated TCF-4 and full-length mCtBP1 protein were produced *in vitro* using the TNT Coupled Reticulocyte System (Promega) and corresponding pK-Myc constructs. All coupled transcription–translations were performed in a total volume of 50 µl using 10 µl of [^{35}S]methionine (ICN Biomedicals) per reaction. Twenty microliters of radiolabeled TCFs or mCtBP1 were incubated with GST–mCtBP1 or GST–mCtBP2 proteins bound to glutathione–Sepharose 4B beads (Amersham Pharmacia Biotech) in GST binding buffer [phosphate-buffered saline, pH 7.4, 0.5% (v/v) Nonidet P-40, 20 µM NADH (Sigma) and Protease Inhibitor Cocktail (Sigma)] for 1 h at 4°C. Beads were collected by centrifugation and washed five times in GST binding buffer. Bound proteins were separated by SDS–PAGE and analyzed by autoradiography.

Antibodies and immunoblotting

The following commercially available antibodies were used: β-catenin, CtBP, mouse monoclonal (Santa Cruz); EGFP, mouse monoclonal (BD Clontech); Myc tag, mouse monoclonal 9E10 (Roche Molecular Biochemicals); TCF-4, mouse monoclonal (Sigma); Wnt-1, rabbit polyclonal (Santa Cruz); and LEF-1, goat polyclonal (Santa Cruz). To monitor protein expression, 2×10^5 293 cells, seeded into 6-well plates, were transfected with 3 µg of expression vector. Twenty-four hours later cells were harvested and disrupted directly in SDS–PAGE sample buffer. The cell lysates were cleared of cell debris and chromosomal DNA by ultracentrifugation at 200 000 *g*, then loaded onto SDS–PAGE gels, transferred to polyvinylidene fluoride membranes (Pall Gelman Laboratory)

and immunoblotted with the appropriate antibodies. Proteins were visualized with an enhanced chemiluminiscence system (Pierce).

EMSA

The nuclear extracts were prepared according to Dignam *et al.* (67), snap frozen in liquid nitrogen and stored at –70°C. The final buffer composition was 20 mM HEPES, 100 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF and 20% glycerol. Extracts were prepared from intact nuclei that were washed three times to avoid contamination with cytoplasmic β-catenin. As the optimal Tcf/Lef probe, we used a double-stranded 19-nucleotide oligomer AGAACCCTTTGATCTT-AGG; the control probe was AGAACCCTTTGGCCTTAGG. The oligonucleotides were end-labeled using T4 polynucle-otide kinase (Fermentas) and [γ-^{32}P]ATP (3000 Ci/mmol; ICN Biomedicals). A typical binding reaction contained 8 µg of nuclear protein, 1 ng of radiolabeled probe and 300 ng of poly-(deoxyinosic–deoxycytidylic) acid (poly [dIdC]; Sigma) in 25 µl of binding buffer (60 mM KCl, 1 mM EDTA, 1 mM DTT, 10 mM HEPES, pH 6.9 and 10% glycerol). Samples were incubated for 30 min at room temperature, an antibody was added and the samples were incubated for a further 30 min. The binding reactions were loaded onto 5% polyacrylamide gels with 0.5× Tris–borate–EDTA running buffer. Electrophoresis was carried out at 15°C at 220 V constant voltage. Gels were transferred onto Whatman paper, dried and exposed to the BAS-phosphoimager screen (Fuji).

Real-time quantitative RT–PCR

One hundred micrograms of total RNA from Wnt-1-stimulated 293 or control cells isolated by the guanidine thiocyanate (Fluka) method (68) were further purified using the Micro-to-Midi total RNA isolation system (Invitrogen). Random or oligo dT-primed cDNA was prepared in a 20 µl reaction from 2.5 µg of total RNA using Superscript II RNAseH⁻ reverse transcriptase (Invitrogen). One percent of the resulting cDNA was used for one quantitative PCR reaction. The 10 µl reaction mixtures also contained 1× Platinum Quantitative PCR SuperMix-UDG (Invitrogen), acetylated BSA (final concentration 3 µg per ml; New England Biolabs), Sybr Green I (final dilution 1:40 000; Amresco) and 5 pmol of each specific primer. All primers were calculated using Primer 3 computer services at http://www-genome.wi.mit.edu/cgi-bin/primer/primer3.cgi/primer3_www.cgi. The primer pairs were designed and tested to be specific for human genes, i.e. the primers did not prime on rat or mouse cDNA. We used primers for the following human genes (the primers are written in the 5′ to 3′ direction, the first primer is derived from the plus and the second primer from the minus DNA strand): *Axin1*, CCTGTGGTCTACCCGTGTCT, GCTATGAGGAGTGGTCCAGG; *Axin2*, CTGGCTTTGGT-GAACTGTTG, AGTTGCTCACAGCCAAGACA; *GAPDH*, CACCACACTGAATCTCCCCT, CCCCTCTTCAAGGGG-TCTAC; *CyclinD1*, CCATCCAGTGGAGGTTTGTC, AGC-GTATCGTAGGAGTGGGA; *SDHA*, AGATTGGCACCT-AGTGGCTG, ACAAAGGTAAGTGCCACGCT; *CtBP1*, CCTTCGCGTTCCTCGTTA, AAGAACGTTCATGGGAG-AATAA; *Tcf-1*, CCTCTGCCTCCCTAGCTTTT, ATGGGG-GAGATGGGTAGAGA; *Lef-1*, CTGCTAGAGACGCT-GATCCA, TGGCTCTTGCAGTAGACGAA. cDNAs were

produced from at least two independent RNA isolations, and the PCR reactions were performed in triplicate for each primer set. The specificity of the PCR products was verified by sequencing. Two housekeeping genes, *Glyceraldehyde-3-phosphate dehydrogenase* (*GAPDH*) and *Succinate dehydro-genase complex, subunit A* (*SDHA*), were used as internal control genes to standardize the quality of different cDNA preparations (69). The cycling was performed in a LightCycler instrument (Roche Molecular Biochemicals). The results were analyzed using the LightCycler 3 software package. The relative abundance of *Axin1* and *Axin2* mRNA in 293 cells stimulated by Rat-2-Wnt-1/Const cells versus control 293 cells (co-cultivated with the parental Rat2 cell line) was derived from the average CT values of each triplicate after normalizing against the levels of *SDHA* cDNA. Results of a representative experiment are shown.

RESULTS

TCF-4 interacts with the transcriptional co-repressors CtBP1 and CtBP2

To gain insight into the molecular function of TCF-4 protein, we started a search for novel TCF-4-interacting proteins using a yeast two-hybrid system. We selected a 180 amino acid region distal to the HMG box covering the C-terminus of TCF-4 as bait. This region has a unique primary structure within the Tcf/Lef family and displays only limited homology to the C-terminus of TCF-3, the closest relative of TCF-4 (Fig. 1). One strong positive obtained from a day-17 mouse embryo cDNA library corresponded to *CtBP1*, a widely expressed transcriptional co-repressor. The cDNA encoded the entire 430 amino acid CtBP1 polypeptide. The CtBP1–Gal4 activation domain fusion protein interacted specifically with the TCF-4 bait and not with the Gal-4 DBD alone or with the Gal-4 DBD–lamin fusion protein, respectively (see Materials and Methods).

We further attempted to delineate the minimal region of CtBP1 required for association with TCF-4. We generated a series of N- and C-terminal deletions of CtBP1 fused to the Gal4 activating domain and tested their interaction with Gal4 DBD–TCF-4 in a yeast two-hybrid system. Each truncation of CtBP1 displayed a dramatically reduced ability to bind TCF-4 (data not shown). This indicates the complex multidomain mode of interaction between CtBP1 and TCF-4.

Human CtBP1 was originally discovered during a screen for cellular proteins that complex with the C-terminal region of the adenoviral E1A protein (70). Subsequently, a highly homologous human polypeptide termed CtBP2 was identified by analysis of EST database sequences (71). Other vertebrates such as rodents and *Xenopus* also contain two *CtBP* homologs, while invertebrates have a single *CtBP* gene. The CtBP proteins bind to a short sequence motif PLDLS conserved among the E1A proteins of all human and primate adeno-viruses. Different variants of this motif are also present in other CtBP-interacting partners that function mainly as negative regulators of transcription (reviewed in 72). Two putative CtBP-binding sequences are also present in the C-termini of TCF-3 and TCF-4 proteins (Fig. 1); Brannon and others showed that simultaneous mutations in both these sites abolished the association of XTCF-3 with XCtBP, a *Xenopus* homolog of CtBP1, *in vitro* (61).

```
              ▼330      ▼340      ▼350      ▼360      ▼370      ▼380      ▼390
TCF-4     KKPLNAFMLYMKEMRAKVVAECTLKESAAINQILGRRWHALSREEQAKYYELARKERQLHMQLYPGWSAR
consensus KKPLNAFMLYMKEMRAKVVAECTLKESAAINQILGR:WH.LSREEQAKYYELARKERQLH QLYP.WSAR
TCF-3     KKPLNAFMLYMKEMRAKVVAECTLKESAAINQILGRKWHNLSREEQAKYYELARKERQLHSQLYPTWSAR
           ▲350     ▲360      ▲370      ▲380      ▲390      ▲400      ▲410

              ▼400      ▼410    ↓   ▼420      ▼430      ▼440      ▼450      ▼460
TCF-4     DNYGKKKKRKRDKQPGETNEHSECFLNPCLSLPPITDLSAPKKCRARFGLDQQNNWCGPCRRKKKCVRYI
consensus DNYGKKKKKRR:KQ ::T:.: :                          :::.:.   :..:.KK CV:Y:
TCF-3     DNYGKKKKRKREKQLSQTQSQQQ------------------------VQEAEG-ALASKSKKPCVQYL
           ▲420     ▲430                                    ▲440      ▲450

              ▼470      ▼480      ▼490      ▼500      ▼510      ▼520      ▼530
TCF-4     QGEGSCLSPPSSDGSLLDSPPPSPNLLGSPPRDAKSQTEQTQ⌐PLSLSLK¬PDPLAHLSMMPPPPALLLAEA
consensus . E :C SP:SS:GS:LDSP:.::. L:SP:  A :::EQ:Q PLSL: K P:. A:L:: .::: L  .A
TCF-3     PPEKPCDSPASSHGSMLDSPATPSAALASPAAPAATHSEQAQ⌐PLSLTTK¬PETRAQLAL-HSAAFLSAKAA
           ▲460      ▲470      ▲480      ▲490      ▲500      ▲510      ▲520

              ▼540      ▼550      ▼560      ▼570      ▼580              ▼▼596
TCF-4     THKASALCPNGALDLPPAALQPAAPSSSIAQPS-TSWLHSHSSLAGTQPQ⌐PLSLVTK¬SLE
consensus : .::.: :: :L  .P :L : .:   :.PS .: LH:H :L:  Q:Q PLSLVTK S
TCF-3     ASSSGQMGSQPPLLSRPLPLGSMPTALLASPPSFPATLHAHQALPVLQAQ⌐PLSLVTK¬SAH
           ▲530      ▲540      ▲550      ▲560      ▲570              ▲588
```

Figure 1. Amino acid comparison of the C-terminal regions of human TCF-4 and TCF-3. Amino acid identities are indicated by corresponding letters; amino acid similarities are indicated by double dots (closely related residues) or single dots (distantly related residues). Sequences were aligned with CLUSTALW. Overlining indicates highly conserved HMG box sequences; two putative CtBP binding sites are boxed. The arrows depict the amino acid sequence used in a yeast two-hybrid screen.

Given the putative CtBP-binding motifs in the C-terminus of TCF-4, we tested the interaction using bacterially purified GST–CtBP1 or GST–CtBP2 and various forms of TCF-4 translated *in vitro* (Fig. 2A). As shown in Figure 2B, a GST fusion protein containing complete CTBP1 interacted with [^{35}S]methionine-labeled full-length TCF-4 (FLTCF-4) or with its C-terminal fragment (ΔN$_{Nde}$TCF-4). Truncated proteins that lacked either sequences distal to the HMG box (TCF-4– LEF-1 chimera) or the entire C-terminal region (ΔC$_{Nsi}$TCF-4) failed to interact with mCtBP1. GST-tagged CtBP2 showed an identical mode of interaction (not shown), and, additionally, we observed efficient heterodimerization of CtBP1 and CtBP2 *in vitro* (Fig. 2B). Taken together, these data indicate that TCF-4 associates with CtBP1 and CtBP2 proteins and that the TCF-4 C-terminus is indispensable for the interaction.

Wnt signaling is activated in 293 cells co-cultivated with Wnt-1 protein-producing feeder cells

By retrovirus infection we generated several polyclonal rat fibroblast cell lines with constitutive (Rat2-Wnt-1/Const) or doxycycline-repressible (Rat2-Wnt-1/Dox) expression of the mouse *Wnt-1* gene (Fig. 3A). Because Wnt molecules possess only limited solubility and mostly stay attached to the cell surface of the producing cell, we activated Wnt signaling in 293 cells by co-cultivation with *Wnt-1*-expressing feeder cells. The human embryonic kidney 293 cells selected for the study activate the Tcf/β-catenin-dependent reporter if transiently transfected with *Wnt-1* expression plasmid, and, additionally, express high levels of *Tcf-4* mRNA and produce predominantly a longer variant, i.e. the TCF-4E form, of TCF-4 protein, which contains both CtBP-binding motifs [(27); Fig. 3B].

As shown in Figure 3C, Wnt-1-producing feeders stimulated the Tcf-reporter pTOPFLASH 6–7-fold as compared to control feeders. Co-transfection of an expression construct encoding dominant negative TCF-4, which lacks the N-terminal β-catenin interacting domain (ΔN$_{Sma}$TCF-4), completely abrogated the reporter gene activity, whereas a β-catenin expression plasmid strongly enhanced transcription from the pTOPFLASH reporter. The activity of the negative control reporter pFOPFLASH did not display any significant changes. We also employed a gel retardation supershift assay to determine whether Wnt signaling induces a nuclear TCF-4/ β-catenin complex in stimulated 293 cells. We did not detect TCF–DNA complexes in nuclear extracts prepared from parental Rat2 fibroblast cells or Rat2-Wnt-1-transfected cells (not shown), therefore we performed gel retardations with compound nuclear extracts isolated from 293 and feeder cells. Using an optimal Tcf-motif as probe, we readily obtained two types of TCF–DNA complexes from parental and from both unstimulated and stimulated 293 cells; one of these complexes could be supershifted with a monoclonal antibody recognizing human TCF-4 (Fig. 3D). Although 293 cells express all four *Tcf/Lef* genes, previous studies showed that TCF-1 and TCF-3 remain associated with insoluble nuclear components and are not eluted from nuclei by conventional extraction procedures (73,74). Thus, we concluded that the second gel-retarded complex contained endogenous LEF-1 protein and we attempted to supershift this complex with an antibody recognizing LEF-1. Addition of the LEF-1-specific antibody to the binding reaction led to almost complete diminishing of the original protein–DNA complex while the TCF-4–DNA complex stayed intact (Fig. 3D). We assumed that the second TCF–DNA complex indeed contains LEF-1 protein, and that the interaction between LEF-1 and the DNA probe was destabilized by the antibody added. Stimulation of 293 cells by Rat2-Wnt-1 cells resulted in the appearance of additional bands that could be further supershifted with a β-catenin antibody (Fig. 3D). Taken together, these data provide clear proof that the exogenous Wnt signal delivered by the Wnt-1-producing feeder cells, is effectively transmitted into human 293 cells, stimulates the formation of TCF/β-catenin complexes and subsequently activates the transcription of Wnt-responsive promoters. We further used this cellular system to study the effects of CtBP1 on Wnt-induced transcription.

Figure 2. The C-terminus of TCF-4 interacts with CtBP1. (**A**) A schematic representation of the human TCF-4 deletion constructs used in this study. All constructs contained the N-terminal Myc-tag (not depicted). β-cat, β-catenin interaction domain; TLE/Groucho, TLE/Groucho binding domain; CtBP, CtBP-binding sites; HMG, DNA-binding domain; LEF, LEF-1 C-terminus. (**B**) *In vitro* interaction of TCF-4 with CtBP1. GST–CtBP1 and GST–CtBP2 fusion proteins were conjugated to glutathione–Sepharose beads and incubated with the indicated ^{35}S-labeled TCF-4 proteins translated *in vitro*. After washing and recovery of the beads, associated proteins were resolved by SDS–PAGE and analyzed by autoradiography. In lanes 1, 4, 7, 10 and 13, 10% of the input labeled proteins was applied directly onto the gel. Full-length TCF-4 (lane 3) and the TCF-4 C-terminal fragment (lane 12) bind to GST–CtBP1. TCF4–LEF-1 chimera (line 6) or the N-terminal fragment of TCF-4 lacking CtBP-binding sites (lane 9) do not interact with GST–CtBP1. *In vitro* labeled CtBP1 associates with GST–CtBP2 (lane 15). None of the proteins bind to GST-bound Sepharose beads (lanes 2, 5, 8, 11 and 14). The positions of molecular weight markers in kDa are indicated at the left.

CtBP1 represses TCF/β-catenin-dependent transcription by a trichostatin A-sensitive mechanism

CtBP proteins function as short-range transcriptional co-repressors, therefore we examined the functional relevance of the TCF-4–CtBP1 interaction in reporter assays. It has been reported previously that N-terminal modification of the CtBP1 protein may change its association with histone deacetylases (75); for that reason, we tested the activity of three different CtBP1 constructs encoding mCtBP1 with an N-terminal Myc-tag, EGFP-tagged mCtBP1 and, finally, full-length human CtBP1 without N-terminal modification. All three constructs repressed transcription from the Tcf-dependent pTOPFLASH reporter in a concentration-dependent manner in both unstimulated and stimulated 293 cells, whereas the activity

of the control reporter pFOPFLASH was not affected by CtBP1 (Fig. 4A, only data for human CtBP1 are shown). CtBP1 was originally described as a protein interacting with the adenoviral oncogene E1A. Since 293 cells express E1A, we used an alternative cell system to avoid the possibility that the observed effects are dependent on E1A expression. We utilized the previously established transient β-catenin–Tcf reporter assay. In this assay, co-transfection of TCF-4 and β-catenin into COS-7 cells results in transactivation of the Tcf-dependent luciferase reporter gene (Fig. 4B). Upon addition of increasing amounts of CtBP1, the luciferase activity decreases proportionally only when the construct encoding full-length TCF-4 (FLTCF-4) capable of binding to CtBP was co-transfected. Transactivation mediated by β-catenin and C-terminally truncated TCF-4 (TCF4–LEF) was not affected by CtBP1. The reporter gene assays indicated that Tcf/β-catenin transcriptional activity is down-regulated by TCF-4–CtBP1 interaction. To study the mechanisms of CtBP1 action in greater detail, we generated 293 cells with inducible expression of EGFP-tagged mCtBP1. We obtained four polyclonal cell lines (293-EGFP–CtBP1/Dox) producing EGFP–mCtBP1 protein in the quantities representing approximately one-half of the amount of endogenous CtBPs (Fig. 5A). For further analysis we utilized a mixture of these cell lines. We further compared EGFP–CtBP1 production from the *CtBP1* transgene with the EGFP–CtBP1 levels obtained in transient transfections. Results of a western blot analysis showed that transfection of 0.5 μg of the CtBP1 expression construct generated cellular amounts of EGFP–CtBP1 protein similar to the levels obtained in 293-EGFP–CtBP1/Dox cells upon removal of doxycycline. Transfection of a larger quantity of the construct produced even more EGFP–CtBP1 protein than the amount of endogenous CtBPs (Fig. 5A). Nevertheless, the relatively moderate expression of the *EGFP–CtBP1* transgene significantly decreased pTOPFLASH transcription in Wnt-1-stimulated cells, whereas the activities of this reporter in 293-EGFP–CtBP1/Dox cells growing in the presence of doxycycline, i.e. with repressed CtBP1, were comparable to values obtained in the parental cell line (Fig. 5B). We readily obtained almost identical amounts of TCF/β-catenin complexes in Wnt-1-stimulated 293-EGFP–CtBP1 cells independently of the expression status of the *CtBP1* transgene (not shown). This indicates that CtBP levels do not interfere directly with the formation of such complexes or with the upstream steps of Wnt signaling. We further determined whether the mechanism of CtBP1 repression relies on histone deacetylases. As shown in Figure 5C, treatment with trichostatin A, a histone deacetylase inhibitor, alleviated the repressive effect of CtBP1 in 293-EGFP–CtBP1/Dox cells. The trichostatin A treatment also completely neutralized the repressive effect of CtBP1 in transient transfection assays (Fig. 5D). We conclude that CtBP1 acts as a repressor of Wnt-mediated transcription via recruitment of histone deacetylases to the target promoter.

Besides CtBP, 293 cells express other TCF-4-interacting proteins, the TLE/Groucho co-repressors (52). Therefore, we asked next whether both types of negative regulators utilize the same inhibitory mechanisms. We examined the impact of different TCF-4 deletions on the activity of the pTOPFLASH reporter in unstimulated and stimulated 293 cells (see Fig. 2A

for details about the constructs used). TCF-4 constructs, when overexpressed in 293 cells, decreased the basal and the Wnt-1-primed activity of pTOPFLASH but, strikingly, TCF4-LEF, which interacts only with TLE/Groucho and lacks the C-terminal CtBP-binding domain, appeared to be more potent repressor than full-length TCF-4 (Fig. 5E). In addition, only repression mediated by full-length TCF-4, i.e. by a protein containing both TLE/Groucho and CtBP interaction regions, has been almost completely alleviated by the trichostatin A treatment. These results indicate that the TLE/Groucho proteins may utilize different mechanisms than do CtBPs to repress the Tcf-responsive promoter and/or that the action of these repressors might be mutually exclusive.

CtBP1 down-regulates the expression of Axin2, a Tcf/β-catenin target in 293 cells

We examined the expression levels of several human genes related to Wnt signaling in Wnt-1-stimulated 293 cells. We

designed sets of human-specific primers that selectively amplified cDNA produced from 293 mRNA and did not function with rat or mouse cDNAs, respectively (see Materials and Methods). This allowed us to assess the level of expression of the selected human genes even in 293/Rat2 mixed RNA samples. Upon Wnt-1 stimulation, we noticed significant changes in expression of several genes: (i) we detected a moderate up-regulation of presumptive Wnt targets *Cyclin D1*, *Tcf-1* and *Lef-1* (see Supplementary Material) and (ii) we also detected strong transcriptional activation of *Axin2/Conductin*. Axin2 was recently identified by DNA-array technology as a gene positively regulated by TCF/β-catenin complexes in colorectal and liver tumors and in rat RK3E epithelial cells (76,77). We tested the time course of induction of the *Axin2* transcript in stimulated cells (Fig. 6A). We detected an 8-fold increase in *Axin2* mRNA as early as 3 h after stimulation (a 3 h interval was a minimal time period necessary for attachment of feeder cells onto the 293 cells). The maximal quantity of *Axin2* mRNA was reached after 9 h of co-cultivation. Following this time point, *Axin2* levels started to decrease but, nevertheless, after 15 h still remained approximately six times higher than in control 293 cells. Expression of the *Axin1* gene, an *Axin2* homolog, did not change significantly at any time point tested. We further

Figure 3. Wnt-1 protein-producing Rat2 feeder cells activate Wnt signaling in 293 cells. (**A**) Wnt-1 expression is strictly regulated in Rat2 fibroblasts by doxycycline. Western blot analysis of total cell lysates from parental Rat2 cells (lane 1), Rat2 cells with doxycycline-regulated Wnt-1 expression (Rat2-Wnt-1/Dox, lanes 2–5) and Rat2 cells with constitutive production of Wnt-1 (Rat2-Wnt-1/Const, lane 6). The Rat2-Wnt-1/Dox cells were grown at different concentrations (1 µg, 1 ng and 10 pg per ml) or in the absence of doxycycline, as indicated at the bottom. SDS–PAGE and immunoblotting with Wnt-1 antibody resolved cell lysates. The arrow shows the position of the putative Wnt-1 protein; the positions of shorter degradation products are indicated by open arrowheads. Molecular weight markers in kDa are at the left. (**B**) 293 cells express a longer form of TCF-4 protein. A total cell lysate from COS-7 cells transfected with expression vector encoding full-length TCF-4E protein (lane 1), and from cytoplasmic and nuclear fractions prepared from 293 cells (lanes 2 and 3, respectively) were resolved by SDS–PAGE and immunoblotted with an anti-TCF-4 antibody recognizing an epitope proximal to the HMG box. Molecular weight markers in kDa are at the left. (**C**) Wnt-1 expressing Rat2 cells induce the activation of the Tcf reporter in 293 cells. The human embryonic kidney 293 cell line was co-transfected with the expression plasmids indicated on the *y*-axis and the Tcf reporter construct pTOPFLASH (containing wild-type Tcf-binding sites) or pFOPFLASH (with mutated Tcf motifs) as a negative control. Four hours post-transfection, DNA mixtures were removed and Rat2-Wnt-1/Dox fibroblasts were subsequently plated over the 293 cells. Cultures were further grown either in the absence (Wnt-1 induction) or presence of doxycycline (control) for 15 h, then the cells were harvested together and processed to assay the reporter gene activities. Luciferase activities [shown on the *x*-axis as relative light units per second (RLU/s)] were corrected for the efficiency of transfection using the internal control *Renilla* pRL-SV40 expression plasmid. Average values and their standard deviations from three independent experiments are shown. (**D**) Wnt-1 induces nuclear TCF–β-catenin complexes in 293 cells. A gel retardation assay performed with nuclear extracts from parental 293 cells (left) and from 293 cells co-cultivated with Rat2-Wnt-1/Dox cells growing in the presence (control, middle) or absence (Wnt-1 induction, right) of doxycycline. Samples in lanes 1, 8 and 13 were incubated under standard conditions. Anti-β-catenin antibody was added to the samples in lanes 2, 10 and 15. Anti-TCF-4 antibody was added to the samples in lanes 3, 7 and 12. Anti-LEF-1 antibody was added to the sample in lane 5. Filled arrowheads indicate the positions of the TCF/β-catenin complexes. A control antibody (anti-HA tag) was added to the samples in lanes 9 and 14. Asterisks indicate non-specific bands also observed with a probe mutated in the Tcf-binding site (lanes 4, 6 and 11).

Figure 4. CtBP1 represses TCF/β-catenin transcription. (**A**) CtBP1 represses TCF/β-catenin transcription in 293 cells. Human 293 embryonic kidney cells were co-transfected with the indicated amounts of CtBP1 expression plasmid and the Tcf reporter construct pTOPFLASH or the negative control reporter pFOPFLASH using the lipofectamine reagent. Four hours post-transfection, DNA–lipofectamine mixtures were removed and 293 cells were covered with Rat2-Wnt/1/Dox fibroblasts containing the *Wnt-1* gene driven by the doxycycline-repressed promoter. The cultures were further grown in the presence (control) or absence of doxycycline (Wnt-1 stimulated). Following co-cultivation for 15 h, the cells were harvested, and luciferase (firefly) and *Renilla* luciferase activities were determined in cell lysates. (**B**) CtBP1 can repress transactivation mediated by TCF-4 and β-catenin in COS-7 cells. COS-7 cell line was co-transfected with the Tcf reporter constructs and a specific TCF-4 construct, β-catenin and with the indicated amount of CtBP1 plasmid. Luciferase and *Renilla* luciferase activities were determined in cell lysates 15 h following transfection. Whole cell extracts were analyzed by western blotting with TCF-4 monoclonal antibody (inset). All transfections were done in triplicate. Relative luciferase light units per second (RLU/s) are average values corrected for the efficiency of transfection by determining the luciferase/*Renilla* ratio.

examined the influence of CtBP1 overexpression on the activation of the *Axin2* gene. *Axin2* mRNA in 293-EGFP–CtBP1/Dox cells stimulated by Rat2-Wnt-1/Const feeder cells and with the repressed *EGFP–CTBP1* transgene was up-regulated 6-fold (compared to the same cells co-cultivated with parental Rat2 fibroblasts). However, the induction of *CtBP1* in Wnt-1-activated cells significantly down-regulated *Axin2* expression (Fig. 6B). These results indicate that a cellular dose of CtBPs modulates the activity of the Axin-2 promoter and, by implication, might selectively regulate the expression of other Wnt target genes.

DISCUSSION

In this report we provide evidence for an interaction between the TCF-4 protein, a member of the Tcf/Lef family of nuclear mediators of Wnt signaling, and the transcriptional co-repressor CtBP1. Using Wnt-1-stimulated human embryonic kidney 293 cells, we demonstrate that CtBP1 represses the transcriptional activity of a Tcf/β-catenin-dependent synthetic promoter and, furthermore, decreases the expression of the endogenous Wnt target Axin2. We further show that the inhibitory effect of CtBP is neutralized by the histone deacetylase inhibitor trichostatin A.

TCF/LEF proteins represent a specific type of transcription factor. They harbor β-catenin and TLE/Groucho interaction domains that determine whether, under given circumstances, the protein will act as a transcriptional activator or repressor. TCFs display essentially identical DNA-binding specificities, thus they have been considered as equivalent nuclear components of the Wnt signaling pathway. However, recent studies revealed functional differences among TCF family members. The most obvious feature of individual TCFs is their ability to associate with various cellular proteins. From that point of view, LEF-1 and TCF-3 proteins have been the most thoroughly studied Tcf/Lef family members (see Introduction). The main focus of this study is TCF-4 protein.

The limited solubility of Wnt proteins is a critical obstacle to studying the biological function of these molecules *in vitro*. We developed a dual cell system for Wnt pathway activation in which the target cells are stimulated by cells producing Wnt factors and growing in close proximity. This type of stimulation presumably corresponds well to the situation occurring *in vivo* in solid tissues and organs. At first, we generated rat fibroblast cell lines with constitutive or inducible Wnt-1 expression, and, using a Tcf/β-catenin-dependent reporter assay and a β-catenin supershift assay, we showed that these cell lines evidently activate Wnt signaling in neighboring 293 cells. β-Catenin overexpression from a transiently transfected construct resulted in a robust activation of the Tcf/β-catenin-dependent reporter, which was further augmented if the cells were simultaneously stimulated by Wnt-1-producing feeders (Fig. 3C). This indicates that β-catenin is indeed a key and also a limiting molecule in Wnt signaling. We further utilized this cell system to test the function of CtBP1 in the context of a Wnt-responsive promoter. Since 293 cells express E1A protein and CtBP1 was originally described as a protein interacting with this adenoviral oncoprotein, we used the COS-7 cell system in parallel to avoid the possibility that the observed effects are dependent on E1A expression. The repressive effect of CtBP1 depended directly on the expression levels obtained from either transiently or steadily transfected CtBP1 plasmids. This dosage-dependent repression corresponds well to the phenotype of mice harboring various combinations of *CtBP1* and *CtBP2* mutant alleles. *CtBP1*-null mice are small but viable, whereas *CtBP2* mutants die by E10.5 due to aberrant extraembryonic development. Different *CtBP1/CtBP2* compound mutant mice display additional dose-sensitive defects in a wide range of developmental processes (78). It is surprising that although 293 cells produce an abundance of LEF-1 (79), which is a protein that does not interact with CtBP, higher amounts of CtBP1 efficiently suppressed transcription from the Wnt-responsive

Figure 5. Histone deacetylases inhibitor trichostatin A alleviates the repressive effect of CtBP1 on the Wnt-responsive promoter. (**A**) 293-EGFP–CtBP1/Dox cells produce EGFP-tagged mCtBP1 in quantities that represent one-half of the amount of endogenous CtBPs. Total cell lysates from 293 cells expressing EGFP–CtBP1 from a doxycycline-repressive promoter growing in the absence (EGFP–CtBP1 induced, lane 1) or presence (EGFP–CtBP1 repressed, lane 2) of doxycycline (1 μg/ml) and from the parental 293 cell line transiently transfected with different amounts of plasmid encoding EGFP-tagged CtBP1 (lanes 3–5, micrograms of transfected construct are indicated on the top) were analyzed by western blot analysis. The anti-CtBP monoclonal antibody used to visualize proteins on the blots recognizes both human CtBP1 and CtBP2 proteins. The positions of molecular weight markers in kDa are indicated at the left. (**B**) Expression of the *EGFP–CtBP1* transgene down-regulates activity of the Wnt-resposive promoter in 293-EGFP–CtBP1/Dox cells. 293-EGFP–CtBP1/Dox cell line was transfected with the indicated Tcf reporter constructs. Four hours post-transfection, DNA mixtures were removed, the cells washed extensively and Rat2-Wnt-1/Const fibroblasts (steadily producing the Wnt-1 protein) or parental Rat2 cells were subsequently plated over the 293 transfectants. Cultures were further grown for 15 h either in the absence (EGFP–CtBP induction: yes) or presence (EGFP–CtBP induction: no) of doxycycline (1 μg/ml). (**C**) Trichostatin A treatment releases the repressive function of EGFP–CtBP1. The experiment was performed as described above in (B) except that trichostatin A (final concentration 300 nM) was added simultaneously with the feeder cells. (**D**) Trichostatin A treatment alleviates the CtBP1-mediated repression in transient transfection assay. Human 293 embryonic kidney cells were co-transfected with the indicated amounts of CtBP1 expression plasmid and the Tcf reporter constructs using the lipofectamine reagent. Four hours post-transfection, DNA–lipofectamine mixtures were removed and 293 cells were covered with Rat2-Wnt-1/Dox fibroblasts. The cultures were further grown in the presence (control) or absence of doxycycline (Wnt-1 stimulated). Trichostatin A (300 mM final) was added simultaneously with the feeder cells. Following co-cultivation for 15 h, the cells were harvested and luciferase and *Renilla* luciferase activities were determined in cell lysates. (**E**) Tcf-mediated repression is partially insensitive to trichostatin A. Human 293 embryonic kidney cells were co-transfected with empty expression vector pK-Myc or TCF-4 deletion constructs indicated on the *y*-axis and the Tcf reporter plasmid pTOPFLASH. TCF-4 proteins were produced at comparable levels in the transfected cells as shown by western blot analysis (right panel). Four hours post-transfection, cells were covered with Rat2 cells (control) or Rat2-Wnt-1/Const cells (Wnt-1 stimulated), and half of the samples were further treated with trichostatin A (TSA, final concentration 300 nM). Following an additional 12 h, the cells were harvested, and luciferase and *Renilla* luciferase activities were determined in cell lysates. Transfections were done in triplicate. Average luciferase light units per second (RLU/s) corrected to *Renilla* luciferase activities and their standard deviations are shown.

reporter to basal levels (Fig. 4A). This fact might be explained by the greater ability of TCF-4 to form a ternary complex with DNA and β-catenin (80).

TCF-4 (and TCF-3) resembles two other repressors, Hairy and Brinker, which also interact with both TLE/Groucho and CtBP proteins (81,82). The precise mechanisms of how TLE/Groucho and CtBP contribute to gene repression remain to be

elucidated. In *Drosophila*, Groucho functionally interacts with the histone deacetylase Rapd3 (51). Recruitment of Rapd3 to target promoters would result in the formation of a more compact chromatin structure followed by a transcriptionally repressed state. The recruitment of histone deacetylases is likely to be the main function of the TLE/Groucho proteins, although only the partial release of TLE/Groucho-Rapd3

Figure 6. CtBP1 down-regulates the expression of Axin2 in 293 cells. (**A**) Wnt-1 activates *Axin2* mRNA in 293 cells. The results of quantitative real-time PCR performed with cDNA generated from 293 cells stimulated by Wnt-1-producing feeder cells (Rat2-Wnt-1/Const) or by control Rat2 cells are shown. The 293 and feeder cells were co-cultivated for the indicated period of time, then harvested and random primed cDNA was prepared from total RNA. The PCR reactions were performed for each primer set in triplicate using cDNAs produced from at least two independent RNA isolates. (**B**) EGFP–CtBP1 decreases responsiveness of the *Axin2* gene to the Wnt-1 stimulation but has no effect on the expression of the *Axin1* gene. 293-EGFP–CtBP1/Dox cells were co-cultivated with feeder cells stably producing Wnt-1 protein (Rat2-Wnt-1/Const) or control Rat2 fibroblasts as a negative control. Cells were co-cultivated for 15 h in the presence (EGFP–CtBP1 repressed) or absence (EGFP–CtBP1 overexpressed) of doxycycline (1 µg/ml). The random primed cDNAs generated from the relevant RNAs were analyzed. The PCR reactions were performed for each primer set in triplicate using cDNAs produced from at least two independent RNA isolates. The results of a representative experiment are shown. The results were analyzed using the LightCycler 5.1 software package, and the values of a representative experiment are shown. The relative abundance of *Axin1* and *Axin2* mRNA in Wnt-1-stimulated versus control cells was derived from the average CT values of each triplicate after normalizing to the levels of *SDHA* cDNA.

repression by the histone deacetylase inhibitor trichostatin A indicates that additional mechanisms of repression may exist. CtBP also induces transcriptional silencing in a histone deacetylase-dependent or -independent manner. CtBP1 associates with class I and class II histone deacetylases, and CtBP-related down-regulation of certain promoters has been reported to be sensitive to trichostatin A (83). In contrast, repression of several other promoters was insensitive to trichostatin A treatment (75). We detected a complete release of the CtBP-mediated repression by trichostatin A. This clearly indicates the involvement of the histone deacetylases in the repression mechanism. Since 293 cells express both TLE/Groucho and CtBP proteins (52 and this manuscript), we further evaluated the contribution of the TLE/Groucho and CtBP co-repressors to the repression of the activity of the pTOPFLASH reporter. Overexpression of TCF-4–LEF deletion containing only the TLE/Groucho interaction domain significantly inhibited the basal and Wnt-1-dependent activity of the Tcf reporter. This is in agreement with the observation that the C-terminally truncated forms of XTCF-3 keep their repressive potential in *Xenopus* embryos, even if they lack the CtBP-interacting domains (61). Surprisingly, the putative repressive action of TLE/Groucho was only partly suppressed by trichostatin A, and a greater sensitivity to this chemical was only revealed by the full-length TCF-4-mediated repression (Fig. 5E). This implies the possibility of parallel repressive

action of CtBP and TLE/Groucho, which might contribute to the regulation of different Wnt targets. Since the TLE/Groucho and CtBP-binding sites are quite far apart in TCF-4 and TCF-3 proteins, we assume that there is no steric competition for these sites as in Hairy protein (82).

We took advantage of the different origin of human 293 and rat feeder cells and used real-time quantitative RT–PCR to analyze the changes in expression of selected genes upon Wnt stimulation. The strongest up-regulation was observed for *Axin2* mRNA. This finding was rather expected because Axin2 was recently identified as a gene activated by β-catenin overexpression in the related rat RKE3 cells (76). We further evaluated the impact of CtBP1 overexpression on Axin2 activation and detected a strong reduction in the levels of *Axin2* mRNA. Such a robust effect was surprising because the quantities of the ectopically expressed CtBP1 protein represented approximately one-half of the amount of endogenous CtBPs. 293 cells express all four TCF/LEF proteins, although at different levels, TLE/Groucho, and both CtBP1 and CtBP2 co-repressors (V. Korinek, unpublished data). TCF-4 associates with TLE/Groucho proteins and also with CtBPs, and these proteins also form homo- or heterodimers. The strength of the interaction between CtBPs and their partners can be further potentiated by the levels of nuclear NAD(H) (84,85). We propose that the composition of various Wnt signaling pathway components and their expression levels dictate the primary sensitivity of a given cell to the Wnt signal. The balance in such a system can be disturbed by changing the levels of only one component. Likewise the defects in other negative regulators of Wnt signaling (e.g. in the tumor suppressor APC), mutations that inactivate CtBP proteins could also lead to inappropriate activation of the Wnt pathway. On the other hand, non-physiological increases in the expression levels of CtBPs might by implication result in a significant reduction in Wnt signaling output in the stimulated cell.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at NAR Online.

ACKNOWLEDGEMENTS

REFERENCES

1. Cadigan,K.M. and Nusse,R. (1997) Wnt signaling: a common theme in animal development. *Genes Dev.*, **11**, 3286–3305.
2. Bienz,M. and Clevers,H. (2000) Linking colorectal cancer to Wnt signaling. *Cell*, **103**, 311–320.

3. Miller,J.R. and Moon,R.T. (1996) Signal transduction through beta-catenin and specification of cell fate during embryogenesis. *Genes Dev.*, **10**, 2527–2539.

4. Coates,J.C., Grimson,M.J., Williams,R.S., Bergman,W., Blanton,R.L. and Harwood,A.J. (2002) Loss of the beta-catenin homologue aardvark causes ectopic stalk formation in *Dictyostelium. Mech. Dev.*, **116**, 117–127.

5. Hobmayer,B., Rentzsch,F., Kuhn,K., Happel,C.M., von Laue,C.C., Snyder,P., Rothbacher,U. and Holstein,T.W. (2000) WNT signalling molecules act in axis formation in the diploblastic metazoan Hydra. *Nature*, **407**, 186–189.

6. Grimson,M.J., Coates,J.C., Reynolds,J.P., Shipman,M., Blanton,R.L. and Harwood,A.J. (2000) Adherens junctions and beta-catenin-mediated cell signalling in a non-metazoan organism. *Nature*, **408**, 727–731.

7. Pinson,K.I., Brennan,J., Monkley,S., Avery,B.J. and Skarnes,W.C. (2000) An LDL-receptor-related protein mediates Wnt signalling in mice. *Nature*, **407**, 535–538.

8. Tamai,K., Semenov,M., Kato,Y., Spokony,R., Liu,C., Katsuyama,Y., Hess,F., Saint-Jeannet,J.P. and He,X. (2000) LDL-receptor-related proteins in Wnt signal transduction. *Nature*, **407**, 530–535.

9. Wehrli,M., Dougan,S.T., Caldwell,K., O'Keefe,L., Schwartz,S., Vaizel-Ohayon,D., Schejter,E., Tomlinson,A. and DiNardo,S. (2000) arrow encodes an LDL-receptor-related protein essential for Wingless signalling. *Nature*, **407**, 527–530.

10. Aberle,H., Bauer,A., Stappert,J., Kispert,A. and Kemler,R. (1997) beta-catenin is a target for the ubiquitin-proteasome pathway. *EMBO J.*, **16**, 3797–3804.

11. Jiang,J. and Struhl,G. (1998) Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb. *Nature*, **391**, 493–496.

12. Marikawa,Y. and Elinson,R.P. (1998) beta-TrCP is a negative regulator of Wnt/beta-catenin signaling pathway and dorsal axis formation in *Xenopus* embryos. *Mech. Dev.*, **77**, 75–80.

13. Hart,M., Concordet,J.P., Lassot,I., Albert,I., del los Santos,R., Durand,H., Perret,C., Rubinfeld,B., Margottin,F., Benarous,R. *et al.* (1999) The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. *Curr. Biol.*, **9**, 207–210.

14. Hart,M.J., de los Santos,R., Albert,I.N., Rubinfeld,B. and Polakis,P. (1998) Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. *Curr. Biol.*, **8**, 573–581.

15. Fagotto,F., Jho,E., Zeng,L., Kurth,T., Joos,T., Kaufmann,C. and Costantini,F. (1999) Domains of axin involved in protein–protein interactions, Wnt pathway inhibition, and intracellular localization. *J. Cell Biol.*, **145**, 741–756.

16. Liu,C., Li,Y., Semenov,M., Han,C., Baeg,G.H., Tan,Y., Zhang,Z., Lin,X. and He,X. (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. *Cell*, **108**, 837–847.

17. Yanagawa,S., Matsuda,Y., Lee,J.S., Matsubayashi,H., Sese,S., Kadowaki,T. and Ishimoto,A. (2002) Casein kinase I phosphorylates the Armadillo protein and induces its degradation in *Drosophila. EMBO J.*, **21**, 1733–1742.

18. Behrens,J., Jerchow,B.A., Wurtele,M., Grimm,J., Asbrand,C., Wirtz,R., Kuhl,M., Wedlich,D. and Birchmeier,W. (1998) Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. *Science*, **280**, 596–599.

19. Kishida,M., Koyama,S., Kishida,S., Matsubara,K., Nakashima,S., Higano,K., Takada,R., Takada,S. and Kikuchi,A. (1999) Axin prevents Wnt-3a-induced accumulation of beta-catenin. *Oncogene*, **18**, 979–985.

20. Zeng,L., Fagotto,F., Zhang,T., Hsu,W., Vasicek,T.J., Perry,W.L.,3rd, Lee,J.J., Tilghman,S.M., Gumbiner,B.M. and Costantini,F. (1997) The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. *Cell*, **90**, 181–192.

21. Boutros,M., Mihaly,J., Bouwmeester,T. and Mlodzik,M. (2000) Signaling specificity by Frizzled receptors in *Drosophila. Science*, **288**, 1825–1828.

22. Axelrod,J.D., Miller,J.R., Shulman,J.M., Moon,R.T. and Perrimon,N. (1998) Differential recruitment of Dishevelled provides signaling specificity in the planar cell polarity and Wingless signaling pathways. *Genes Dev.*, **12**, 2610–2622.

23. Huber,O., Korn,R., McLaughlin,J., Ohsugi,M., Herrmann,B.G. and Kemler,R. (1996) Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. *Mech. Dev.*, **59**, 3–10.

24. Behrens,J., von Kries,J.P., Kuhl,M., Bruhn,L., Wedlich,D., Grosschedl,R. and Birchmeier,W. (1996) Functional interaction of beta-catenin with the transcription factor LEF-1. *Nature*, **382**, 638–642.

25. Molenaar,M., Roose,J., Peterson,J., Venanzi,S., Clevers,H. and Destree,O. (1998) Differential expression of the HMG box transcription factors XTcf-3 and XLef-1 during early *Xenopus* development. *Mech. Dev.*, **75**, 151–154.

26. Morin,P.J., Sparks,A.B., Korinek,V., Barker,N., Clevers,H., Vogelstein,B. and Kinzler,K.W. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. *Science*, **275**, 1787–1790.

27. Korinek,V., Barker,N., Morin,P.J., van Wichen,D., de Weger,R., Kinzler,K.W., Vogelstein,B. and Clevers,H. (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC–/– colon carcinoma. *Science*, **275**, 1784–1787.

28. He,T.C., Sparks,A.B., Rago,C., Hermeking,H., Zawel,L., da Costa,L.T., Morin,P.J., Vogelstein,B. and Kinzler,K.W. (1998) Identification of c-MYC as a target of the APC pathway. *Science*, **281**, 1509–1512.

29. Kioussi,C., Briata,P., Baek,S.H., Rose,D.W., Hamblet,N.S., Herman,T., Ohgi,K.A., Lin,C., Gleiberman,A., Wang,J. *et al.* (2002) Identification of a Wnt/Dvl/beta-catenin → Pitx2 pathway mediating cell-type-specific proliferation during development. *Cell*, **111**, 673–685.

30. Shtutman,M., Zhurinsky,J., Simcha,I., Albanese,C., D'Amico,M., Pestell,R. and Ben-Ze'ev,A. (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. *Proc. Natl Acad. Sci. USA*, **96**, 5522–5527.

31. Tetsu,O. and McCormick,F. (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature*, **398**, 422–426.

32. Fedi,P., Bafico,A., Nieto Soria,A., Burgess,W.H., Miki,T., Bottaro,D.P., Kraus,M.H. and Aaronson,S.A. (1999) Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. *J. Biol. Chem.*, **274**, 19465–19472.

33. Glinka,A., Wu,W., Delius,H., Monaghan,A.P., Blumenstock,C. and Niehrs,C. (1998) Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. *Nature*, **391**, 357–362.

34. Hsieh,J.C., Kodjabachian,L., Rebbert,M.L., Rattner,A., Smallwood,P.M., Samos,C.H., Nusse,R., Dawid,I.B. and Nathans,J. (1999) A new secreted protein that binds to Wnt proteins and inhibits their activities. *Nature*, **398**, 431–436.

35. Rattner,A., Hsieh,J.C., Smallwood,P.M., Gilbert,D.J., Copeland,N.G., Jenkins,N.A. and Nathans,J. (1997) A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. *Proc. Natl Acad. Sci. USA*, **94**, 2859–2863.

36. Leyns,L., Bouwmeester,T., Kim,S.H., Piccolo,S. and De Robertis,E.M. (1997) Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. *Cell*, **88**, 747–756.

37. Melkonyan,H.S., Chang,W.C., Shapiro,J.P., Mahadevappa,M., Fitzpatrick,P.A., Kiefer,M.C., Tomei,L.D. and Umansky,S.R. (1997) SARPs: a family of secreted apoptosis-related proteins. *Proc. Natl Acad. Sci. USA*, **94**, 13636–13641.

38. Rocheleau,C.E., Yasuda,J., Shin,T.H., Lin,R., Sawa,H., Okano,H., Priess,J.R., Davis,R.J. and Mello,C.C. (1999) WRM-1 activates the LIT-1 protein kinase to transduce anterior/posterior polarity signals in *C.elegans. Cell*, **97**, 717–726.

39. Ishitani,T., Ninomiya-Tsuji,J., Nagai,S., Nishita,M., Meneghini,M., Barker,N., Waterman,M., Bowerman,B., Clevers,H., Shibuya,H. *et al.* (1999) The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. *Nature*, **399**, 798–802.

40. Meneghini,M.D., Ishitani,T., Carter,J.C., Hisamoto,N., Ninomiya-Tsuji,J., Thorpe,C.J., Hamill,D.R., Matsumoto,K. and Bowerman,B. (1999) MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in *Caenorhabditis elegans. Nature*, **399**, 793–797.

41. Bauer,A., Chauvet,S., Huber,O., Usseglio,F., Rothbacher,U., Aragnol,D., Kemler,R. and Pradel,J. (2000) Pontin52 and reptin52 function as antagonistic regulators of beta-catenin signalling activity. *EMBO J.*, **19**, 6121–6130.

42. Barker,N., Hurlstone,A., Musisi,H., Miles,A., Bienz,M. and Clevers,H. (2001) The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. *EMBO J.*, **20**, 4935–4943.

43. Hecht,A., Vleminckx,K., Stemmler,M.P., van Roy,F. and Kemler,R. (2000) The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. *EMBO J.*, **19**, 1839–1850.

44. Kramps,T., Peter,O., Brunner,E., Nellen,D., Froesch,B., Chatterjee,S., Murone,M., Zullig,S. and Basler,K. (2002) Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. *Cell*, **109**, 47–60.

45. Parker,D.S., Jemison,J. and Cadigan,K.M. (2002) Pygopus, a nuclear PHD-finger protein required for Wingless signaling in *Drosophila*. *Development*, **129**, 2565–2576.

46. Zorn,A.M., Barish,G.D., Williams,B.O., Lavender,P., Klymkowsky,M.W. and Varmus,H.E. (1999) Regulation of Wnt signaling by Sox proteins: XSox17 alpha/beta and XSox3 physically interact with beta-catenin. *Mol. Cell*, **4**, 487–498.

47. Tago,K., Nakamura,T., Nishita,M., Hyodo,J., Nagai,S., Murata,Y., Adachi,S., Ohwada,S., Morishita,Y., Shibuya,H. *et al.* (2000) Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. *Genes Dev.*, **14**, 1741–1749.

48. Clevers,H. and van de Wetering,M. (1997) TCF/LEF factor earn their wings. *Trends Genet.*, **13**, 485–489.

49. Eastman,Q. and Grosschedl,R. (1999) Regulation of LEF-1/TCF transcription factors by Wnt and other signals. *Curr. Opin. Cell Biol.*, **11**, 233–240.

50. Roose,J., Molenaar,M., Peterson,J., Hurenkamp,J., Brantjes,H., Moerer,P., van de Wetering,M., Destree,O. and Clevers,H. (1998) The *Xenopus* Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. *Nature*, **395**, 608–612.

51. Chen,G., Fernandez,J., Mische,S. and Courey,A.J. (1999) A functional interaction between the histone deacetylase Rpd3 and the corepressor groucho in *Drosophila* development. *Genes Dev.*, **13**, 2218–2230.

52. Brantjes,H., Roose,J., van De Wetering,M. and Clevers,H. (2001) All Tcf HMG box transcription factors interact with Groucho-related co-repressors. *Nucleic Acids Res.*, **29**, 1410–1419.

53. van Genderen,C., Okamura,R.M., Farinas,I., Quo,R.G., Parslow,T.G., Bruhn,L. and Grosschedl,R. (1994) Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. *Genes Dev.*, **8**, 2691–2703.

54. Verbeek,S., Izon,D., Hofhuis,F., Robanus-Maandag,E., te Riele,H., van de Wetering,M., Oosterwegel,M., Wilson,A., MacDonald,H.R. and Clevers,H. (1995) An HMG-box-containing T-cell factor required for thymocyte differentiation. *Nature*, **374**, 70–74.

55. Korinek,V., Barker,N., Moerer,P., van Donselaar,E., Huls,G., Peters,P.J. and Clevers,H. (1998) Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. *Nature Genet.*, **19**, 379–383.

56. Yasumoto,K., Takeda,K., Saito,H., Watanabe,K., Takahashi,K. and Shibahara,S. (2002) Microphthalmia-associated transcription factor interacts with LEF-1, a mediator of Wnt signaling. *EMBO J.*, **21**, 2703–2714.

57. Bruhn,L., Munnerlyn,A. and Grosschedl,R. (1997) ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCRalpha enhancer function. *Genes Dev.*, **11**, 640–653.

58. Sachdev,S., Bruhn,L., Sieber,H., Pichler,A., Melchior,F. and Grosschedl,R. (2001) PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. *Genes Dev.*, **15**, 3088–3103.

59. Billin,A.N., Thirlwell,H. and Ayer,D.E. (2000) Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. *Mol. Cell. Biol.*, **20**, 6882–6890.

60. Lee,E., Salic,A. and Kirschner,M.W. (2001) Physiological regulation of [beta]-catenin stability by Tcf3 and CK1epsilon. *J. Cell Biol.*, **154**, 983–993.

61. Brannon,M., Brown,J.D., Bates,R., Kimelman,D. and Moon,R.T. (1999) XCtBP is a XTcf-3 co-repressor with roles throughout *Xenopus* development. *Development*, **126**, 3159–3170.

62. Hecht,A. and Stemmler,M.P. (2002) Identification of a promoter-specific transcriptional activation domain at the C-terminus of the Wnt-effector protein TCF4. *J. Biol. Chem.*, **22**, 22.

63. Hovanes,K., Li,T.W., Munguia,J.E., Truong,T., Milovanovic,T., Lawrence Marsh,J., Holcombe,R.F. and Waterman,M.L. (2001) Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. *Nature Genet.*, **28**, 53–57.

64. Roose,J., Huls,G., van Beest,M., Moerer,P., van der Horn,K., Goldschmeding,R., Logtenberg,T. and Clevers,H. (1999) Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. *Science*, **285**, 1923–1926.

65. Gradl,D., Konig,A. and Wedlich,D. (2002) Functional diversity of *Xenopus* lymphoid enhancer factor/T-cell factor transcription factors relies on combinations of activating and repressing elements. *J. Biol. Chem.*, **277**, 14159–14171.

66. Hoshimaru,M., Ray,J., Sah,D.W. and Gage,F.H. (1996) Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myc oncogene. *Proc. Natl Acad. Sci. USA*, **93**, 1518–1523.

67. Dignam,J.D., Lebovitz,R.M. and Roeder,R.G. (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. *Nucleic Acids Res.*, **11**, 1475–1489.

68. Chomczynski,P. and Sacchi,N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.*, **162**, 156–159.

69. Vandesompele,J., De Preter,K., Pattyn,F., Poppe,B., Van Roy,N., De Paepe,A. and Speleman,F. (2002) Accurate normalization of real-time quantitative RT–PCR data by geometric averaging of multiple internal control genes. *Genome Biol.*, **3**, RESEARCH0034.

70. Boyd,J.M., Subramanian,T., Schaeper,U., La Regina,M., Bayley,S. and Chinnadurai,G. (1993) A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. *EMBO J.*, **12**, 469–478.

71. Katsanis,N. and Fisher,E.M. (1998) A novel C-terminal binding protein (CTBP2) is closely related to CTBP1, an adenovirus E1A-binding protein, and maps to human chromosome 21q21.3. *Genomics*, **47**, 294–299.

72. Chinnadurai,G. (2002) CtBP, an unconventional transcriptional corepressor in development and oncogenesis. *Mol. Cell*, **9**, 213–224.

73. Korinek,V., Barker,N., Willert,K., Molenaar,M., Roose,J., Wagenaar,G., Markman,M., Lamers,W., Destree,O. and Clevers,H. (1998) Two members of the Tcf family implicated in Wnt/beta-catenin signaling during embryogenesis in the mouse. *Mol. Cell. Biol.*, **18**, 1248–1256.

74. Van de Wetering,M., Castrop,J., Korinek,V. and Clevers,H. (1996) Extensive alternative splicing and dual promoter usage generate Tcf-1 protein isoforms with differential transcription control properties. *Mol. Cell. Biol.*, **16**, 745–752.

75. Koipally,J. and Georgopoulos,K. (2000) Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity. *J. Biol. Chem.*, **275**, 19594–19602.

76. Leung,J.Y., Kolligs,F.T., Wu,R., Zhai,Y., Kuick,R., Hanash,S., Cho,K.R. and Fearon,E.R. (2002) Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. *J. Biol. Chem.*, **277**, 21657–21665.

77. Lustig,B., Jerchow,B., Sachs,M., Weiler,S., Pietsch,T., Karsten,U., van de Wetering,M., Clevers,H., Schlag,P.M., Birchmeier,W. *et al.* (2002) Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. *Mol. Cell. Biol.*, **22**, 1184–1193.

78. Hildebrand,J.D. and Soriano,P. (2002) Overlapping and unique roles for C-terminal binding protein 1 (CtBP1) and CtBP2 during mouse development. *Mol. Cell. Biol.*, **22**, 5296–5307.

79. Porfiri,E., Rubinfeld,B., Albert,I., Hovanes,K., Waterman,M. and Polakis,P. (1997) Induction of a beta-catenin-LEF-1 complex by wnt-1 and transforming mutants of beta-catenin. *Oncogene*, **15**, 2833–2839.

80. Pukrop,T., Gradl,D., Henningfeld,K.A., Knochel,W., Wedlich,D. and Kuhl,M. (2001) Identification of two regulatory elements within the high mobility group box transcription factor XTCF-4. *J. Biol. Chem.*, **276**, 8968–8978.

81. Zhang,H., Levine,M. and Ashe,H.L. (2001) Brinker is a sequence-specific transcriptional repressor in the *Drosophila* embryo. *Genes Dev.*, **15**, 261–266.

82. Poortinga,G., Watanabe,M. and Parkhurst,S.M. (1998) *Drosophila* CtBP: a Hairy-interacting protein required for embryonic segmentation and hairy-mediated transcriptional repression. *EMBO J.*, **17**, 2067–2078.

83. Sundqvist,A., Sollerbrant,K. and Svensson,C. (1998) The carboxy-terminal region of adenovirus E1A activates transcription through targeting of a C-terminal binding protein-histone deacetylase complex. *FEBS Lett.*, **429**, 183–188.

84. Kumar,V., Carlson,J.E., Ohgi,K.A., Edwards,T.A., Rose,D.W., Escalante,C.R., Rosenfeld,M.G. and Aggarwal,A.K. (2002) Transcription corepressor CtBP is an NAD(+)-regulated dehydrogenase. *Mol. Cell*, **10**, 857–869.

85. Zhang,Q., Piston,D.W. and Goodman,R.H. (2002) Regulation of corepressor function by nuclear NADH. *Science*, **295**, 1895–1897.

Wnt-1 upregulates Wnt-targets *Cyclin D1*, *Lef-1* and *Tcf-1* mRNA in 293 cells

A, Results of quantitative real-time PCR performed with cDNA generated from 293 cells stimulated by feeder cells stably producing Wnt-1 protein (Rat2-Wnt-1/Const) or by control Rat2 cells are shown. The 293 and feeder cells were co-cultivated for the indicated period of time, then harvested, and random primed cDNA was prepared from total RNA.

B, CtBP1 overexpression has no obvious effect on the levels of *Cyclin-1*, *Lef-1*, *Tcf-1*, *CtBP1,* and *CtBP2* RNA in Wnt-1-stimulated 293 cells. 293-EGFP-CtBP1/Dox cells were co-cultivated with Rat2-Wnt-1/Const or control Rat2 fibroblasts as a negative control for 15 hours in the presence (EGFP-CtBP1 repressed) or absence (EGFP-CtBP1 over-expressed) of Doxycycline (1 µg/ml). The random primed cDNAs generated from the relevant RNAs were analysed.   The picture shows the relative abundance of *Cyclin D1, Lef-1*, *Tcf-1*, *CtBP1* and *CtBP2* mRNAs in Wnt-1-stimulated 293-EGFP-CtBP1/Dox cells versus control 293-EGFP-CtBP1/Dox in two situations: (1) when EGFP-CtBP1 is expressed (-Dox) or (2) repressed (+Dox).

The results were analyzed using the LightCycler 5.1 software package, and the values of a representative experiment are shown. The relative abundance of *Cyclin-1*, *Lef-1*, *Tcf-1*, *CtBP1* and *CtBP2* mRNA in Wnt-1-stimulated   versus control cells was derived from the average CT values of each triplicate after normalizing to the levels of *SDHA* cDNA.

Figure 6 -supplementary data

3.2 HIC1 snižuje aktivitu signalizace Wnt prostřednictvím strhávání TCF-4 a β-kateninu do jaderných tělísek

Několik prací publikovaných v posledních letech ukázalo, že represivní aktivita zprostředkovaná proteiny CtBP1 a CtBP2 může být výrazně ovlivněna změnami v jejich vnitrobuněčné lokalizaci. Proteiny CtBP se mohou nacházet jak v cytoplazmě, tak v buněčném jádře, kde se podílejí na represi transkripce. Vliv na lokalizaci těchto proteinů mohou mít proteinové modifikace. Zatímco fosforylace prostřednictvím Pak1 kinázy relokuje CtBP1 do cytoplazmy, sumoylace je určující pro jadernou lokalizaci CtBP1 [205-207]. Distribuce CtBP může být rovněž ovlivněna přímou interakcí s proteiny schopnými vázat CtBP. Protein nNOS zadržuje CtBP1 v cytoplazmě, naproti tomu protein HIC1 relokuje CtBP1 do specifických jaderných tělísek (Hic1 bodies) [208, 209]. Přepokládali jsme, že změny v lokalizaci proteinu CtBP1 by mohly ovlivňovat jeho represivní aktivitu na transkripci mediovanou TCF-4/β-kateninem. Proto jsme se v následující práci zaměřili na působení proteinu HIC1.

HIC1 (Hypermethylated In Cancer 1) byl identifikován jako potenciální nádorový supresor, jehož gen je často epigeneticky inaktivován prostřednictvím methylace promotorové oblasti, a to v řadě různých typů nádorů. [210]. Gen *HIC1* kóduje transkripční faktor ze skupiny proteinů BTB/POZ (Broad-complex, Tramtrack, Bric à brac/Poxvirus, and Zinc finger). Protein HIC obsahuje na svém N-konci doménu BTB/POZ, která je zodpovědná za multimerizaci a interakce s ostaními proteiny. Multimerizce proteinu HIC1 se projevuje morfologicky v podobě specifických distinktních jaderných struktur. V centrální části proteinu HIC1 je lokalizován specifický motiv GLDLSKK, jenž zprostředkovává vazbu s proteiny CtBP. C-konec obsahuje několik DNA-vazebných motivů typu "Zn-finger" . [209, 211, 212]. Experimenty s aberantní inaktivací genu *HIC1* u myší potvrdily jeho roli jako buněčného tumorového supresoru. Zatímco myši *Hic1*[-/-] umírají v průběhu embryonálního vývoje nebo perinatálně, tak u heterozygotů *Hic1*[+/-] se v dospělosti objevuje řada maligních spontánních tumorů, které jsou pohlavně specifické. Pro tyto tumory je charakteristická silná methylace zbývající alely *Hic1*, která vede k úplné absenci exprese *HIC1* v těchto nádorech. [213]. Gen *HIC1* je lokalizován v oblasti chromozomu 17p13.3, která je často deletována u pacientů s Miller-Diekerovým syndromem. K projevům tohoto syndromu patří řada mozkových a obličejových defektů, které jsou prakticky totožné s defekty u myší *Hic1*[-/-] [214]. Aktivita proteinu HIC1 je spojena s aktivitou jiného tumor supresoru – p53. HIC1 tvoří transkripčně represivní

komplex s histon deacetylázou SIRT1, který reprimuje transkripci genu *SIRT1*. V normálních buňkách je tak hladina proteinu SIRT1 udržována na nízké úrovni. V řadě nádorů, u nichž je gen *HIC1* epigeneticky inaktivován, je naopak úroveň exprese *SIRT1* zvýšená. Deacetyláza SIRT1 je schopna deacetylovat tumor supresor p53 a způsobuje tak jeho inaktivaci. V normálních buňkách je navíc protein p53 schopen stimulovat expresi *HIC1*. Vztah mezi p53 a HIC1 je tedy typickým příkladem autoregulační smyčky. [215-218].

V naší práci jsme potvrdili, že HIC1 je schopen relokovat CtBP1 do specifických nukleárních struktur. V případě koexprese *HIC1* a *CtBP1* současně s *TCF-4*, dochází ke změně lokalizace TCF-4 a transkripční faktor TCF-4 je rovněž relokován do jaderných tělísek. HIC1 je schopen změnit lokalizaci TCF-4 v buněčném jádře nezávisle na CtBP1, jak jsme ukázali v buňkách CtBP(-/-), které mají prostřednictvím rekombinace inaktivovány geny *CtBP1* a *CtBP2*. K podobnému závěru vedly experimenty založené na expresi různých mutantních forem *TCF-4* a *HIC1*. Protein CtBP1 má ovšem v procesu relokace TCF-4 důležitou strukturní roli a je významný pro efektivitu této relokace. V buňkách, v nichž je *CtBP1* expremován, způsobuje HIC1 takřka úplnou relokaci TCF-4, na rozdíl od buněk CtBP(-/-), kde je relokována jen určitá část TCF-4.

Protein HIC1 přímo interaguje s TCF-4 a to jak *in vitro* tak *in vivo*. Koimunoprecipitace provedená z extraktů buněk CtBP(-/-) navíc potvrdila, že zprostředkující role CtBP pro interakci mezi HIC1 a TCF-4 není v buňkách nutná.

HIC1 výrazným způsobem redukuje úroveň transkripce mediované komplexy Tcf/β-katenin. Represivní aktivita HIC1 byla prokázána pomocí dvou různých luciferázových reportérů obsahujících buď syntetický Lef/Tcf responsibilní promotor, nebo promotor genu *Axin2*, který je cílovým genem signalizace Wnt. V několika buněčných liniích jsme prokázali schopnost nádorového supresoru HIC1 blokovat transkripci cílových genů signalizace Wnt. Potvrzením represivní funkce HIC1 byly rovněž výsledky experimentů založených na nefyziologickém snížení exprese HIC1 pomocí RNA-interference v primárních (nenádorových) buněčných liniích. Tyto buňky přirozeně exprimují HIC1 a ten je, stejně jako v případě nefyziologicky exprimovaného proteinu, lokalizován ve specifických nukleárních strukturách. Snížení exprese HIC1 vede nejen k vymizení těchto struktur z buněčného jádra, ale zvyšuje transkripční aktivitu Tcf-specifického genu *Axin2* u buněk stimulovaných ligandem Wnt3a. Při studiu exprese cílových genů signalizace Wnt jsme potvrdili, že jejich exprese je silně závislá na buněčném typu. Pokud byly buňky stimulovány ligandem Wnt3a, pak došlo u buněk HEK293 k aktivaci transkripce genů *Sp5*,

Axin2 a *CyklinD1*. Stejný typ aktivace vedl naproti tomu u primárních buněk pouze k transkripci genu *Axin2*.

HIC1 by mohl inhibovat transkripci tak, že by svojí interakcí s TCF-4 bránil vazbě β-kateninu na transkripční faktor TCF-4, a tím by blokoval tvorbu transkripčně aktivních heterokomplexů TCF-4/β-katenin. Jak jsme ukázali v případě buněk DLD-1, u kterých je díky mutaci proteinu APC signalizace Wnt konstitutivně aktivní, HIC1 tímto způsobem transkripci nereprimuje. Pokud je HIC1 v těchto buňkách exprimován, je lokalizován v komplexu společně s TCF-4 a β-kateninem. Přesto v těchto buňkách HIC1 účinně inhibuje transkripci Wnt-specifického genu *Tenascin C*. Jiným možným způsobem působení represoru HIC1 by mohla být jeho přímá represivní aktivita na promotorech cílových genů Wnt-signalizace. HIC1 je schopen přímo inhibovat transkripci, jak bylo ukázáno v případě genu *SIRT1*. Je rovněž známo, že jiný člen rodiny transkripčních faktorů BTB/POZ protein Kaiso interaguje přímo se sekvenčně specifickými elementy cílových genů signalizace Wnt. Chromatinová imunoprecipitace ovšem ukázala, že protein HIC1 není přímo ani nepřímo (tzn. prostřednictvím TCF-4) asociován s promotorovými oblastmi Wnt-specifických genů. Na druhou stranu pokud je v buňkách DLD-1 exprimován HIC1 dochází k výrazné redukci v množství β-kateninu a TCF-4, které jsou asociovány s promotorem Wnt-specifického genu *TenascinC*. Podobné výsledky jsme získali v případě genu *Sp5* u buněk HEK293 v nichž byl ektopicky exprimován HIC1 a β-katenin.

Mechanismus represivního působení tumor supresoru HIC1 na transkripci Wnt-specifických genů je tedy pravděpodobně založený na relokaci komplexů Tcf/β-katenin do již zmíněných specifických nukleárních struktur, které jsou prostorově a funkčně vzdálené od míst, kde dochází k transkripci Wnt-specifických genů. Tato relokace je umožněna přímou interakcí mezi proteiny HIC1 a TCF-4. β-katenin je mimo specifické promotorové oblasti relokován pravděpodobně prostřednictvím TCF-4, ačkoliv se nedá vyloučit existence zatím neznámého faktoru, který by tento proces medioval nezávisle na TCF-4. Strukturní funkce proteinu CtBP může zvýšit efektivitu této relokace, a tím také efektivitu transkripční represe způsobenou proteinem HIC1.

Vzájemná interakce mezi efektory signalizace Wnt a proteinem HIC1 může být významná v procesu nádorové transformace. Epigenetická inaktivace genu *HIC1* v buňkách s nefyziologicky aktivovanou Wnt-signalizací může přispět spolu se ztrátou aktivity tumor supresoru p53 ke vzniku nádorů.

HIC1 attenuates Wnt signaling by recruitment of TCF-4 and β-catenin to the nuclear bodies

Tomas Valenta, Jan Lukas, Lenka Doubravska, Bohumil Fafilek and Vladimir Korinek*

Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic

The hypermethylated in cancer 1 (*HIC1*) gene is epigenetically inactivated in cancer, and in addition, the haploinsufficiency of *HIC1* is linked to the development of human Miller–Dieker syndrome. *HIC1* encodes a zinc-finger transcription factor that acts as a transcriptional repressor. Additionally, the HIC1 protein oligomerizes via the N-terminal BTB/POZ domain and forms discrete nuclear structures known as HIC1 bodies. Here, we provide evidence that HIC1 antagonizes the TCF/β-catenin-mediated transcription in Wnt-stimulated cells. This appears to be due to the ability of HIC1 to associate with TCF-4 and to recruit TCF-4 and β-catenin to the HIC1 bodies. As a result of the recruitment, both proteins are prevented from association with the TCF-binding elements of the Wnt-responsive genes. These data indicate that the intracellular amounts of HIC1 protein can modulate the level of the transcriptional stimulation of the genes regulated by canonical Wnt/β-catenin signaling.

Introduction

The Wnt signaling pathway plays essential roles in different developmental processes, including cell determination, stem cell survival and organogenesis. In addition, mutational activation of this pathway is implicated in deregulated cell growth and cancerogenesis (reviewed in Logan and Nusse, 2004; Reya and Clevers, 2005). The stabilization of β-catenin is central to the canonical Wnt pathway. In the absence of Wnt signals, β-catenin is phoshorylated by a complex of proteins, including adenomatous polyposis coli (APC), glycogen synthase kinase-3β and axin. Phosphorylation of β-catenin results in its ubiquitylation and degradation by the proteasome. Wnt factors inhibit the APC complex. The result of such inhibition is the stabilization of β-catenin, which accumulates in the cell and translocates into the nucleus where it associates with transcription factors of the

*Corresponding author. Institute of Molecular Genetics AS CR, Videnska 1083, 142 20 Prague 4, Czech Republic. Tel.: +4202 41062471; Fax: +4202 44472282; E-mail: korinek@biomed.cas.cz

TCF/LEF family. TCF/LEF proteins function as nuclear effectors of the Wnt signaling pathway. The DNA-binding specificity of these polypeptides is defined by the HMG box, an 80 amino-acid domain whose primary sequence is virtually identical in all TCF/LEF family members (reviewed in Clevers and van de Wetering 1997). TCF/LEF factors possess only a limited ability to activate transcription. They act as 'connectors' linking other polypeptides to a distinct set of promoters. β-Catenin contains a strong transcription activation domain, thus its interaction with TCFs results in transcription of the Wnt-responsive genes. Many of these genes execute Wnt-mediated cell specification during development or regulate cell proliferation (for more detailed information, refer to the Wnt homepage http://www.stanford.edu/~rnusse/wntwindow.html). In contrast, mammalian TCFs also bind to TLE/Groucho corepressors and, in the absence of the Wnt signal, repress the transcription of TCF-specific promoters (Roose *et al*, 1998). Additionally, two TCF/LEF family members, TCF-3 and TCF-4, associate with C-terminal binding proteins (CtBPs) (Brannon *et al*, 1999; Valenta *et al*, 2003).

The CtBP proteins bind to a short sequence motif PLDLS conserved among the E1A proteins of all human and primate adenoviruses. Different variants of this motif are also present in many other CtBP-interacting partners that function mainly as sequence-specific DNA-binding transcription factors.

In this study, we focused on one of the CtBP-associating proteins, hypermethylated in cancer 1 (HIC1), which redirects CtBP to a specific set of nuclear dot-like structures called HIC1 bodies (Deltour *et al*, 2002). The *HIC1* gene was identified as a candidate tumor suppressor gene frequently epigenetically silenced or deleted in different types of solid tumors (Herman and Baylin, 2003). *HIC1* encodes a zinc-finger transcription factor that belongs to a group of proteins known as the BTB/POZ family (Broad-Complex, Tramtrack, Bric à brac/poxvirus, and zinc finger) (reviewed in Albagli *et al*, 1995). A 714 amino-acid human HIC1 polypeptide contains the N-terminal BTB/POZ domain involved in dimerization and in protein–protein interactions. The C-terminal region interacts with a specific DNA sequence; the GLDLSKK motif responsible for the interaction with the CtBP proteins is located in the central part. Gene inactivation experiments in mice recently confirmed that HIC1 is a genuine tumor suppressor. Heterozygous $Hic1^{+/-}$ mice develop malignant spontaneous tumors after a year of life (Chen *et al*, 2003, 2004). These tumors show dense methylation of the remaining wild-type *Hic1* allele promoter accompanied by a complete absence of *Hic1* expression in the cancer tissue. *HIC1* gene resides within a 350 kb region on chromosome 17p13.3, deleted in most patients with Miller–Dieker syndrome (MDS) (Dobyns and Truwit, 1995). This links (in addition to tumorigenesis) the haploinsufficiency of *HIC1* to the development of MDS.

In the present study, we show specific binding between HIC1 and a principal Wnt signaling pathway component, TCF-4. We further demonstrate that overexpression of HIC1

suppresses the TCF-mediated transcription, and *vice versa*, the inactivation of endogenous HIC1 by RNA interference (RNAi) increases the basal expression of the *Axin2* gene and elevates the transcriptional response of this Wnt signaling target to Wnt stimulation. A deletion mutant of HIC1 lacking the oligomerization BTB/POZ domain can neither form the nuclear bodies, nor antagonize Wnt signaling, nor interact with TCF-4 *in vivo*. This clearly indicates that the HIC1 inhibitory function depends on the ability to form nuclear bodies and to recruit TCF-4 into these structures. Interestingly, β-catenin is also relocated by HIC1, but this sequestration seems to be indirect and mediated via its interaction with TCF-4. In addition, we provide evidence that CtBP1 increases the efficiency of recruitment of the TCF-4 into the HIC1 bodies and further strengthens the suppressive effect of the HIC1 protein on Wnt signaling. Finally, using chromatin immunoprecipitation (ChIP), we show that as a consequence of the relocation into the HIC1 speckles, TCF-4 and β-catenin are prevented from binding to the promoters of the TCF-responsive genes.

Results

HIC1 sequesters TCF-4 into nuclear bodies

Exogenous CtBP1 is distributed in the cytoplasm and in the nucleus in a mostly diffused pattern. Only a fraction of nuclear CtBP1 is localized into distinct structures, described previously as CtBP bodies (Sewalt *et al*, 1999). Cotransfection of the full-length HIC1 construct results in complete relocation of CtBP1 into the nuclear HIC1 bodies (Figure 1B). This relocation is dependent on the direct interaction between HIC1 and CtBP1, as the HIC1-ΔCtBP polypeptide lacking the CtBP-interacting motif loses the translocative properties of the wild-type HIC1 protein. The HIC1 mutant with a deletion encompassing the N-terminal oligomerization BTB/POZ domain still preserved the ability to 'pull' CtBP1 into the nucleus. However, the localization of both proteins was diffuse and no formation of nuclear punctuated structures was observed.

Previously, we have shown an interaction between CtBP1 and TCF-4 in yeast and *in vitro* (Valenta *et al*, 2003). However, we and others in following studies were unable to detect the association of these proteins in mammalian cells. We took advantage of the clear nuclear targeting of CtBP1 by HIC1 and visualized TCF-4 and CtBP1 using confocal microscopy.

In CtBP-positive COS-7 cells, TCF-4 was efficiently sequestered into the HIC1 bodies (Figure 2B). Triple staining and the overlay of the images showed that in these bodies TCF-4, HIC1 and CtBP1 co-localized. CtBP interacts with both, TCF-4 and HIC1 proteins, thus we supposed that the TCF-4 recruitment was mediated by CtBP. As expected, mutated TCF-4 (TCF-4mutCtBP), which is unable to bind CtBP, was not sequestered into the HIC1 bodies even in the *CtBP1* background (Figure 2C). Surprisingly, in *CtBP(−/−)* cells (these cells were derived from *CtBP1⁻/⁻CtBP2⁻/⁻* embryos (Hildebrand and Soriano, 2002)), wild-type HIC1 and TCF-4 still partially colocalized in the nuclear dots. We examined next, whether variants of HIC1 differ in their ability to concentrate TCF-4 into the HIC1 bodies in *CtBP1(+)* cells. Whereas wild-type proteins perfectly colocalized in nuclear dots, the HIC1-ΔCtBP mutant displayed only limited capability to sequester nuclear TCF-4.

Figure 1 HIC1 targets CtBP into the nuclear bodies. (**A**) A schematic representation of the human HIC1 constructs used in this study. tag, Flag or EGFP tag; BTB/POZ, the BTB/POZ domain; CtBP, CtBP-binding site; ZF, five C_2H_2 Krüppel-like zinc fingers. Right, Western blots of total cell extracts after transfection with the Flag-HIC1 constructs, probed with anti-Flag or with anti-α-tubulin as internal control. (**B**) Confocal microscopy images of *CtBP(−/−)* cells trasfected with constructs indicated on the left and subsequently stained with mouse anti-Flag and rabbit anti-CtBP antibody. The DRAQ5 nuclear stain was gained in the blue channel. Mutant HIC1-ΔCtBP polypeptide lacking the CtBP-interacting motif displays the punctuated expression of the wild-type HIC1 protein (compare (e) and (i)) but does not influence the distribution of CtBP (compare (b) and (j)). As seen in (j, k), a fraction of nuclear CtBP is still localized in the CtBP bodies (arrows in insets (c, k)), which evidently differ from the HIC1 bodies. Bar, 10 μm.

Taken together, these results suggested that TCF-4 and HIC1 could form nuclear aggregates even in the absence of CtBP; nevertheless, CtBP mediates more efficient recruitment of TCF-4 into the HIC1 bodies.

TCF-4 binds directly to HIC1

The existence of HIC1/TCF-4 complexes in mammalian cells was evidenced using co-immunoprecipitation of HIC1 with endogenous TCF-4. By using anti-TCF-4 antibody, a robust coisolation of TCF-4 with wild-type HIC1, and with HIC1-ΔCtBP, was obtained from lysates of human 293 cells; the truncated HIC1-ΔPOZ protein did not co-immunoprecipitate with TCF-4 (Figure 3A). TCF-4 was also isolated from the Flag-tagged HIC1 using anti-Flag or anti-HIC1 antibodies. Furthermore, we immunoprecipitated the endogenous HIC1/TCF-4 complexes from whole-cell lysates prepared from mouse embryos on day 12.5 p.c. We also performed coimmunoprecipitation experiments in mouse *CtBP(−/−)*

Figure 2 TCF-4 and HIC1 form nuclear protein complexes in mammalian cells. (**A**) TCF-4 expression constructs. The TCF-4mutCtBP polypeptide has a triple amino-acid substitution of each CtBP-binding motif as indicated. tag, myc or EGFP tag; β-cat, β-catenin interaction domain; TLE/Groucho, TLE/Groucho binding domain; CtBP, CtBP binding sites; HMG, DNA-binding domain. Right, Western blots of total cell extracts after transfection with the indicated TCF-4 constructs, probed with anti-TCF-4 or with anti-α-tubulin. (**B**) CtBP, HIC1 and TCF-4 colocalize in COS-7 cells. (**C**) Simultaneous interaction between CtBP, TCF-4 and HIC1 is essential for the efficient nuclear sequestration of TCF-4 into the HIC1 bodies. Confocal microscopy images of *CtBP(−/−)* and *CtBP1(+)* cells transfected with the indicated constructs (left) and stained with anti-Flag and anti-TCF-4 antibody. The right panel shows the overlap of fluorescence intensity peaks along profiles as indicated in the merged micrographs. The nuclear sequestration of TCF-4 by HIC1 is less efficient in *CtBP(−/−)* than in *CtBP(+)* cells (compare (e, f, g, h) to (i, j, k, l)). The formation of the TCF-4/HIC1 bodies in *CtBP(+)* cells strictly depends on the presence of the intact CtBP-binding sites in TCF-4 (m, n, o, p). Notice only a partial colocalization of TCF-4 and HIC1-ΔCtBP (q, r, s, t). Bar, 10 μm.

and *CtBP1(+)* cells, and we detected association of EGFP-tagged HIC1 and TCF-4 in both *CtBP*-negative and *CtBP1*-positive cells. The coimmunoprecipitation was specific for HIC1, because a parallel assay did not show any binding of a control, EGFP-nls protein to TCF-4 (Figure 3B, only results from *CtBP(−/−)* cells are shown). These results implied a direct interaction between TCF-4 and HIC1.

The direct binding between TCF-4 and HIC1 was studied *in vitro* by pull-down assays between bacterially expressed GST-tagged TCF-4 and *in vitro* translated HIC1. GST-TCF-4 associated only with *in vitro* translated full-length HIC1 and not with the N-terminally truncated HIC1-ΔPOZ (Figure 4B).

As was shown by others, the deletion of the BTB/POZ domain involved in the homo- and heteromeric interactions often prevents the association of HIC1 with other partners, although this domain is not directly included in the protein–protein interaction (Deltour *et al*, 2002). Due to extensive degradation of GST-HIC1 in bacterial lysates, we could not test the binding of the full-length HIC1 immobilized on the glutathione-Sepharose beads to *in vitro* translated TCF-4. Nevertheless, we prepared GST-fusion proteins containing partly overlapping N-terminal, internal, and C-terminal HIC1 fragments (Figure 4A), and used these more stable proteins in pull-down assays. As shown in Figure 4B, all three

Figure 3 Association between TCF-4 and HIC1 *in vivo*. (**A**) Left, coimmunoprecipitations between endogenous TCF-4 and various exogenous HIC1 proteins in human 293 cells. Right, coimmunoprecipitations of endogenous HIC1 and TCF-4 in cells derived from mouse embryos on day 12.5 p.c. IP, immunoprecipitation; IB, immunoblotting; in lanes denoted 'lysate' five percent of the total sample were loaded. (**B**) TCF-4 associates with HIC1 in *CtBP(−/−)* cells. Coimmunoprecipitation of endogenous TCF-4 with EGFP-HIC1 is specific for HIC1 as evidenced by no detectable interaction between TCF-4 and EGFP-nls in a control experiment (right).

GST-HIC proteins interacted with full-length TCF-4; however, the strongest interacting domain was localized in the internal and C-terminal region of HIC1. Importantly, TCF-4mutCtBP binds to GST-HIC1 proteins equally well as the wild-type protein. Two nonoverlapping TCF-4 fragments were used to delineate domains involved in binding to HIC1. Whereas the C-terminus of TCF-4 interacted strongly with the GST-linked C-terminal part and the HIC1 internal fragments, a substantially less avid interaction was observed between the TCF-4 C-terminus and the GST-HIC1 N-terminus. Finally, the N-terminal part of TCF-4 did not show any affinity to HIC1. TCF-4 and HIC1 bind specific DNA sequences and their interaction domains were mapped in part to the DNA-binding regions of these proteins. To exclude the possibility that the association between TCF-4 and HIC1 is indirect and might be mediated by a DNA bridge from contaminating DNA, we performed a GST-pull-down with translated HIC1-mutZF3 protein containing a single amino acid exchange in the third zinc finger (Figure 4A). This mutation abolishes the DNA binding of the mutated protein to its recognition motif (Pinte *et al*, 2004). We also treated translated TCF-4 and glutathione-Sepharose bound GST-HIC1 with DNase I prior to the pull-down. As shown in Figure 4C, the HIC1-ZF3 associates with GST-TCF-4 with a comparable avidity to the wild-type protein and, moreover, the DNase I treatment even slightly improved *in vitro* binding of TCF-4 and HIC1.

Altogether, the data reported here indicated that HIC1 interacts directly with TCF-4 in a complex multidomain mode of interaction. These data also implied that this interaction is not dependent on the presence of the intact CtBP-binding sites in TCF-4.

HIC1 inhibits TCF/β-catenin-driven transcription

To examine whether HIC1-mediated sequestration of TCF-4 affects the Wnt-dependent transcription, pTOPFLASH was cotransfected with each of the HIC1 constructs into 293 cells, the cells were subsequently stimulated by the Wnt ligand and the levels of the TCF-mediated transcription were determined. In 293 cells, Wnt3a-containing medium induced robust 25-five fold activation of the Tcf reporter pTOPFLASH as compared to the control medium (Figure 5). The cotransfection of wild-type HIC1 resulted in a substantial decrease of the pTOPFLASH activity, the HIC1-ΔCtBP was less than half as effective as wild-type HIC1, and finally, the HIC1-ΔPOZ mutant appeared to be completely inefficient in the downregulation of the pTOPFLASH-driven transcription. We did not observe any effect whatsoever on the pTOPFLASH reporter in the nonstimulated cells. Nevertheless, HIC1 repressed the Wnt-induced transcription of a luciferase reporter containing a 5 kb promoter region of the well-established Wnt target *Axin2* gene (Figure 5) (Jho *et al*, 2002). Conversely, the HIC1 overexpression did not disturb the transcription from the negative-control reporter pFOPFLASH, or from the synthetic reporter G1E1B-Luc activated by Gal4-DBD-VP16 fusion protein (data not shown).

HIC1 contains five Krüppel-like C_2H_2 zinc fingers in its C-terminal part. Recently, Pinte *et al* (2004) investigated the DNA binding properties of the isolated zinc finger domain and defined a specific DNA motif recognized by HIC1. Full-length HIC1 binds probes with a single recognition site poorly; however, the wild-type protein interacts cooperatively with complex probes containing multiple HIC1-specific

Figure 4 *In vitro* interaction of TCF-4 and HIC1. (**A**) Structures of HIC1 and TCF-4 proteins used in the *in vitro* pull-down assays (see also the diagrams of the additional HIC1 and TCF-4 constructs depicted in Figures 1A and 2A). (**B**) Pull-down assays between bacterially expressed GST-fusion and *in vitro* translated proteins, as indicated. Ten percent of the total reactions were loaded in lanes denoted 'input'. (**C**) Right, TCF-4/HIC1 interaction is resistant to DNase I treatment; left, the intact DNA-binding domain of HIC1 is not essential for the interaction with TCF-4.

sequences. In contrast, the N-terminally truncated HIC1-ΔPOZ, lacking the BTB/POZ domain, interacts preferentially with a probe containing a single HIC1-binding site. We performed an electrophoretic mobility-shift assay (EMSA) with *in vitro* translated TCF-4 and HIC1. HIC1-ΔPOZ, and with a lower efficiency, full-length HIC1, bound to a simple HIC1-specific probe, but these proteins did not interact directly with probes containing single or multiple TCF recognition motifs (Supplementary Figure 1).

The inhibitory effect of HIC1 on the transcriptional activation of pTOPFLASH was also found in DLD-1 cells, that is, cells with a mutant *APC* gene. The lack of functional APC protein in these adenocarcinoma cells results in the accumulation of β-catenin and in constitutive activation of the TCF-dependent target genes (van de Wetering *et al*, 2002; Rosin-Arbesfeld *et al*, 2003). By retroviral transduction, we generated DLD/HIC1 cells containing the *HIC1-EGFP* regulated by AP21967, a synthetic dimerizer (Ariad). We

examined the levels of the TCF/β-catenin-dependent transcription simultaneously in three independent DLD/HIC1 cell lines at three different levels of HIC1-EGFP expression (dimerizer concentrations: 0, 0.25 and 25 nM). The result of a representative experiment is shown in Figure 6A. At maximum induction when HIC1 was produced in amounts comparable to the physiological levels of endogenous HIC1 in primary human WI38 cells (Figure 9C), the pTOPFLASH activity decreased to approximately 40% when compared to the DLD/HIC1 cells growing without the inducer (Figure 6A). Transcription from the negative control reporter pFOPFLASH did not change during the experiment. Since DLD-1 cells express high amounts of both TCF-4 and β-catenin (Korinek *et al*, 1997), we asked first whether HIC1 can function by decreasing the intracellular levels of β-catenin and/or TCF-4. Using anti-TCF-4 and β-catenin antibodies, we performed immunoblotting of cell lysates prepared from DLD/HIC1 growing with dimerizer for 5 days or without HIC1 induction.

Figure 5 HIC1 represses the Wnt-stimulated transcription. Reporter gene assay with the Wnt-responsive promoters. 293 cells were cotransfected with the reporters and the HIC1 constructs as indicated and stimulated for 24 h with Wnt3a-conditioned or control medium. Luciferase (firefly) activities were corrected for the efficiency of transfection using the internal control *Renilla* luciferase expression plasmid. The reporter activity in unstimulated mock-transfected cells was arbitrarily set to 1. The histograms represent mean values of triplicate experiments and SDs (standard deviations) are shown by error bars.

The analysis revealed that HIC1 overexpression does not reduce the overall levels of the endogenous TCF-4 and β-catenin proteins in the cells (Figure 6A). However, HIC1 sequestered endogenous β-catenin and TCF-4 into the nuclear HIC1 bodies (Figure 6B and Supplementary Figure 2). Using anti-GFP antibody, we coimmunoprecipitated β-catenin, HIC1 and TCF-4 in one complex from 293 cells (Figure 6C). As we did not observe a direct interaction between β-catenin and HIC1 *in vitro* using pull-down assays (Supplementary Figure 3), we concluded that β-catenin associates with HIC1 indirectly, possibly by binding to TCF-4.

In summary, these data indicated that HIC1 specifically represses TCF-mediated transcription. Intriguingly, the repression is dependent on the recruitment of the TCF-4 to the HIC1 bodies rather than on the direct interaction of HIC1 with the promoters of the repressed genes.

HIC1 regulates Axin2 transcription

The *HIC1* gene is silenced by promoter methylation in most of the tumor-derived cell lines tested so far; nevertheless, we detected *HIC1* mRNA expression in human medulloblastoma DAOY cells, human primary fibroblast WI38 cells and also in mouse embryo STO cells. Using anti-HIC1 antibody, we visualized the nuclear HIC1 bodies in all these cells (see higher magnification insets in Figures 7B and 8A; staining of STO cells is not shown). Treatment of DAOY cells with 5-aza-2′-deoxycytidine (5-aza-2′-dCyt), that is, with an agent blocking DNA methylation, resulted in two-fold increase in the levels of *HIC1* mRNA (Figure 7A). This increased *HIC1* expression was also detected at the protein level and the 5-aza-2′-dCyt-treated cells contained a higher amount of larger HIC1 bodies than untreated cells (Figure 7B, insets). We further tested the effect of HIC1 knockdown on Wnt signaling. We found that in WI38 cells the *HIC1* mRNA level was reduced to 20% upon transfection with HIC1 short inhibitory RNAs (siRNAs), compared to an irrelevant control (a mixture of anti-GFP and anti-luciferase siRNAs) (Figure 8A). The effective downregulation of HIC1 in the transfected cells was confirmed by Western blotting and confocal microscopy (Figure 8A, inset). Recently, it was shown by Chen *et al* (2005) that HIC1 binds the SIRT1 promoter and directly

represses its transcription. Thus, as expected, upon HIC1 knockdown we observed increased levels of the *SIRT1* mRNA; we also noted a 60% increase of basal transcription of *Axin2*, the Wnt signaling pathway target gene (Figure 8A). Interestingly, upon Wnt stimulation, the HIC1 siRNAs remarkably (almost two-fold) elevated only the transcriptional response of the Axin2 promoter, while the expression of the *SIRT1* and two housekeeping genes remained unchanged (Figure 8B). Such robust activation of *Axin2* was quite astonishing as the HIC1 siRNAs treatment already increased the levels of the *Axin2* mRNA in unstimulated cells. These data, obtained with physiological amounts of HIC1 and with the endogenous Wnt signaling target, supported our observations about HIC1 antagonizing Wnt signaling.

HIC1 diverts TCF-4 and β-catenin from the Wnt-responsive promoters

The mechanism of the HIC1 action on the endogenous TCF-responsive promoters was first studied by ectopic expression of full-length HIC1 in 293 cells. At the mRNA level, HIC1 overexpression partly blocked the increase in abundance of three Wnt signaling responsive genes *Axin2*, *Sp5* and *Cyclin D1* (Shtutman *et al*, 1999; Leung *et al*, 2002; Weidinger *et al*, 2005) observed in control cells upon 12- or 24-h stimulation with Wnt3a (Figure 9A). The inhibition appeared to be incomplete because about 50% transfection efficiency was routinely achieved for the 293 cells (data not shown). Thus, although HIC1 obviously inhibited the *Axin2*, *Sp5* or *CyclinD1* stimulation in the transfected cells, the overall amounts of the corresponding mRNAs were moderately elevated in Wnt3a-treated cell cultures. The mRNA abundance of *GAPDH* and *CtBP2*, that is genes with no direct relationship to Wnt signaling, did not change in the experiment.

To clarify the mechanisms of the HIC1-mediated repression, ChIP was performed on a cluster of TCF-binding sites in the Sp5 promoter (Supplementary Figure 4) (Takahashi *et al*, 2005). The ChIP assay showed that HIC1 did not associate with the Sp5 promoter; furthermore, the binding of endogenous TCF-4 to this promoter was decreased by wild-type HIC1 overexpression and not by HIC1-ΔPOZ in both stimulated and nonstimulated 293 cells (Figure 9B, only data for Wnt3a-

Figure 6 HIC1 represses TCF/β-catenin signaling in DLD-1 adenocarcinoma cells. (**A**) Right, transgenic DLD/HIC1 cells growing at higher concentrations of a synthetic compound AP21967 (dimerizer) contain increasing amounts of the HIC1 protein as evidenced by Western blots of total cell extracts probed with anti-HIC1 antibody. Middle, HIC1 expression does not influence the protein levels of TCF-4 and β-catenin. Left, the constitutive activity of the TCF-dependent reporter pTOPFLASH is suppressed by increasing amounts of the HIC1 protein. Average luciferase light units per second (RLU/s) corrected for the efficiency of transfection determined as the luciferase/*Renilla* ratio from five experiments are given (right, pFOPFLASH values). (**B**) Colocalization of HIC1 with endogenous β-catenin. Confocal micrographs of DLD-1 cells transfected with the full-length Flag-HIC1 construct stained with anti-Flag and anti-β-catenin antibody. Bar, 10 μm. (**C**) HIC1 expression does not disrupt the binding between TCF-4 and β-catenin. Coimmunoprecipitation of endogenous TCF-4 with ectopically expressed β-catenin is not affected by co-expression of HIC1 (compare left and middle panel). The coimmunoprecipitation is specific for β-catenin as indicated by a control experiment using the EGFP-nls instead of β-catenin-EGFP fusion protein (right).

induced cells are shown). We then co-transfected HIC1 and β-catenin, and performed ChIP with an antibody directed against this Wnt effector protein. The results unambiguously showed the presence of β-catenin on the Sp5 promoter in control cells (transfected with an empty vector or with the HIC1-ΔPOZ mutant which is deficient in TCF binding). In contrast, wild-type HIC1 completely eliminated association of exogenous β-catenin with the TCF-responsive element of the *Sp5* gene (Figure 9B).

In DLD-1 cells, we did not detect any *Sp5* mRNA and, moreover, expression of *Axin2* and *Cyclin D1* seemed to be independent of the TCF/β-catenin as the transient transfection of a dominant-negative form of TCF-4 (ΔN-TCF-4) did not reduce transcription of these Wnt signaling target genes. However, ΔN-TCF-4 inhibited production of *Tenascin C*, a recently identified TCF/β-catenin target gene active in colon carcinoma cells growing at the invasive front of the tumors (data not shown) (Beiter *et al*, 2005). For the ChIP assay we used DLD/HIC1 cells with regulated expression of the HIC1-EGFP transgene. Predictably, HIC1 expression did not inhibit the activity of the in DLD-1 cells TCF-independent Axin2 and Cyclin D1 promoters (Figure 9C). This was not caused by

Figure 7 The nuclear HIC1 bodies in DAOY cells. (**A**) Increased expression of *HIC1* mRNA and protein in the cell line DAOY after treatment with 1 μM 5-aza-2′-deoxycytidine for 6 days. The expression was analyzed by qRT–PCR (left) or by Western blotting using anti-HIC1 antibody. In lane 3, a lysate from 293 cells transfected with 0.5 μg of the Flag-HIC1 construct was loaded. (**B**) Confocal micrographs of DAOY cells treated with 5-aza-2′-deoxycytidine (c, d) or with a vehicle (a, b) stained with the affinity purified anti-HIC1 antibody. Bar, 10 μm.

a dysfunction of the HIC1-EGFP fusion protein as HIC1-EGFP efficiently attenuated pTOPFLASH transcription (Figure 6A) and the ectopically expressed HIC1-EGFP construct displayed the same activity as wild-type HIC1 in suppressing. Nevertheless, HIC1 efficiently blocked transcription from a promoter of the *Tenascin C* gene (Figure 9C). ChIP analysis of the proximal TCF-dependent DNA element in the *Tenascin C* promoter (Supplementary Figure 4) revealed a clear binding of TCF-4 and β-catenin in parental DLD-1 cells. In DLD/HIC1, upon induction with the dimerizer HIC1 significantly decreased the association of both TCF-4 and β-catenin with the *Tenascin C* promoter, but no interaction of this promoter, with HIC1 was observed (Figure 9D). Simultaneously, the functionality of HIC1-EGFP to bind its cognate DNA motif was confirmed by ChIP of the HIC1-recognition element in the SIRT1 promoter (Figure 9D). These data indicate that as a result of the recruitment to the HIC1 bodies, TCF-4 and β-catenin are prevented from associating with TCF target genes.

Discussion

Since the canonical Wnt/β-catenin signaling alone is unlikely to regulate multiple developmental programs initiated by the Wnt ligands, we searched for additional proteins that could modulate the function of the TCF/LEF factors. In the present study, we identified tumor suppressor HIC1 as a new nuclear modulator of the Wnt signaling pathway.

Nuclear sequestration of TCF-4 into the HIC1 bodies

HIC1 encodes a zinc-finger transcription factor that acts as a transcriptional repressor. Additionally, the HIC1 protein binds CtBP and via its N-terminal BTB/POZ domain forms nuclear aggregates known as HIC1 bodies. Here, we present convincing data based on confocal microscopy showing the colocalization of the Wnt signaling effector protein, TCF-4, HIC1 and CtBP1 in these nuclear bodies. We further show that HIC1 directly associates with TCF-4 *in vitro* and *in vivo*. However, the efficient sequestration of TCF-4 into the HIC1 bodies depends on the presence of the CtBP in the TCF-4/HIC1 complex. Strikingly, in CtBP-positive cells, wild-type HIC1 and the TCF-4mutCtBP protein (this variant lacks the CtBP-binding motifs but is still able to interact with HIC1 *in vitro* (Figure 4A and B)) do not display an overlapping localization (Figure 2C). We speculate that CtBP induces a specific spatial arrangement of the HIC1 bodies. Such arrangement possibly favors the recruitment of TCF-4 via the interaction with CtBP. This conclusion is supported by a different morphology of the HIC1 aggregates, which in the presence of CtBP show more compact appearance than the HIC1/TCF-4 bodies without CtBP (Figure 2C). The absence of HIC1 and TCF-4mutCtBP colocalization argues against the obvious objection that overexpressed proteins aggregate and sequester other proteins that they do not normally interact with.

Using *in vitro* pull-down assays, we mapped the main regions of the interaction to the C-terminal parts of HIC1 and TCF-4. Surprisingly, whereas GST-HIC C-terminal and GST-HIC internal fragments interacted with *in vitro* translated TCF-4, the N-terminally truncated HIC-ΔPOZ variant failed to interact with full-length GST-TCF-4. We assume that the anchoring of the HIC1 protein fragments to GST-beads possibly prevents the incorrect folding induced by the deletion of the structurally essential BTB/POZ domain.

Many nuclear factors involved in pre-mRNA splicing, regulation of transcription, apoptosis or cell cycle progression are localized in distinct structures called speckles or nuclear bodies (reviewed in Lamond and Spector, 2003). Using confocal microscopy we visualized HIC1 bodies at endogenous expression levels in the nuclei of three different cell types. Is the physical sequestration of the transcription factors main function of the HIC1 bodies or are there some other physiological roles for these structures? What is the proportion between the 'free' HIC1 protein (i.e. HIC1 associated with promoters or other factors) and HIC1 aggregated in the bodies? More experimental work needs to be carried out to answer these questions.

HIC1 represses TCF-mediated transcription

The results presented here show that full-length HIC1 substantially reduced the levels of TCF-mediated transcription of two different TCF/β-catenin-regulated reporters (Figure 5), and furthermore, several selected endogenous Wnt signaling target genes were also affected by HIC1 expression (Figures 8 and 9). Importantly, HIC1 knockdown in normal cells enhanced the levels of the transcriptional stimulation induced by the Wnt3a ligand (Figure 8B). Thus, HIC1 specifically repressed transcription dependent on TCF and this repression occurred at physiological levels of the HIC1 protein. Interestingly, we observed that the activator role of Wnt signaling was dependent on the particular cellular back-

Figure 8 HIC1 knockdown increases the TCF-mediated transcription. (**A**) Human primary cells WI38 were transfected with HIC1 siRNAs or control siRNAs and the changes in the levels of *HIC1* mRNA or protein were tested 24 h post-transfection. Left, results of the qRT–PCR analysis. The relative abundance of the given mRNA in HIC1 siRNA versus control siRNA-transfected cells was derived from the average CT values of four independent experiments after normalizing to the levels of β-*actin* cDNA. Right, Western blots of nuclear extracts prepared from the indicated cells. Bottom, confocal micrographs of WI38 cells transfected with the indicated siRNAs and stained with the affinity purified anti-HIC1 antibody. Bar, 10 μm. (**B**) The activity of the Wnt-dependent promoter of the *Axin2* gene is increased by HIC1 knockdown. Results of qRT–PCR analysis performed with cDNA generated from WI38 cells transfected with the indicated siRNAs upon 24-h stimulation with Wnt3a. Six PCR reactions were done for each primer set. The relative abundance of the indicated mRNA in Wnt3a-stimulated versus control cells was derived from the average CT values after normalizing to the levels of β-*actin* cDNA.

ground. For example, the stimulation by Wnt3a activated transcription of *Sp5*, *Axin2* and *Cyclin D1* in 293; in primary fibroblast WI38 cells, only robust transactivation of the *Axin2* gene was detected, while the expression levels of *Sp5* and *Cyclin D1* remained under detection limits. In colon carcinoma DLD-1 cells, that is, in cells with constitutive active Wnt signaling, ectopic expression of a dominant-negative (blocking) form of TCF-4 inhibited expression of *Tenascin C* but not *Axin2* and *Cyclin D1* mRNA. This clearly indicates that gene expression is in general regulated by inputs from various cellular pathways that integrate in the regulatory regions of a particular gene. Nevertheless, HIC1 regulated the transcriptional response of all tested genes showing the reactivity to the Wnt signal in the given cell type.

Mechanisms of HIC1-mediated inhibition

It was well documented that Kaiso, a member of the BTB/POZ protein family, interacts with sequence-specific elements in several Wnt target genes (Park *et al*, 2005). In *Xenopus*, Kaiso and TCF act in concert on the *siamois* promoter. The Kaiso's general role is not completely understood, but it is likely to also include a direct binding and the recruitment of corepressors such as N-CoR to a subset of Wnt targets. Recently, Chen *et al* (2005) showed that HIC1 forms a transcriptional repression complex with SIRT1 deacetylase. This complex directly binds and represses transcription from the promoter of the *SIRT1* deacetylase gene.

ChIP analysis revealed that HIC1 does not bind directly or indirectly (i.e. via TCF-4) the regulatory elements in the TCF-responsive genes. In contrast, HIC1 partly reduces the occupancy of the promoter of the *Sp5* gene by endogenous TCF-4. This partial sequestration was expected as only a fraction of the cells expressed exogenous HIC1. In addition, HIC1 eliminated binding of ectopically expressed β-catenin to the *Sp5* promoter.

ChIP analysis of the TCF-binding element in the *Tenascin C* promoter in DLD/HIC1 cells showed a substantial decrease in association of TCF-4 and β-catenin upon HIC1 induction. Taken together, these data indicate that HIC1-mediated sequestration prevents TCF-4 from binding its target promoter. Although β-catenin targeting to the HIC1 bodies seems to be indirect and mediated via its interaction with TCF-4, we cannot completely exclude participation of an unknown factor involved in relocation of β-catenin into the HIC1 bodies (Figure 10). These results imply that HIC1-mediated sequestration can uncouple the TCF/β-catenin-regulated promoters from various inputs related to Wnt signaling, but still may leave such promoters responsive to other regulatory signals.

Materials and methods

Plasmids and RNAi
All constructs were made by standard molecular biology techniques. Triple amino-acid substitutions (Q_{509} to N_{509}, P_{510} to A_{510}, L_{511} to S_{511}, Q_{586} to N_{586}, P_{587} to A_{587}, L_{588} to S_{588}) were introduced into

Figure 9 HIC1 sequesters TCF and β-catenin from the TCF-dependent promoters. (**A**) HIC1 blocks transcriptional activation of the Wnt signaling target genes. Results of qRT–PCR analyses performed with cDNA generated from 293 cells transfected with the indicated constructs upon 12- or 24-h stimulation with Wnt3a. Four to six PCR reactions were performed for each primer set. The relative abundance of the indicated mRNA in Wnt3a-stimulated versus control cells was derived from the average CT values after normalizing to the levels of β-*actin* cDNA. (**B**) HIC1 is not associated with the Sp5 promoter but sequesters TCF-4 and β-catenin from the TCF-specific DNA element of this promoter. ChIP analysis of chromatin isolated from 293 cells transfected with the indicated constructs. The diagram at the left represents real-time PCR values obtained with primers spanning the respective DNA element, normalized to the inputs. The image on the right depicts relevant PCR products after 29 cycles of amplification. (**C**) HIC1-EGFP blocks transcription of the Tenascin C promoter in DLD-1 cells. Left, results of qRT–PCR analyses performed with cDNA prepared from DLD/HIC1 cells growing in the presence of the dimerizer (25 nM; HIC1 induction) or without induction. Right, Western blot analysis of nuclear extracts isolated from DLD/HIC1 and WI38 cells. (**D**) HIC1 sequesters TCF-4 and β-catenin from the *Tenascin C* promoter. Left, ChIP analysis of chromatin isolated from DLD/HIC1 cells prior to and upon HIC1-EGFP induction. The diagram at the left represents real-time PCR values obtained with primers spanning the proximal TCF-binding element in the *Tenascin C* promoter, normalized to the inputs. The image on the right depicts relevant PCR products after 29 cycles of amplification. Right bottom, although HIC1-EGFP is not associated with the *Tenascin C* promoter, it binds its recognition element in the SIRT1 promoter.

Figure 10 A model for HIC1 suppression of the transcriptional response induced by Wnts. The regulation of a complex promoter integrating inputs from the Wnt and other signaling pathways is depicted. At low levels of HIC1 the activity of the promoter depends mainly on the Wnt signaling components. High levels of HIC1 uncouple the promoter from Wnt signaling. X depicts a hypothetical factor mediating besides TCF-4 the interaction between β-catenin and HIC1.

each of the CtBP-binding sites in TCF-4mutCtBP by using a site-directed mutagenesis kit (Stratagene). For gene knockdowns HIC1 siRNAs were purchased from Ambion. See the Supplementary data for more detailed description of the plasmids used in this study.

Cell culture and transfections
Cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Hyclone) and antibiotics. All cell lines were regularly checked for the presence of mycoplasma. Transfections were performed using the Lipofectamine reagent (Invitrogen) as described by the manufacturer. DLD/HIC1 cells were produced using ARGENT Regulated Transcription Retrovirus Kit (Ariad). CtBP(−/−) cells derived from the CtBP1$^{-/-}$CtBP2$^{-/-}$ embryos were kindly provided by J Hildebrand.

Production of Wnt3a-conditioned medium
Mouse Wnt3a-producing L cells (L Wnt-3A; ATCC No. CRL-2647) were cultured in complete DMEM supplemented with G418 (0.5 mg per ml; Alexis). Control and Wnt3a-conditioned medium was prepared according to the protocol provided by the supplier.

Luciferase assays
Reporter gene assays were performed as described previously (Valenta *et al*, 2003). To assay TCF-mediated transcription, firefly luciferase pTOPFLASH and pFOPFLASH (Korinek *et al*, 1997) and the *Axin2* promoter reporter constructs (Jho *et al*, 2002) (a gift from F Costantini) were used. The G1-E1B-Luc reporter and the Gal4-DBD-VP16 construct were kindly provided by C Svensson.

EMSA
Full-length TCF-4, full-length human HIC1 and HIC1-ΔPOZ protein were produced *in vitro* using the Quick TNT Coupled Reticulocyte System (Promega). The assay was performed as reported previously (Valenta *et al*, 2003).

GST interaction assays and DNase I treatment
GST-TCF-4, GST-β-catenin, GST-HIC1-N-term (aa 1–398), GST-HIC1-C-term (aa 396–714) and GST-HIC1-internal (aa 234–551) fusion proteins were expressed in the BL21 (DE3) strain of *Escherichia coli* using the pET-42b vector (Novagen). Relevant proteins were produced *in vitro* using the Quick TNT Coupled Reticulocyte System (Promega). The detailed protocol for the GST pull-downs was described previously (Valenta *et al*, 2003). DNase I treatment of GST-bound or *in vitro* translated proteins was performed in 1 × DNase I buffer (Invitrogen), for 30 min at RT with 0.2 U of DNase I (Invitrogen) per 1 μl of the reaction mixture.

Antibodies
Antisera to TCF-4, HIC1, CtBP1, β-catenin and EGFP were produced by immunization of rabbits with bacterially expressed proteins; mouse mAbs to TCF-4 and HIC1 were prepared using standard techniques from splenocytes of mice immunized with a bacterially produced TCF-4 fragment (aa 31–333) and HIC1 fragment (aa 230–404) respectively. The following commercially available mouse monoclonal antibodies were used: anti-β-catenin (Santa Cruz Biotechnology), anti-dephospho-β-catenin (Alexis), anti-CtBP (Santa Cruz Biotechnology), anti-GFP (BD Clontech), anti-Myc 9E10 (Roche Molecular Biochemicals), anti-Flag M2 (Sigma), anti-Flag (Exbio Praha).

Immunofluorescent microscopy
Cells grown on coverslips were fixed 24 h after transfection in cold methanol (−20°C, 5 min) and then briefly in acetone (−20°C). Fluorochromes were ALEXA 488, 594, and 680 dyes (dilution 1:500; Invitrogen), Cy5 dye (1:500, Amersham Pharmacia Biotech). The samples were mounted in MOWIOL (Calbiochem) containing nuclear staining dye DRAQ 5 (1:750; Alexis). Immunofluorescences were visualized using a confocal laser scanning microscope (TCS SP; Leica). All images were scanned separately in the 'sequential scanning mode' for the green, red and blue channels using a × 100/1.40 oil-immersion objective. The ratio of colocalization was quantified by measuring the overlap in the fluorescence intensities of corresponding channels along selected profiles using Leica confocal software. Image files were processed with Adobe Photoshop.

RNA purification and real-time qRT–PCR
Standard procedures were used for RNA purification and reverse transcription. The primers used are listed in Supplementary Table S1 (Supplementary data). The cycling was performed in an Mxp3000 instrument (Stratagene).

ChIP
293 cells stimulated with Wnt3a-conditioned or control medium, DLD-1 and DLD/HIC1 cells were subjected to the ChIP assays according to Kirmizis *et al* (2004). See the Supplementary data for the primer sequences.

Supplementary data
Supplementary data are available at *The EMBO Journal* Online.

References

Albagli O, Dhordain P, Deweindt C, Lecocq G, Leprince D (1995) The BTB/POZ domain: a new protein–protein interaction motif common to DNA- and actin-binding proteins. *Cell Growth Differ* **6:** 1193–1198

Beiter K, Hiendlmeyer E, Brabletz T, Hlubek F, Haynl A, Knoll C, Kirchner T, Jung A (2005) Beta-Catenin regulates the expression of tenascin-C in human colorectal tumors. *Oncogene* **24:** 8200–8204

Brannon M, Brown JD, Bates R, Kimelman D, Moon RT (1999) XCtBP is a XTcf-3 co-repressor with roles throughout *Xenopus* development. *Development* **126:** 3159–3170

Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M, Karp JE, Gokgoz N, Wunder JS, Andrulis IL, Levine AJ, Mankowski JL, Baylin SB (2004) Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. *Cancer Cell* **6:** 387–398

Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB (2005) Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. *Cell* **123:** 437–448

Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, Watkins DN, Herman JG, Mankowski JL, Baylin SB (2003) Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. *Nat Genet* **33:** 197–202

Clevers H, van de Wetering M (1997) TCF/LEF factor earn their wings. *Trends Genet* **13:** 485–489

Deltour S, Pinte S, Guerardel C, Wasylyk B, Leprince D (2002) The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif. *Mol Cell Biol* **22:** 4890–4901

Dobyns WB, Truwit CL (1995) Lissencephaly and other malformations of cortical development: 1995 update. *Neuropediatrics* **26:** 132–147

Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. *N Engl J Med* **349:** 2042–2054

Hildebrand JD, Soriano P (2002) Overlapping and unique roles for C-terminal binding protein 1 (CtBP1) and CtBP2 during mouse development. *Mol Cell Biol* **22:** 5296–5307

Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F (2002) Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. *Mol Cell Biol* **22:** 1172–1183

Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R, Farnham PJ (2004) Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. *Genes Dev* **18:** 1592–1605

Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. *Science* **275:** 1784–1787

Lamond AI, Spector DL (2003) Nuclear speckles: a model for nuclear organelles. *Nat Rev Mol Cell Biol* **4:** 605–612

Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S, Cho KR, Fearon ER (2002) Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. *J Biol Chem* **277:** 21657–21665

Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. *Annu Rev Cell Dev Biol* **20:** 781–810

Park JI, Kim SW, Lyons JP, Ji H, Nguyen TT, Cho K, Barton MC, Deroo T, Vleminckx K, McCrea PD (2005) Kaiso/p120-catenin and TCF/beta-catenin complexes coordinately regulate canonical Wnt gene targets. *Dev Cell* **8:** 843–854

Pinte S, Stankovic-Valentin N, Deltour S, Rood BR, Guerardel C, Leprince D (2004) The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties. *J Biol Chem* **279:** 38313–38324

Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. *Nature* **434:** 843–850

Roose J, Molenaar M, Peterson J, Hurenkamp J, Brantjes H, Moerer P, van de Wetering M, Destree O, Clevers H (1998) The *Xenopus* Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. *Nature* **395:** 608–612

Rosin-Arbesfeld R, Cliffe A, Brabletz T, Bienz M (2003) Nuclear export of the APC tumour suppressor controls beta-catenin function in transcription. *EMBO J* **22:** 1101–1113

Sewalt RG, Gunster MJ, van der Vlag J, Satijn DP, Otte AP (1999) C-Terminal binding protein is a transcriptional repressor that interacts with a specific class of vertebrate Polycomb proteins. *Mol Cell Biol* **19:** 777–787

Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. *Proc Natl Acad Sci USA* **96:** 5522–5527

Takahashi M, Nakamura Y, Obama K, Furukawa Y (2005) Identification of SP5 as a downstream gene of the beta-catenin/Tcf pathway and its enhanced expression in human colon cancer. *Int J Oncol* **27:** 1483–1487

Valenta T, Lukas J, Korinek V (2003) HMG box transcription factor TCF-4's interaction with CtBP1 controls the expression of the Wnt target Axin2/Conductin in human embryonic kidney cells. *Nucleic Acids Res* **31:** 2369–2380

van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. *Cell* **111:** 241–250

Weidinger G, Thorpe CJ, Wuennenberg-Stapleton K, Ngai J, Moon RT (2005) The Sp1-related transcription factors sp5 and sp5-like act downstream of Wnt/beta-catenin signaling in mesoderm and neuroectoderm patterning. *Curr Biol* **15:** 489–500

Supplementary information

Materials and Methods

Plasmids and mutagenesis

Full-length HIC1, HIC1-ΔCtBP (deleted aa 222-228) and HIC1-ΔPOZ (aa 136-714) constructs encoding proteins of human origin containing N-terminal or C-terminal EGFP were generated by standard cloning procedures in pEGFP-C1 and pEGFP-N3 vector (BD Clontech), respectively. Constructs encoding HIC1 with an N-terminal Flag-tag (in pcDNA3) (Deltour et al., 2002) were provided by D. Leprince. Plasmids encoding HIC1 tagged with a C-terminal Flag were generated by subcloning into pCMV-Flag-5a vector (Sigma). Myc- and EGFP-tagged constructs encoding full-length mouse or human CtBP1 and human TCF-4 were described previously (Valenta et al., 2003). Plasmids encoding the N-terminal (TCF-4-N-term; aa 1-333) or C-terminal fragment of human TCF-4 (TCF-4-C-term; aa 333-596) were prepared in the pK-myc vector (Valenta et al., 2003) by standard cloning techniques. For retroviral transduction, EGFP-tagged human HIC1 was ligated into the pLHIT variant of pLNIT vector (provided by F.H.Gage); untagged mouse CtBP1 was expressed from pBABE-puro retroviral plasmid (a gift from J. Hildebrand). Details of plasmids and sequences of primers used for the mutagenesis are available on request.

Primers for ChIP

The primers used for the PCR amplification were: *Sp5* promoter, sense: 5'-TCCAGACCAACAAACACACC -3' and antisense 5'- GCTTCAGGATCACCTCCAAG -3'; *Tenascin C* promoter, sense: 5'-ACTGGGGCTGGAACAAAGAT-3' and antisense 5'-AGCGAGTACAGGGACTGAGC-3'; *SIRT1* promoter, sense: 5'- GATAGAAACG CTGTGCTCCA-3' and antisense 5'- CCTTCCTTTCTAGCGTGAGC-3'; negative control regions were derived from the distal exon of the *Axin2* gene, sense: 5'-CTGGCTTTGGTGAACTGTTG-3' and antisense 5'- AGTTGCTCACAGCCAAGACA-3', or from the distal exon of the *Tenascin C* gene, sense: 5'-CAGTAGAGGCAGCCCAGAAC-3' and antisense 5'- AGAGAGAGGGGTTGTGCTGA-3'.

Supplementary Table S1 A set of oligonucleotide primers used for RT-PCR

gene	origin		sequence
Axin1	human	forward	5'-CCTGTGGTCTACCCGTGTCT-3'
		reverse	5'-GCTATGAGGAGTGGTCCAGG-3'
	mouse	forward	5'-ACCCAGTACCACAGAGGACG-3'
		reverse	5'-CTGCTTCCTCAACCCAGAAG-3'
Axin2	human	forward	5'-CTGGCTTTGGTGAACTGTTG-3'
		reverse	5'-AGTTGCTCACAGCCAAGACA-3'
	mouse	forward	5'-TAGGCGGAATGAAGATGGAC-3'
		reverse	5'-CTGGTCACCCAACAAGGAGT-3'
beta-actin	human	forward	5'-GGCATCCTCACCCTGAAGTA-3'
		reverse	5'-AGGTGTGGTGCCAGATTTTC-3'
	mouse	forward	5'-GATCTGGCACCACACCTTCT-3'
		reverse	5'-GGGGTGTTGAAGGTCTCAAA-3
CtBP2	human	forward	5'-CCATCCAGTGGAGGTTTGTC-3'
		reverse	5'-AGCGTATCGTAGGAGTGGGA-3'
Cyclin D1	human	forward	5'-CCATCCAGTGGAGGTTTGTC-3'
		reverse	5'-AGCGTATCGTAGGAGTGGGA-3'
GAPDH	human	forward	5'-CACCACACTGAATCTCCCCT-3'
		reverse	5-CCCCTCTTCAAGGGGTCTAC-3'
	mouse	forward	5'-AACTTTGGCATTGTGGAAGG-3'
		reverse	5-ATCCACAGTCTTCTGGGTGG-3'
HIC1	human	forward	5'-CGACGACTACAAGAGCAGCA-3'
		reverse	5'-TGCACACGTACAGGTTGTCA-3'
	mouse	forward	5'-CAACCTGTACGTGTGCATCC-3'
		reverse	5'-ACGTGTGCATTCAGCTGTTC-3'
HIC2	human	forward	5'-CTCCACAGTGTTCCAGCAGA-3'
		reverse	5'- CAGCAGCTTGCCTGTGTAGA-3'
SDHA	human	forward	5'-AGATTGGCACCTAGTGGCTG-3'
		reverse	5'-ACAAAGGTAAGTGCCACGCT-3'
	mouse	forward	5'-AAGGCAAATGCTGGAGAAGA-3'
		reverse	5'-TGGTTCTGCATCGACTTCTG-3'
SIRT1	human	forward	5'-GCAGATTAGTAGGCGGCTTG-3'
		reverse	5'-AGCGCCATGGAAAATGTAAC-3'
Sp5	human	forward	5'-ACTTTGCGCAGTACCAGAGC-3'
		reverse	5'-ACGTCTTCCCGTACACCTTG-3'
TCF-4	human	forward	5'-TAGCTTTAGCGTCGTGAACC-3'
		reverse	5'-GGGGGCAAATTAAGAAAAGTG-3'
Tenascin C	human	forward	5'-GTCACCGTGTCAACCTGATG-3'

reverse   5'-GTTAACGCCCTGACTGTGGT-3'

Supplementary figures

Supplementary Figure S1   TCF-4 and HIC1 differ in the DNA-binding specificities.

A gel-retardation assay performed with the TCF-4 and HIC1 proteins translated *in vitro*. As the optimal Tcf/Lef probe, a double-stranded 12-nucleotide oligomer 5'-ACCCTTTGATCT-3' was used; the control probe was 5'-ACCCTTTGGCCT-3'. A PCR fragment amplified from pTOPFLASH (Upstate Biotechnology) containing 6 copies of the Tcf/Lef interaction motif was used as the multiple TCF-specific (6xTOP) probe. The wild-type HIC1 probe was double-stranded oligonucleotide 5'-GGGCCTGGGGGCAACCCAATCAC-3', the negative control HIC1mut was 5'-GGGCCTGGGGATGACCCAATCAC-3'.   TCF-4/DNA and HIC1/DNA complexes and the positions of the free probes are indicated by arrows. Stars indicate non-specific bands.

Supplementary figure 1

Supplementary Figure S2 HIC1 bodies in DLD-1 adenocarcinoma cells contain endogenous TCF-4. Colocalization of HIC1 with endogenous TCF-4. Confocal micrographs of DLD-1 cells transfected with full-length Flag-HIC1 construct stained with anti-Flag and anti-TCF-4 . Bar, 10μm.

Supplementary figure 2

Supplementary Figure S3 HIC1 and β-catenin do not interact directly. Pull-down assays between bacterially expressed GST-fusion and *in vitro* translated proteins as indicated. Ten percent of the total reactions were loaded in lanes denoted "input". The gel images marked "long exposure" were obtained after a three-day exposition to the BAS-phosphoimager screen, the image named "short exposure" was gained after a standard overnight exposition. No obvious interaction was detected between β-catenin and HIC1, although the same isolate of GST-β-catenin clearly interacted with full-length TCF-4. A structure of the dominant negative

TCF-4-ΔN construct lacking the main β-catenin interaction domain (used as a negative control) is also shown (bottom).

Supplementary figure 3

Supplementary Figure S4 Schematic representation of the human   *Sp5* and *Tenascin C* promoters. The TCF-binding sites are depicted by open (basic) or filled (optimal) triangles. The orientation of these sites is indicated by (+) or (-). Areas used for ChIP are shown above the relevant promoter.

Supplementary Figure 4

3.3 Interakce mezi nukleárním receptorem a β-kateninovou signalizací rozhoduje o osudu buněk v somatické gonádě *Caenorhabditis elegans*

Gonáda hlístice *Caenorhabditis elegans* je modelovým příkladem situace, kdy z jedné mateřské buňky vznikají asymetrickým buněčným dělením dvě odlišné buňky dceřiné. Takto vzniklé dceřiné buňky se vzájemně liší přítomností a aktivitou různých molekul, které určují různý vývojový potenciál každé z těchto buněk. Asymetrické buněčné dělení je opakem situace, kdy z mateřské buňky vznikají dvě naprosto identické dceřiné buňky, jejichž rozdílný osud je pak až následně určen různými vnějšími faktory [219, 220]. Gonáda *C. elegans* se vyvíjí ze dvou somatických buněčných prekurzorů (označovaných jako Z1 a Z4), které ohraničují prekurzory zárodečných buněk (Z2 a Z3). Distální dceřiné buňky prekurzorů Z1 a Z4 se po dalším asymetrickém dělení mění v unikátní buňky označované jako DTC (Distal Tip Cell), přičemž jedna DTC je výsledkem několika dělení buňky Z1 a druhá DTC buňka vzniká z buňky Z4. V případě hermafrodita (v populaci výrazně převažující pohlaví) *C. elegans*, je každá z DTC buněk lokalizována na opačném konci gonády a je zodpovědná za růst jednotlivých gonadálních ramen a stimulaci dělení zárodečných buněk. Proximální dceřiné buňky vzniklé z buněk Z1 a Z4 se dále dvakrát dělí a z takto vzniklých buněk dává jedna vznik kotvící buňce (anchor cell) AC. Aktivita AC buňky je nezbytná pro indukci vulvy [221, 222].

Pro určení osudu buňky, a to rovněž v případě *C. elegans* je rozhodující aktivita evolučně konzervovaných signálních kaskád. Jednou z takových klíčových kaskád je signalizace Wnt. Současný model popisující vývoj gonády *C. elegans* vychází ze skutečnosti, že u přímých dceřiných buněk vzniklých z buněk Z1/Z4 je asymetricky distribuován transkripční faktor POP-1, který je jediným zástupcem transkripčních faktorů Lef/Tcf u *C. elegans*. Zvláštností signalizace Wnt u *C. elegans* je existence několika signalizačních β-kateninů (WRM-1, SYS-1 a BAR-1). Při vývoji gonády se uplatňují dva z těchto β-kateninů. V buňce s distálním osudem (buňka DTC) se WRM-1 spolu s kinázou LIT-1 podílí na fosforylaci transkripčního faktoru POP-1. Fosforylovaný POP-1 je exportován ven z buněčného jádra. Zbývající nefosforylovaná frakce POP-1 se váže na druhý typ β-kateninu, SYS-1, který je v buňkách exprimován konstantně na relativně nízké úrovni. Heterokomplexy POP-1/SYS-1 aktivují transkripci distálně specifických genů. V proximálních (AC) buňkách k fosforylaci POP-1, a tím k jeho exportu z jádra nedochází. Množství POP-1 v jádře proximálních buněk tak mnohonásobně převyšuje množství SYS-1, a tudíž většina volného proteinu POP-1 působí jako transkripční represor. Ovlivnění

funkce genů *pop-1, sys-1, wrm-1, lit-1* mutací nebo nefyziologickou inaktivací vede k takzvanému Sys (S̲ymetrical s̲isters) fenotypu, kdy se všechny somatické prekuzorové buňky gonády (dále jen SGP, S̲omatic G̲onad P̲recursors) mění v buňky s proximálním osudem (AC) a to na úkor buněk distálních (DTC). Signalizace Wnt v tomto případě tedy funguje jako rozhodující faktor pro určení distálního osudu SGP. [106, 107, 223, 224].

Spolu s kolegy z Biologického centra v Českých Budějovicích jsme si položili otázku, zda existuje nějaký faktor, jenž by naopak determinoval proximální osud somatických prekurzorů gonády. Jak se ukázalo takovým faktorem je protein NHR-25 (Nuclear Hormone Receptor 25), transkripční faktor ze skupiny jaderných receptorů pro hormony. NHR-25 je v gonádě exprimován v prekurzorových buňkách Z1 a Z4, jak na úrovni mRNA, tak proteinu. Pokud je u *C. elegans* NHR-25 nefyziologicky inaktivován objevují se v jeho gonádě nadbytečné distální buňky, a to na úkor buněk proximálních. Jedinci s takto inaktivovaných genem nemají funkční gonádu a jsou sterilní. Tento fenotyp je přesně komplementární k Sys fenotypu, tedy k fenotypu jedinců, u nichž došlo k mutaci nebo inaktivaci genů pro komponenty signalizace Wnt. Výsledkem Sys fenotypu je také nefunkční gonáda a reprodukční sterilita. Pokud ovšem nefyziologicky inaktivujeme NHR-25 u jedinců se Sys fenotypem, dochází k normálnímu vývoji gonády. Tento výsledek naznačuje, že pro správný vývoj gonády u *C. elegans* je důležitá rovnováha mezi aktivitou NHR-25 a signalizací Wnt.

V další části práce jsme se zaměřili na studium vzájemného vztahu mezi NHR-25 a signalizací Wnt. Data získaná prostřednictvím kvasinkového dvouhybridního systému naznačovala možnost interakce mezi NHR-25 a některými komponentami signalizace Wnt. Později jsme potvrdili, že NHR-25 je schopen přímo interagovat s oběma β-kateniny, které jsou důležité při vývoji gonády, tj. s WRM-1 a SYS-1. Schopnost vzájemné interakce mezi těmito proteiny je základem pro modulaci transkripční aktivity proteinu NHR-25 a rovněž tak heterokomplexu POP-1/SYS-1. Pomocí luciferázových reportérů jsme ukázali, že se jednotlivé β-kateniny liší ve svém vlivu na transkripci iniciovanou z NHR-25- senzitivních promotorů. Zatímco WRM-1 tuto transkripci inhibuje, tak SYS-1 působí jako aktivátor. Na druhé straně ovšem také protein NHR-25 významně působí na transkripci cílových promotorů signalizace Wnt. NHR-25 reprimuje transkripci mediovanou komplexy POP-1/SYS-1 (tj. komplexy Tcf/β-katenin).

Vliv jaderného receptoru NHR-25 na transkripci aktivovanou signalizací Wnt a naopak působení signalizace Wnt na transkripci mediovanou NHR-25 je pravděpodobně klíčovým

mechanismem při regulaci vývoje gonády u *C. elegans*. Porušení vzájemné rovnováhy mezi oběma procesy vede k vážným defektům, jak vyplývá z experimentů s nefyziologickou inaktivací NHR-25 a komponent signalizace Wnt. Modelově si můžeme představit dvě vzájemně kompatibilní situace (viz obr.6 v publikaci), jak by mohla interakce mezi NHR-25 a signalizací Wnt určovat vývoj prekurzorových buněk gonády.

První situace vychází z předpokladu, že NHR-25 působí jako modulátor signalizace Wnt a sám neaktivuje transkripci. V tomto případě v distálních buňkách udržuje WRM-1 spolu s kinázou LIT-1 nízkou jadernou koncentraci transkripčního faktoru POP-1, který tvoří heterokomplexy s limitním množstvím proteinu SYS-1, a tak dochází k transkripci distálně specifických genů. V distálních buňkách zároveň WRM-1 brání proteinu NHR-25 v represi transkripce POP1/SYS1-specifických genů. Naproti tomu v proximálních buněčných prekurzorech, NHR-25 blokuje transkripci distálně specifických genů, neboť na sebe váže protein SYS-1 a tím ještě zvyšuje množství volného transkripčního faktoru POP-1 v jádře. Volný POP-1 pak není schopen iniciovat transkripci. Je také možné, že NHR-25 inhibuje transkripci POP1/SYS1-specifických genů v proximální buňce svojí přímou interakcí s transkripčním komplexem.

Druhý možný způsob regulace vývoje gonády u *C. elegans* předpokládá existenci proximálně specifických genů, které ovšem doposud nebyly popsány. V tomto případě by v proximální buňce NHR-25 v komplexu spolu se SYS-1 inicioval transkripci proximálně specifických genů, zatímco volný POP-1 by reprimoval expresi genů distálních. Ovšem v distální buňce by signalizace Wnt prostřednictvím proteinu WRM-1 bránila transkripční aktivitě jaderného receptoru NHR-25, a tak by se veškerý SYS-1 v distální buňce vázal na POP-1 a heterokomplexy POP-1/SYS-1 by pak mohly iniciovat transkripci distálně specifických genů.

Předkládaná práce ukázala význam interakce mezi jaderným receptorem NHR-25 a různými β-kateniny a význam této interakce pro správný vývoj gonády u *C. elegans*. Ovšem tato interakce se zdá být evolučně poměrně konzervovanou. Synergická aktivita mezi β-kateninem a savčími orthology proteinu NHR-25 byla dokumentována několika pracemi. U savců existují orthology dva, a to protein LRH-1 (Liver Receptor Homolog 1) a SF-1 (Steroidogenic Factor 1). V případě LRH-1 vede jeho asociace s β-kateninem k zesílení transkripce specifických genů, a navíc LRH-1 je schopen svojí vazbou na β-katenin zesílit transkripci cílových genů signalizace Wnt. Oba tyto procesy vedou k aktivaci transkripce G_1 cyklinů a přispívají tím k indukci buněčné proliferace [225].

Vzájemná kooperace mezi jaderným receptorem SF-1 a β-kateninem (a tím i signalizací Wnt) je nezbytná při vývoji samčích pohlavních orgánů [226-228]. Rovněž jiné typy jaderných receptorů mohou interferovat se signální dráhou Wnt. Tak například androgenní receptor (AR) za určitých okolností kompetuje s transkripčním faktorem TCF-4 o stabilizovaný nukleární β-katenin, a tak blokuje signalizaci Wnt. Navíc komplexy AR/β-katenin jsou významnými aktivátory transkripce. Přestože se interakce mezi AR a komponentami signální dráhy Wnt může odehrávat ještě na několika dalších úrovních, je pravděpodobné, že má nezanedbatelný význam při vzniku některých prostatických nádorů [229-231].

Vyvážená interakce mezi signální drahou Wnt a aktivitou jaderných receptorů je tedy molekulárním mechanismem, který hraje významnou roli při regulaci řady vývojových procesů.

Crosstalk between a Nuclear Receptor and β-Catenin Signaling Decides Cell Fates in the *C. elegans* Somatic Gonad

Masako Asahina,[1,*] Tomas Valenta,[3]
Marie Silhankova,[2] Vladimir Korinek,[3]
and Marek Jindra[1,2,*]
[1] Biology Center
Czech Academy of Sciences
[2] Department of Molecular Biology
University of South Bohemia
Budweis 37005
Czech Republic
[3] Institute of Molecular Genetics
Czech Academy of Sciences
Prague 14220
Czech Republic

Summary

β-Catenin signaling determines the proximal-distal axis of the *C. elegans* gonad by promoting distal fate in asymmetrically dividing somatic gonad precursor cells (SGPs). Impaired function of the Wnt effector POP-1/TCF, its coactivator SYS-1/β-catenin, and of upstream components including β-catenin WRM-1 causes all SGP daughters to adopt the proximal fate. Consequently, no distal tip cells (DTCs) that would lead differentiation of gonad arms form in the affected hermaphrodites. Here, we show that deficiency of the nuclear receptor NHR-25 has the opposite effect: extra DTCs develop instead of proximal cells. NHR-25 knockdown restores DTC formation and fertility in *pop-1* and *sys-1* mutants, suggesting that a balance between NHR-25 and β-catenin pathway activities is required to establish both proximal and distal fates. This balance relies on direct crossregulation between NHR-25 and the distinct β-catenin proteins WRM-1 and SYS-1. The nuclear receptor-β-catenin interaction may be an ancient mechanism of cell-fate decision.

Introduction

Diverse cell types can arise either from initially identical daughter cells that receive different instructions or by intrinsically asymmetric cell divisions whereby the two daughters inherit different molecular determinants and with them unequal developmental potentials (Kemphues, 2000; Betschinger and Knoblich, 2004; Roegiers and Jan, 2004). Conserved transduction pathways, such as Wnt signaling (Logan and Nusse, 2004), are critical for cell-fate decisions. In canonical cascades, a Wnt glycoprotein signals its receptor to stabilize β-catenin, which in turn cooperates with TCF/LEF transcription factors to activate a specific set of genes; in the absence of the Wnt signal, TCF/LEF proteins repress these genes. In *C. elegans*, polarity of asymmetric cell divisions is dictated by noncanonical Wnt pathways involving distinct β-catenins WRM-1 and SYS-1 and a MAPK-related

kinase, LIT-1 (Thorpe et al., 1997; Rocheleau et al., 1997, 1999; Meneghini et al., 1999; Ishitani et al., 1999; Korswagen et al., 2000; Korswagen, 2002; Siegfried and Kimble, 2002; Herman and Wu, 2004; Kidd et al., 2005). These pathways converge at the TCF/LEF homolog POP-1, whose asymmetric distribution is key to the polarity of cell fates (Lin et al., 1995, 1998; Meneghini et al., 1999; Herman, 2001; Maduro et al., 2002; Lo et al., 2004; Siegfried et al., 2004; Kidd et al., 2005; Shetty et al., 2005).

The gonad of *C. elegans* is a remarkable example of how a single asymmetric cell division establishes the axis of the entire organ. The gonad develops from two somatic gonad precursors (SGPs) Z1 and Z4 that flank germline founder cells Z2 and Z3 (Kimble and Hirsh, 1979) (Figure 1A). Distal daughters of Z1 and Z4 cells by their next division produce a unique distal tip cell (DTC), one per each lineage. In hermaphrodites, the two DTCs reside at the opposite poles of the gonad and guide elongation of its arms and proliferation of the germline. Thus, each gonadal arm is organized along a proximal-distal axis. The proximal SGP daughters divide twice to produce cells of which one is selected as the anchor cell (AC) (Figure 1A) that will induce the vulva (Kimble, 1981).

The current model for axis formation in the somatic gonad (Kidd et al., 2005) relies on asymmetric distribution of POP-1 between the immediate Z1/Z4 daughter cells (Siegfried et al., 2004). Based on evidence from the early embryo, this asymmetry can be generated by LIT-1- and WRM-1-dependent nuclear export of POP-1 (Rocheleau et al., 1999; Maduro et al., 2002; Lo et al., 2004) in the distal daughters, where the remaining nuclear POP-1 combines with limiting amounts of β-catenin SYS-1 to activate distal fate genes. One such POP-1 target required for DTC formation is a Hox gene, *ceh-22/tinman* (Lam et al., 2006), originally uncovered as *sys-3* (Siegfried et al., 2004). In the proximal daughters, SYS-1-free nuclear POP-1 is thought to be a repressor (Kidd et al., 2005). Impaired function of *lit-1*, *wrm-1*, *pop-1*, *sys-1*, or *ceh-22* leads to a Sys (symmetrical sisters) phenotype, when all SGP daughters adopt the proximal fate, thus increasing the number of AC precursors at the expense of DTCs (Miskowski et al., 2001; Siegfried and Kimble, 2002; Siegfried et al., 2004). Conversely, misexpression of SYS-1 or CEH-22 transforms proximal cells into extra DTCs (Kidd et al., 2005; Lam et al., 2006). As no factor that would be required for the proximal fate commitment has yet been reported, the proximal fate appears to be a signaling-independent "default state."

Here, we show that the establishment of both the distal and the proximal cell fates requires a proper balance between POP-1 activity and the action of the nuclear receptor NHR-25. Depletion of NHR-25 causes extra DTCs to form at the expense of the proximal AC precursors and reverts the Sys phenotype of the β-catenin/MAPK pathway mutants. NHR-25 antagonizes POP-1- and SYS-1-dependent transcription, while WRM-1 inhibits and SYS-1 stimulates activation by NHR-25. Since

*Correspondence: jindra@entu.cas.cz (M.J.); masako@paru.cas.cz (M.A.)

Figure 1. Excessive DTCs Form Instead of the Proximal Anchor Cell in *nhr-25(RNAi)* Hermaphrodites

(A) The asymmetric division of the somatic gonad precursors Z1 and Z4 occurs during the L1 stage at around 8 hr posthatching (Kimble and Hirsh, 1979). The following divisions produce two distal tip cells (DTC) and proximal cells, one of which is selected as the anchor cell (AC).

(B) Two DTCs and one AC in a normal worm (top) are visualized by *lag-2::gfp* and *cdh-3::gfp* markers, respectively. *nhr-25* RNAi applied by feeding since the time of hatching causes one (middle) or two (bottom) extra DTCs to form at the expense of the AC (arrows indicate the normal AC position).

(C) In situ hybridization reveals that *nhr-25* mRNA is expressed in the early gonad primordium (brackets). Bar = 20 μm.

(D) The endogenous NHR-25 protein is detected in the nuclei of Z1 and Z4 (arrows) but not in the Z2/Z3 germline precursors (arrowheads). The yellow line shows the approximate shape of the gonad primordium, and *lag-2::gfp* expression marks Z1 and Z4 cells.

(E) NHR-25 is also present in the immediate Z4 (yellow lines) and Z1 (out of focus) daughters. Bars in (D) and (E) = 10 μm. In all panels, anterior is to the left.

NHR-25 belongs to an ancient nuclear receptor family whose members functionally interact with β-catenin in mammals, the crosstalk between NHR-25 and β-catenin signaling, uncovered in the *C. elegans* gonad, may present a broadly conserved principle of cell-fate decision.

Results

Impaired *nhr-25* Function Causes an "All-Distal" Sys Phenotype

Unlike normal hermaphrodites with two DTCs, up to 55% of worms that were subjected to *nhr-25* RNAi silencing from the time of hatching developed three or four DTCs (Figure 1, Table 1, and Table S1). The ectopic DTCs could not be distinguished from normal DTCs by morphology or expression of a transgenic GFP marker derived from the *Delta*-like gene *lag-2* (Blelloch et al., 1999) (Figure 1B). Consistently, these cells were func-

tional in promoting germline differentiation and in leading the migration of gonadal arms; in case of four DTCs, two arms extended in the anterior and two in the posterior direction. The total number of DTCs never exceeding four and the simultaneous loss of the AC (Figure 1B and Table S1) argued that *nhr-25* RNAi disrupted the asymmetry of the fate-determining Z1/Z4 division that occurs at about 8 hr posthatching (Kimble and Hirsh, 1979) (Figure 1A) and not by causing proliferation of already distally specified cells. To confirm this idea, we applied *nhr-25* RNAi at increasing intervals after hatching. The latest time at which the DTC number could be altered (three DTCs in 3% of animals, n = 196) was 4 hr posthatching; starting from 7 hr, it was too late for *nhr-25* RNAi to affect the critical Z1/Z4 division (Table S1).

To verify the specificity of the *nhr-25* RNAi effect, we repeated feeding with dsRNA spanning two nonoverlapping regions of the *nhr-25* mRNA. Regardless of whether the region included the conserved DNA binding domain, the same gonad phenotype was observed (data not shown). Moreover, we used a related nuclear receptor gene, *nhr-23*, for control. While *nhr-23* RNAi caused expected Dumpy (Dpy) defects (Kostrouchova et al., 1998), it could not elicit the extra DTC phenotype at any time.

Because silencing of *nhr-25* causes extra DTCs to form at the expense of proximal Z1/Z4 descendants, it disrupts the gonad asymmetry in a sense opposite to all thus far reported Sys defects. These results therefore suggest that the normal role of NHR-25 is to promote the proximal fate or to antagonize the distal fate. Consistent with such a role, *nhr-25* mRNA is present in the SGPs (Figure 1C). The NHR-25 protein can be detected in the nuclei of Z1 and Z4 (Figure 1D) as well as in the nuclei of their daughter cells (Figure 1E), but not in the Z2 and Z3 precursors of the germline.

Table 1. *nhr-25* Genetically Interacts with *wrm-1* and *lit-1* during Gonad Development

RNAi Targets[a]		DTC Number (% Animals)		
Injection	Feeding	Missing (0–1)	Extra (3–4)	n
None	empty vector	1	0	516
	nhr-25	6[b]	55	228
wrm-1	empty vector	91	0	214
	nhr-25	27	14	193
lit-1	empty vector	23	0	66
	nhr-25	3	14	347

[a] Homozygous *rde-1* hermaphrodites were injected with either *wrm-1* or *lit-1* dsRNA and mated to *rde-1*[+/+] males carrying the *lag-2::gfp* DTC marker on plates seeded with either control bacteria with the empty pPD129.36 vector or bacteria expressing *nhr-25* dsRNA.
[b] Maternal contribution of *nhr-25* dsRNA prevents formation of the gonad primordium.

nhr-25 Antagonizes pop-1 and Other β-Catenin/MAPK Pathway Genes

While *nhr-25* is required for the specification of the proximal fate, *pop-1*, *sys-1*, *wrm-1*, and *lit-1* all promote the distal fate. To test for genetic interaction between *nhr-25* and the β-catenin/MAPK pathway, we primarily chose a *pop-1* mutation *(q645)* and a *sys-1* mutation *(q544)*, which both are fully penetrant for the gonadal Sys defect (Miskowski et al., 2001; Siegfried and Kimble, 2002). Because all SGP daughters become proximally specified and none yields a DTC in either *pop-1(q645)* or *sys-1(q544)* homozygous hermaphrodites, all adults lack both gonadal arms and are sterile. We found that *nhr-25* silencing applied from the time of hatching (but not after the critical Z1/Z4 division; Table S2) allowed 61% (n = 44) of *pop-1(q645)* hermaphrodites to develop one or both gonadal arms, i.e., clear evidence that DTCs also were formed (Figure 2). In addition, fertility was restored in 23 out of 141 examined *pop-1(q645); nhr-25(RNAi)* adults, indicating that the germline differentiated properly. The same suppression of the Sys phenotype was also observed in *sys-1(q544)* mutants subjected to *nhr-25* RNAi (Figure 2 and Table S2). This effect was specific to *nhr-25*, since the Sys phenotype of neither mutant could be reversed by RNAi targeting of the related nuclear receptor NHR-23 (data not shown).

The observed suppression was striking since the *pop-1(q645)* mutation was 100% penetrant for the Sys defect in animals with undisturbed *nhr-25* function. It implied that the MAPK/β-catenin pathway, which is essential for DTC formation, can signal even in the *pop-1(q645)* background. This finding and also the fact that the *pop-1(q645)* allele caused a single conservative substitution of aspartic acid 9 to glutamic acid (D9E) (Siegfried and Kimble, 2002) prompted us to examine whether the POP-1(q645) mutant protein might be partly functional. We therefore tested POP-1(q645) along with a nonconservative mutant version, POP-1(D9A), for the ability to activate a TCF-dependent pTOPFLASH reporter in SYS-1/β-catenin-dependent manner. Whereas the POP-1(D9A) protein did not activate at all, the ability of POP-1(q645) to induce pTOPFLASH expression in the presence of SYS-1 was only lowered as compared to wild-type POP-1 (Figure 3).

Simultaneous RNAi silencing of *pop-1* and *nhr-25* reduced the effect of *pop-1* RNAi on DTC loss as well as the effect of *nhr-25* RNAi on DTC surplus, respectively (Table S3). In comparison to *pop-1* RNAi, *sys-1* knockdown was more effective in suppressing the extra DTC phenotype caused by *nhr-25* RNAi. Conversely, silencing of *nhr-25* only mildly suppressed the effect of *sys-1* RNAi on DTC loss (Table S3). Since *sys-1* is dose-sensitive and haploinsufficient (Kidd et al., 2005), these differences may reflect a relatively higher sensitivity of *sys-1* to RNAi.

The above results further confirmed that NHR-25 antagonized POP-1 and SYS-1. A similar relationship was also found between *nhr-25* and genes encoding the kinase LIT-1 and the β-catenin WRM-1 (Table 1). *nhr-25* RNAi reduced to about one-third the effect of *wrm-1* RNAi and abolished the effect of *lit-1* RNAi on DTC loss. Conversely, silencing of either *wrm-1* or *lit-1* reduced frequency of the extra DTC phenotype caused by *nhr-25* RNAi from 55% to 14% (Table 1). Together,

Figure 2. *nhr-25* Counteracts *pop-1* and *sys-1* during Gonad Development

The absence of DTCs and hence of the gonad arms caused in hermaphrodites by *pop-1(q645)* (top left) or by *sys-1(q544)* (not shown) (Miskowski et al., 2001) mutations can be reverted by *nhr-25* RNAi. Three DTCs may develop and consequently two gonadal arms migrate in the same direction in some *sys-1(q544); nhr-25(RNAi)* (bottom) or *pop-1(q645); nhr-25(RNAi)* (not shown) hermaphrodites. Arrowheads point to DTCs; asterisk indicates an embryo.

these results suggested that NHR-25 opposed β-catenin/MAPK signaling during cell fate decision in the somatic gonad precursors. Since *nhr-25* RNAi did not appear to alter the distribution of a transgenic GFP::POP-1 fusion protein (Siegfried et al., 2004) (Figure S1), NHR-25 likely acted in parallel to β-catenin/MAPK signaling and POP-1.

NHR-25 Binds β-Catenins WRM-1 and SYS-1

We next asked whether NHR-25 interacts with the β-catenin/MAPK pathway by making direct contact with some of its components. Yeast two-hybrid assay

Figure 3. POP-1(q645) Mutant Protein Retains Partial Function

When transfected to HEK239 cells, the POP-1(q645) mutant bearing a D9E substitution could still activate the pTOPFLASH reporter in a SYS-1/β-catenin-dependent manner (gray columns), albeit at a reduced rate compared to wild-type POP-1 (black columns). Mutation of D9 to alanine (D9A) abolished the activation completely (open columns). Inset shows that protein expression levels did not differ among the three POP-1 variants. pFOPFLASH was used for negative control. Luciferase activities normalized for the *Renilla* internal control are expressed relative to the activity of wild-type POP-1 in the absence of SYS-1, arbitrarily set to 1. Values are average plus standard deviation of three independent experiments, each of which was done in triplicate; the amounts of transfected plasmid DNAs are given for the entire triplicate experiment.

Figure 4. NHR-25 Interacts with β-Catenins WRM-1 and SYS-1

(A) In yeast two-hybrid assay, deletion of 23 C-terminal amino acids prevented reporter activation by WRM-1 in the presence of a control (T-antigen), but not its interaction with NHR-25ΔD (lacking the DNA binding domain). Removal of either the 216 N-terminal amino acids (WRM-1ΔN), of the C terminus (WRM-1ΔC236) or both (WRM-1AR) abolished the interaction. LIT-1 and POP-1 bound their partners, WRM-1 and SYS-1, respectively, but neither bound NHR-25ΔD. In all assays, fusions with the Gal4 activation domain (AD) are on the left. S, selective conditions; C, control plate.

(B) In vitro-translated and ^{35}S-labeled NHR-25 was pulled down in complexes with bacterially produced GST-WRM-1 and GST-SYS-1 fusion proteins, but not with another β-catenin BAR-1. Bottom gel shows Coomassie blue staining of the GST fusion proteins.

(C) NHR-25 immunoprecipitated with full-length WRM-1 (W, lane 3) but not with its truncated version WRM-1(AR) (AR, lane 4). Lysates from transfected HEK239 cells were precipitated with anti-NHR-25 or an unrelated (α-IR) antibody. Control cells received no NHR-25 (lanes 7 and 8). Epitope-tagged WRM-1 proteins were detected with α-Myc antibody.

(D) SYS-1 (detected with α-Myc) immunoprecipitated with NHR-25 (N, lane 1) but not with NHR-25ΔL lacking the ligand binding domain (ΔL, lane 2). Because the NHR-25 antibody is directed against the deleted ligand binding domain (Silhankova et al., 2005), NHR-25 was tagged with EGFP to allow immunoprecipitation and detection with an anti-EGFP antibody. No complex was recovered from the transfected cells with the control α-IR antibody.

revealed binding of NHR-25 to β-catenin/WRM-1 but not to POP-1 or LIT-1 proteins (Figure 4A); SYS-1 could not be tested because when fused to the Gal4 DNA binding domain, it strongly activated gene expression in the yeast. WRM-1 was only a moderate transcriptional activator, and by deleting 23 amino acids from its carboxyl end, we obtained WRM-1ΔC that did not activate alone but still interacted with NHR-25 (Figure 4A). Removal of either the N-terminal 216 amino acids (WRM-1ΔN) or the C-terminal 236 amino acids from WRM-1 abolished the interaction. WRM-1 lacking both ends and containing the armadillo repeats (WRM-1AR) was also incapable of binding NHR-25 (Figure 4A). GST pull-down with in vitro-translated NHR-25 and bacterially produced β-catenin proteins was performed to confirm that the binding was direct. In this assay, NHR-25 bound WRM-1 and SYS-1 but not another *C. elegans* β-catenin, BAR-1 (Figure 4B). Finally, interaction of NHR-25 with WRM-1 and SYS-1 was verified by coimmunoprecipitation in transfected cell culture. Consistent with the yeast two-hybrid data, WRM-1 but not WRM-1AR could be immunoprecipitated with NHR-25 by using a NHR-25-specific antibody (Figure 4C, lanes 3 and 4). SYS-1 coimmunoprecipitated with NHR-25, but not with its C-terminally truncated version lacking the ligand binding domain (NHR-25ΔL) (Figure 4D, lanes 1 and 2). As the NHR-25-specific antibody reacted poorly with the truncated NHR-25 protein, EGFP-tagged proteins and an anti-EGFP antibody were used in these experiments. Nevertheless, coimmunoprecipitation with SYS-1 was specific to full-length NHR-25 because in a parallel assay, neither EGFP-NHR-25ΔL nor a control, EGFP protein, bound to SYS-1 (Figure 4D and data not shown).

Crosstalk between NHR-25 and β-Catenins WRM-1 and SYS-1 at the Level of Transcriptional Activation

The antagonism between NHR-25 and β-catenin/MAPK signaling that was uncovered by genetic experiments suggested that WRM-1 might be a negative regulator of NHR-25. We tested the relationship between NHR-25 and WRM-1 in cell transfection assays with NHR-25-dependent luciferase reporters, one containing a tandem of Ftz-F1/SF-1 consensus binding sites (designated 2×TCA) or their mutated version 2×TCT (Figure 5A), and the other based on five SF-1 binding sites from the mouse *CYP21* gene (Figure 5B). NHR-25 alone stimulated transcription of both reporters in a dose-dependent manner (not shown and Figure 5B). Activation by an intermediate dose of NHR-25 was progressively suppressed by increasing doses of WRM-1 (Figures 5A and 5B), while the truncated WRM-1AR version that failed to bind NHR-25 (Figures 4A and 4C) had no effect. In contrast, the other β-catenin SYS-1 stimulated NHR-25-dependent transactivation of both reporters (Figures 5A and 5B). Thus, the two functionally distinct β-catenins modulated NHR-25 activity in opposite ways.

In addition to being regulated by WRM-1 and SYS-1, NHR-25 itself might antagonize POP-1 by interfering with transcription activated by the POP-1/SYS-1 nuclear complex. We verified this possibility by using the pTOP-FLASH reporter. While full-length NHR-25 clearly inhibited pTOPFLASH activation by POP-1 and SYS-1, NHR-25 lacking its ligand binding domain (NHR-25ΔL) had no effect (Figure 5C). The inhibition likely occurred through NHR-25 binding to SYS-1, since full-length NHR-25 but not NHR-25ΔL coimmunoprecipitated with SYS-1 (Figure 4D, lanes 1 and 2).

Discussion

Role of NHR-25 in the Early Somatic Gonad

The effect of NHR-25 in the early gonad opposed that of MAPK/β-catenin signaling because only distal cells formed when NHR-25 function was reduced, and only proximal cells resulted from the compromised

Figure 5. Crossregulation between β-Catenin, NHR-25, and POP-1

(A and B) WRM-1 inhibits and SYS-1 stimulates NHR-25-dependent transcription. HEK293 cells were cotransfected with an NHR-25 expression plasmid and either with luciferase reporters driven by two Ftz-F1/SF-1 consensus binding elements (2×TCA) and their mutant version (2×TCT) (A) or with the 5×SF-1-luc reporter (B). Activation by intermediate NHR-25 levels (broken line in B) was suppressed by increasing doses (0.5, 1.0, and 1.5 μg DNA) of WRM-1 (gray columns), but not by the truncated WRM-1AR (hatched columns). SYS-1 (open columns) enhanced NHR-25-dependent activation of both 2×TCA and 5×SF-1-luc reporters. Inset in (B) shows that NHR-25 expression did not change among experiments.

(C) NHR-25 interferes with POP-1/SYS-1 activity. pTOPFLASH activation by cotransfected POP-1 and SYS-1 was inhibited by increasing doses (0.5, 1.0, and 1.5 μg DNA) of NHR-25 (open columns) but not by NHR-25ΔL (gray columns). The inhibition was not due to altered POP-1 or SYS-1 expression (bottom). In all panels, luciferase activities corrected for the *Renilla* internal control are expressed relative to reporter activities in control cells, arbitrarily set to 1. Values are average plus standard deviation of three independent experiments, each of which was done in triplicate; the microgram amounts of transfected plasmid DNAs are given for the entire triplicate experiment.

MAPK/β-catenin pathway activity. Perturbing NHR-25 and this pathway simultaneously permitted both the distal and proximal fates to be established. Strikingly, depletion of NHR-25 restored gonad differentiation in *pop-1(q645)* mutants that otherwise never develop DTCs (Siegfried and Kimble, 2002). Although mutation of the invariably conserved aspartate to a glutamate residue disrupted POP-1 binding to SYS-1/β-catenin in yeast (Kidd et al., 2005), we suspected that the POP-1(q645) mutant protein was still partly active. That this was indeed true was not surprising given the conservative nature of the substitution and the fact that POP-1(q645) weakly bound β-catenin BAR-1 (Kidd et al., 2005). Interestingly, *ceh-22b::VENUS* expression was not completely abolished in *pop-1(q645)* worms (Lam et al., 2006), indicating that the mutant protein was also partly functional in vivo.

Since neither the mutationally induced POP-1 defect nor RNAi knockdown of *nhr-25* (whose deletion is embryonic lethal, Asahina et al., 2000) represent complete loss-of-function situations, epistasis between NHR-25 and POP-1 is not obvious. Like SYS-1, NHR-25 does not seem to be required for POP-1 asymmetry. In fact, NHR-25 role in POP-1 distribution between the SGP daughters may not be expected since neither equal POP-1 distribution (Siegfried et al., 2004) nor its reversed asymmetry (Chang et al., 2005) transforms proximal cells to distal. Defects in the MAPK/β-catenin pathway and NHR-25 complement each other: whereas *nhr-25* knockdown allows more cells to become DTCs in *pop-1*, *sys-1*, *lit-1*, or *wrm-1* RNAi backgrounds, silencing of any of these genes reduces the frequency of extra DTCs caused by shortage of NHR-25. In our view, these interactions reflect a mutual balance that must exist between competing NHR-25 and MAPK/β-catenin programs in order for both fates to be established.

To explain how this balance may be achieved, we propose two alternative but compatible models (Figure 6). Both models rely on unequal distribution of WRM-1 and LIT-1 between daughters of asymmetric cell divisions, which has been demonstrated in the early embryo (Lo et al., 2004; Nakamura et al., 2005) and in several cell types during postembryonic development (Takeshita

Figure 6. Model for NHR-25 Interaction with the β-Catenin/MAPK Pathway during Cell-Fate Specification of the Somatic Gonad Precursors

(A) NHR-25 promotes proximal fate as a negative modulator of SYS-1/POP-1 activity in the proximal Z1/Z4 daughter cell. In the distal daughter, WRM-1 and LIT-1 mediate nuclear export of excess POP-1, allowing the remaining POP-1 to combine with SYS-1 and to activate distal genes (based on the model in Kidd et al., 2005). NHR-25 may be inactivated by WRM-1 binding (dotted line).

(B) NHR-25 promotes proximal fate by regulating its own target gene(s). SYS-1 enhances NHR-25 activity. In the distal cell, WRM-1 prevents NHR-25-dependent activation of "proximal genes." Both the A and B models may apply together.

and Sawa, 2005). In all cases (including the distal daughters of Z1 and Z4, H. Sawa, personal communication), WRM-1 and LIT-1 accumulate in the nuclei of those cells that display less nuclear POP-1, presumably due to LIT-1- and WRM-1-mediated nuclear export of POP-1 (Rocheleau et al., 1999; Lo et al., 2004).

In model A, NHR-25 ensures the correct fate of the proximal SGP daughter by preventing POP-1/SYS-1-dependent activation of distal genes (Figure 6). In the distal cell, WRM-1 plays two roles. First, as proposed by Kidd and colleagues, WRM-1 and LIT-1 mediate nuclear export of excess POP-1, allowing the remaining POP-1/SYS-1 complex to trigger distal genes (Kidd et al., 2005). Second, WRM-1 may prevent NHR-25 from binding SYS-1 and thus from inhibiting POP-1 activation. Whether WRM-1 and SYS-1 compete for NHR-25 binding remains to be tested, but this idea is suggested by apparently stronger NHR-25 interaction with WRM-1 as compared to SYS-1 in vitro (Figure 4B). If WRM-1 prevails in the distal cell nucleus, NHR-25 would be more likely combined with it rather than with SYS-1. Model B predicts that the absence of nuclear WRM-1 in the proximal cell allows NHR-25 to turn on its own proximal target gene(s). In this case, SYS-1 can enhance NHR-25 activity. In the distal cell, WRM-1 would prevent NHR-25-dependent activation of these proximal genes. Since we have not yet identified any direct NHR-25 target, there is no definite proof for model B.

Future studies on NHR-25 may help us resolve some open questions about gonad development. According to the recent model (Kidd et al., 2005), high nuclear POP-1 is a repressor of distal genes in the proximal SGP daughter. However, POP-1-dependent repression could not be demonstrated for the freshly characterized distal gene ceh-22b (Lam et al., 2006). Whether NHR-25 represses ceh-22b or whether it acts upon POP-1-independent targets needs to be tested. Another question concerns a missing signal that would polarize the early somatic gonad. Although upstream Wnt signaling components such as LIN-17/Frizzled (Sternberg and Horvitz, 1988; Siegfried and Kimble, 2002) and DSH-2/Disheveled (Chang et al., 2005) contribute to SGP asymmetry, none of the five known C. elegans Wnts appears to be required for it (Siegfried and Kimble, 2002). Recently, mammalian NHR-25 homologs have been shown to bind phospholipid ligands (Krylova et al., 2005; Li et al., 2005). If NHR-25 requires an activating ligand, then this molecule, rather than a Wnt, might be the missing polarizing cue for the somatic gonad precursors.

NHR-25 Interaction with β-Catenin Signaling Is Evolutionarily Conserved
The present study introduces NHR-25 as a new player and, to our knowledge, as the first C. elegans nuclear receptor to be involved in β-catenin signaling. Homologs of NHR-25, the steroidogenic factor 1 (SF-1) and the liver receptor homolog 1 (LRH-1), have been shown to interact with β-catenin in mammalian models. Thus, a functional relationship between β-catenin and the NR5 family of nuclear receptors is common to worms and mammals.

Synergy between SF-1 and β-catenin is important for male sexual differentiation, e.g., for TCF4-dependent expression of a Müllerian inhibiting substance receptor (Hossain and Saunders, 2003). Conversely, the β-cate-

nin-SF-1 complex stimulates SF-1-dependent activation of the Dax-1 (Mizusaki et al., 2003) and α-inhibin (Gummow et al., 2003) genes. Interestingly, the Wnt4 signal opposes male sexual development by repressing the cooperation between β-catenin and SF-1 (Jordan et al., 2003). A two-way synergy between β-catenin and LRH-1 has been proposed to stimulate cell proliferation in mice: whereas β-catenin enhances expression of an LRH-1 target gene, cyclin E1, LRH-1 serves as a coactivator to the TCF4-β-catenin complex on the cyclin D1 promoter (Botrugno et al., 2004). This LRH-1-TCF4 crossregulation perhaps best parallels a scenario in which NHR-25 and POP-1 act on their own target genes (Figure 6).

In the light of the above examples of mutual synergy, it was somewhat surprising that NHR-25 inhibited POP-1- and SYS-1-dependent gene expression, whereas WRM-1 inhibited the transcriptional activity of NHR-25. One reason may be that in contrast to mammals, the noncanonical C. elegans pathway employs structurally unusual and functionally distinct β-catenin molecules (Korswagen et al., 2000; Natarajan et al., 2001; Kidd et al., 2005). Unlike WRM-1, SYS-1 (which serves as coactivator to POP-1) stimulated NHR-25-dependent reporter expression, a situation similar to the synergy between β-catenin and SF-1 (Gummow et al., 2003; Hossain and Saunders, 2003; Jordan et al., 2003; Mizusaki et al., 2003) or LRH-1 (Botrugno et al., 2004). Additionally, Gummow and colleagues showed that increased levels of TCF4 disrupted the synergy between SF-1 and β-catenin on the SF-1-responsive α-inhibin promoter (Gummow et al., 2003). Therefore, both positive and negative regulation can occur between nuclear receptors NHR-25 or SF-1 and β-catenin signaling.

Accumulating literature shows that modulation between Wnt/β-catenin signaling and numerous types of nuclear receptors proceeds in both directions: nuclear receptors block or stimulate Wnt signaling, while Wnt pathways positively or negatively affect the transcriptional activity of nuclear receptors (reviewed in Mulholland et al., 2005). This regulatory interplay emerges as an important means of controlling cell differentiation. Our study shows that the β-catenin-nuclear receptor crosstalk has been conserved in distant animal phyla and that the C. elegans system allows us to link it with developmental decisions of specific cells in vivo.

Experimental Procedures

Worms and RNA Interference
C. elegans was reared at 20°C according to standard protocols (Brenner, 1974). The following strains were used. GS2806 dpy-20(e1362); arIs51[dpy-20(+); cdh-3::gfp] (Pettitt et al., 1996) strain was a gift from I. Greenwald (Columbia University, New York, NY). JK3785 sys-1(q544)/hT2(qIs48); qIs90 (Lam et al., 2006) was kindly provided by J. Kimble (University of Wisconsin, Madison, WI). JK2868 qIs56[lag-2::gfp] (Blelloch et al., 1999), JK2944 pop-1(q645) (Siegfried and Kimble, 2002), JK3437 him-5(e1490); qIs74 (Siegfried et al., 2004), and WM27 rde-1(ne219) (Tabara et al., 1999) were obtained from the Caenorhabditis Genetics Center, supported by the National Institutes of Health. GS2806 and JK2868 were crossed to generate a strain carrying both cdh-3::gfp and lag-2::gfp. The N2 variety Bristol was used as the wild-type.

RNA interference (RNAi) by feeding was essentially performed as described (Timmons et al., 2001). pPD129.36 vector (a gift from A. Fire, Carnegie Institution of Washington, Baltimore, MD) was

used for dsRNA expression in *Escherichia coli* HT115 (a gift from D. Court, National Cancer Institute, Frederick, MD). Bacteria carrying a pPD129.36 construct were grown to $OD_{600} = 0.4$ in LB medium containing 50 μg/ml carbenicillin and 12.5 μg/ml tetracycline, and dsRNA was induced for 4 hr with 0.4 mM isopropyl-β-D-thiogalactoside (IPTG). Bacteria were concentrated by centrifugation and seeded on nematode growth medium (NGM) agarose plates containing both antibiotics and 0.4 mM IPTG. Bacteria carrying pPD129.36 without an insert were used for control.

To synchronize the worms, eggs from hermaphrodites were harvested by using the hypochlorite method and were placed on nonseeded NGM plates. Larvae that hatched within the first 2 hr were discarded. Fresh L1 larvae that hatched within 30 min were then collected, transferred to seeded plates, and kept at 20°C. For RNAi applied at later times than immediately from hatching, the fresh L1 larvae were first fed (for 4, 7, 10, or 20 hr) on plates seeded with IPTG-induced control HT115 bacteria carrying the empty pPD129.36 vector and then transferred to dsRNA-expressing bacteria.

For double-target RNAi, cultures of *E. coli* expressing dsRNAs were pooled at equal ratio of cells, concentrated by centrifugation and seeded. Alternatively, zygotic RNAi was performed by injecting *rde-1(ne219)* (Tabara et al., 1999) hermaphrodites with in vitro-synthesized *wrm-1* or *lit-1* dsRNA. Injected worms were then mated with wild-type males carrying the *lag-2::gfp* transgene on plates seeded either with IPTG-induced bacteria containing the empty pPD129.36 vector or on bacteria that expressed *nhr-25* dsRNA.

Plasmid Constructs

The following yk clones were used to prepare RNAi constructs in pPD129.36: yk342d8 (*nhr-25*), yk1529d11 (*lit-1*), yk1201e5 (*wrm-1*). For *pop-1* and *sys-1* RNAi constructs, cDNAs were amplified from N2 worms by using RT-PCR.

cDNAs containing the complete open-reading frames of each gene were obtained from N2 worms by using RT-PCR and were sequenced in their entirety before cloning into expression vectors. Deletion mutants of each protein were generated either by subcloning restriction fragments of the cDNAs or by PCR with internally positioned primers; in the latter case, the resulting DNA was resequenced. Plasmids for yeast two-hybrid assays were prepared in the pGADT7 (Gal4AD fusion) and pGBKT7 (Gal4DBD fusion) vectors (Clontech). The Gal4AD fusion vectors included: pGADT7(T-ant), control construct with SV40 large T-antigen; pGADT7(NHR-25ΔD), NHR-25(117–572), deletion of the DNA binding domain; pGADT7(WRM-1), full-length WRM-1; and pGADT7(SYS-1), full-length SYS-1. The Gal4DBD fusion vectors included: pGBKT7(Lam), control construct with human lamin C; pGBKT7(WRM-1), full-length WRM-1; pGBKT7(WRM-1ΔC), WRM-1(1–773), deletion of the 23 C-terminal amino acids; pGBKT7(WRM-1ΔN), WRM-1(217–796), deletion of the 216 N-terminal amino acids; pGBKT7(WRM-1ΔC236), WRM-1(1–560), deletion of the 236 C-terminal amino acids; pGBKT7(WRM-1AR), WRM-1(135–560), deletion of the 134 N-terminal and of the 236 C-terminal amino acids; pGBKT7(POP-1), full-length POP-1; and pGBKT7(LIT-1), full-length LIT-1.

For transfections of mammalian cells, the following constructs encoding Myc epitope-tagged proteins were prepared in the pK-Myc-C3 vector (Valenta et al., 2003): pK-Myc-C3(SYS-1), full-length SYS-1; pK-Myc-C3(WRM-1), full-length WRM-1; and pK-Myc-C3(WRM-1AR), WRM-1(135–560), deletion of the 134 N-terminal and of the 236 C-terminal amino acids. The following HA-tagged proteins were expressed from pHAK-B vectors, HA-tag variants of the pK-Myc-C plasmids: pHAK-B2(NHR-25), full-length NHR-25; pHAK-B2(NHR-25ΔL), NHR-25(1–320), deletion of the ligand binding domain; and pHAK-B3(POP-1), full-length wild-type POP-1. Mutant forms POP-1(D9E), corresponding to POP-1(p645) (Siegfried and Kimble, 2002), and POP-1(D9A) were generated by PCR with forward primers, in which the ninth GAT codon had been mutated either to GAA (glutamic acid) or to GCT (alanine) and expressed from pHAK-B3. The pEGFP-C2 plasmid (Clontech) was used for expression of full-length NHR-25 and its truncated version NHR-25ΔL, N-terminally fused with EGFP.

Yeast Two-Hybrid Assay

Yeast two-hybrid analyses were performed by using the Matchmaker Two-Hybrid System 3 (Clontech). Yeast transformation was done with the lithium acetate method as described by the manufacturer. Bait (Gal4 DNA binding domain fusion) and prey (Gal4 activation domain fusion) plasmids in the 2:1 ratio, respectively, were cotransformed in a single step. Transformants were selected on SD/-Leu/-Trp plates after incubation at 30°C for 3 days. Several single colonies were picked for each transformant, resuspended in 100 μl of water, and cell numbers were counted. Suspensions were diluted about ten and 100 times to equal cell concentrations, and 5 μl aliquots from each dilution were spotted onto SD/-Leu/-Trp and SD/-Ade/-His/-Leu/-Trp plates. Yeast growth was photographed after 3 days of incubation at 30°C.

GST Pull-Down Assay

GST alone and full-length GST-BAR-1, GST-WRM-1, and GST-SYS-1 fusion proteins were expressed from pET-42b (Novagen) in *E. coli* strain BL21-CodonPlus (Stratagene) and bound to Glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech). The full-length NHR-25 protein was produced from the pHAK-B2(NHR-25) construct in vitro by using the T7 TNT Coupled Reticulocyte System (Promega). Standard 50 μl transcription-translation reactions were supplemented with 4 μl [^{35}S]-methionine (ICN Biomedicals) per reaction. Four microliters of the radiolabeled NHR-25 were incubated with the immobilized GST-fused proteins in 20 mM HEPES (pH 7.9), 150 mM KCl, 10% glycerol, 0.2% Tween-20, 1 mM DTT, Protease Inhibitor Cocktail (Roche) for 1 hr at 4°C. Beads were collected by centrifugation and washed six times, 10 min per wash, in 20 mM HEPES (pH 7.9), 200 mM KCl, 10% glycerol, 0.2% Tween-20, 1 mM DTT at 4°C. Bound proteins were separated on 10% SDS-PAGE and analyzed by autoradiography.

Cell Culture, Transfections, and Luciferase Assays

Human embryonic kidney (HEK) cell line 293 (EAAC) was maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (Hyclone) and antibiotics. Only mycoplasma-free cells were used in the experiments. Transfections were performed with the Lipofectamine reagent (Invitrogen).

Reporter gene assays were performed as described previously (Valenta et al., 2003) with the firefly luciferase pTOPFLASH and pFOPFLASH reporters (Korinek et al., 1997) to assay POP-1/TCF-mediated transcription. The transcriptional activity of NHR-25 was tested with two types of reporters. First, pOLDO-luciferase constructs were driven by two copies of the SF-1/Ftz-F1 binding consensus sequence TCAAGGTCA or by two copies of the ROR binding site TCTAGGTCA, a gift from M. Van Gilst (Fred Hutchinson Cancer Research Center, Seattle, WA) (Van Gilst et al., 2002). Second, a 5×SF-1 luciferase reporter containing five copies of the SF-1 response element from the mouse *CYP21* gene (Ikeda et al., 1993) was provided by G. Hammer (University of Michigan, Ann Arbor, MI).

Cells were seeded onto 12-well plates (approximately 2×10^5 cells per well) and in triplicates were transfected 4 hr later with a Lipofectamine mixture containing 50 ng pTK-*Renilla* plasmid (Promega) as an internal control, 400 ng luciferase reporter plasmid, and up to 3 μg appropriate expression vector(s) (these DNA amounts therefore apply to the whole set of three wells). The total amount of DNA was kept constant by adding empty expression vector where necessary. Twenty-four hours posttransfection, the cells were harvested and processed by using the Dual Luciferase Reporter Assay System (Promega). All reporter gene assays were done in triplicates, and data were presented as average values with standard deviations from a minimum of three independent experiments after normalization against the *Renilla* luciferase activities.

In Situ Hybridization

In situ hybridization of *nhr-25* mRNA was performed on wild-type (N2) animals with a digoxigenin-labeled cDNA probe (clone *yk663g4*) as previously described (Asahina et al., 2000 and http://nematode.lab.nig.ac.jp/method/index.php).

Antibody Staining and Coimmunoprecipitation

Rabbit antiserum against a portion of the ligand binding domain of NHR-25 was described previously (Silhankova et al., 2005). For immunostaining of *C. elegans*, this antiserum was purified on a PROSEP-rA High Capacity recombinant protein A column (Millipore). Larvae were prepared and stained as described (Silhankova et al.,

2005), except that the purified anti-NHR-25 antibody was diluted 1:200, and detection was with 1:500 goat anti-rabbit IgG conjugated with biotin (Molecular Probes), followed by 1:500 streptavidin-Alexa 568 (Molecular Probes). Worms were mounted in the VectaShield (Vector) medium containing 1 μg/ml DAPI for DNA counterstaining. Images were captured with Axioplan 2 Zeiss fluorescent microscope.

Epitope-tagged proteins were detected with anti-Myc 9E10 (Roche), anti-HA 12CA5 (Roche), and anti-GFP JL-8 (Clontech) mouse monoclonals or with rabbit antiserum against bacterially expressed full-length EGFP. For coimmunoprecipitations, 0.5–1.0 $\times$ 10^7 cells were harvested, washed twice in ice-cold PBS, and lysed in extraction buffer: 20 mM Tris-HCl (pH 7.5), 200 mM NaCl, 0.5% Triton X-100, 0.2 mM EDTA, 0.75 mM β-mercaptoethanol, and protease inhibitors (Roche) for 10 min on ice. Lysates were briefly sonicated on ice, incubated in a rotator for 15 min at 4ºC, and centrifuged (13,000 rpm, 4ºC, 20 min). The supernatant was transferred to a fresh tube and incubated with the appropriate antibody coupled to protein A Sepharose beads (Pierce) (20 μl rabbit antiserum were preincubated with 25 μl of beads for 1 hr at 4ºC and then washed three times with the extraction buffer). The mixture was incubated in a rotator for 3 hr at 4ºC, centrifuged, the supernatant was removed, and the precipitate was washed four times with 1 ml extraction buffer containing 0.3% Tween-20 (Fluka) instead of Triton X-100. Proteins were boiled in SDS sample buffer, separated on SDS-PAGE, and transferred to polyvinylidene fluoride membranes (Pall Gelman Laboratory). After incubation with the appropriate primary antibodies, proteins were detected with horseradish peroxidase-conjugated goat anti-mouse (BioRad) or goat anti-rabbit (Sigma) polyclonal antisera, followed by visualization with an enhanced chemiluminescence system (Pierce).

Supplemental Data

Supplemental Data include one figure and three tables and are available at http://www.developmentalcell.com/cgi/content/full/11/2/203/DC1/.

References

Asahina, M., Ishihara, T., Jindra, M., Kohara, Y., Katsura, I., and Hirose, S. (2000). The conserved nuclear receptor Ftz-F1 is required for embryogenesis, moulting and reproduction in *Caenorhabditis elegans*. Genes Cells *5*, 711–723.

Betschinger, J., and Knoblich, J.A. (2004). Dare to be different: asymmetric cell division in *Drosophila, C. elegans* and vertebrates. Curr. Biol. *14*, R674–R685.

Botrugno, O.A., Fayard, E., Annicotte, J.S., Haby, C., Brennan, T., Wendling, O., Tanaka, T., Kodama, T., Thomas, W., Auwerx, J., and Schoonjans, K. (2004). Synergy between LRH-1 and beta-catenin induces G(1) cyclin-mediated cell proliferation. Mol. Cell *15*, 499–509.

Blelloch, R., Anna-Arriola, S.S., Gao, D., Li, Y., Hodgkin, J., and Kimble, J. (1999). The *gon-1* gene is required for gonadal morphogenesis in *Caenorhabditis elegans*. Dev. Biol. *216*, 382–393.

Brenner, S. (1974). The genetics of *C. elegans*. Genetics *77*, 71–94.

Chang, W., Lloyd, C.E., and Zarkower, D. (2005). DSH-2 regulates asymmetric cell division in the early *C. elegans* somatic gonad. Mech. Dev. *122*, 781–789.

Gummow, B.M., Winnay, J.N., and Hammer, G.D. (2003). Convergence of Wnt signaling and steroidogenic factor-1 (SF-1) on transcription of the rat inhibin α gene. J. Biol. Chem. *278*, 26572–26579.

Herman, M.A. (2001). *C. elegans* POP-1/TCF functions in a canonical Wnt pathway that controls cell migration and in a noncanonical Wnt pathway that controls cell polarity. Development *128*, 581–590.

Herman, M.A., and Wu, M. (2004). Noncanonical Wnt signaling pathways in *C. elegans* converge on POP-1/TCF and control cell polarity. Front. Biosci. *9*, 1530–1539.

Hossain, A., and Saunders, G.F. (2003). Synergistic cooperation between the β-catenin signaling pathway and steroidogenic factor 1 in the activation of the Mullerian inhibiting substance type II receptor. J. Biol. Chem. *278*, 26511–26516.

Ikeda, Y., Lala, D.S., Luo, X., Kim, E., Moisan, M.P., and Parker, K.L. (1993). Characterization of the mouse *FTZ-F1* gene, which encodes a key regulator of steroid hydroxylase gene expression. Mol. Endocrinol. *7*, 852–880.

Ishitani, T., Ninomiya-Tsuji, J., Nagai, S., Nishita, M., Meneghini, M., Barker, N., Waterman, M., Bowerman, B., Clevers, H., Shibuya, H., and Matsumoto, K. (1999). The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature *399*, 798–802.

Jordan, B.K., Shen, J.H.C., Olaso, R., Ingraham, H.A., and Vilain, E. (2003). Wnt4 overexpression disrupts normal testicular vasculature and inhibits testosterone synthesis by repressing SF-1/b-catenin synergy. Proc. Natl. Acad. Sci. USA *100*, 10866–10871.

Kemphues, K. (2000). PARsing embryonic polarity. Cell *101*, 345–348.

Kidd, A.R., III, Miskowski, J.A., Siegfried, K.R., Sawa, H., and Kimble, J. (2005). A β-catenin identified by functional rather than sequence criteria and its role in Wnt/MAPK signaling. Cell *121*, 761–772.

Kimble, J. (1981). Alterations in cell lineage following laser ablation of cells in the somatic gonad of *Caenorhabditis elegans*. Dev. Biol. *87*, 286–300.

Kimble, J., and Hirsh, D. (1979). The postembryonic cell lineages of the hermaphrodite and male gonads in *Caenorhabditis elegans*. Dev. Biol. *70*, 396–417.

Korinek, V., Barker, N., Morin, P.J., van Wichen, D., de Weger, R., Kinzler, K.W., Vogelstein, B., and Clevers, H. (1997). Constitutive transcriptional activation by a β-catenin-Tcf complex in APC$^{-/-}$ colon carcinoma. Science *275*, 1784–1787.

Korswagen, H.C. (2002). Canonical and non-canonical Wnt signaling pathways in *Caenorhabditis elegans*: variations on a common signaling theme. Bioessays *24*, 801–810.

Korswagen, H.C., Herman, M.A., and Clevers, H.C. (2000). Distinct β-catenins mediate adhesion and signalling functions in *C. elegans*. Nature *406*, 527–532.

Kostrouchova, M., Krause, M., Kostrouch, Z., and Rall, J.E. (1998). CHR3: a *Caenorhabditis elegans* orphan nuclear hormone receptor required for proper epidermal development and molting. Development *125*, 1617–1626.

Krylova, I.N., Sablin, E.P., Moore, J., Xu, R.X., Waitt, G.M., MacKay, J.A., Juzumiene, D., Bynum, J.M., Madauss, K., Montana, V., et al. (2005). Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1. Cell *120*, 343–355.

Lam, N., Chesney, M.A., and Kimble, J. (2006). Wnt Signaling and CEH-22/tinman/Nkx2.5 specify a stem cell niche in *C. elegans*. Curr. Biol. *16*, 287–295.

Li, Y., Choi, M., Cavey, G., Daugherty, J., Suino, K., Kovach, A., Bingham, N.C., Kliewer, S.A., and Xu, H.E. (2005). Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1. Mol. Cell *17*, 491–502.

Lin, R., Thompson, S., and Priess, J.R. (1995). *pop-1* encodes an HMG box protein required for the specification of a mesoderm precursor in early *C. elegans* embryos. Cell *83*, 599–609.

Lin, R., Hill, R.J., and Priess, J.R. (1998). POP-1 and anterior-posterior fate decisions in *C. elegans* embryos. Cell *92*, 229–239.

Lo, M.C., Gay, F., Odom, R., Shi, Y., and Lin, R. (2004). Phosphorylation by the β-catenin/MAPK complex promotes 14-3-3-mediated nuclear export of TCF/POP-1 in signal-responsive cells in *C. elegans*. Cell *117*, 95–106.

Logan, C.Y., and Nusse, R. (2004). The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. *20*, 781–810.

Maduro, M.F., Lin, R., and Rothman, J.H. (2002). Dynamics of a developmental switch: Recursive intracellular and intranuclear redistribution of *Caenorhabditis elegans* POP-1 parallels Wnt-inhibited transcriptional repression. Dev. Biol. *248*, 128–142.

Meneghini, M.D., Ishitani, T., Carter, J.C., Hisamoto, N., Ninomiya-Tsuji, J., Thorpe, C.J., Hamill, D.R., Matsumoto, K., and Bowerman, B. (1999). MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in *Caenorhabditis elegans*. Nature *399*, 793–797.

Miskowski, J., Li, Y., and Kimble, J. (2001). The *sys-1* gene and sexual dimorphism during gonadogenesis in *Caenorhabditis elegans*. Dev. Biol. *230*, 61–73.

Mizusaki, H., Kawabe, K., Mukai, T., Ariyoshi, E., Kasahara, M., Yoshioka, H., Swain, A., and Morohashi, K. (2003). Dax-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome, gene 1) gene transcription is regulated by Wnt4 in the female developing gonad. Mol. Endocrinol. *17*, 507–519.

Mulholland, D.J., Dedhar, S., Coetzee, G.A., and Nelson, C.C. (2005). Interaction of Nuclear receptors with Wnt/beta-catenin/Tcf signalling: Wnt you like to know? Endocr. Rev. *26*, 898–915.

Nakamura, K., Kim, S., Ishidate, T., Bei, Y., Pang, K., Shirayama, M., Trzepacz, C., Brownell, D.R., and Mello, C.C. (2005). Wnt signaling drives WRM-1/β-catenin asymmetries in early *C. elegans* embryos. Genes Dev. *19*, 1749–1754.

Natarajan, L., Witwer, N.E., and Eisenmann, D.M. (2001). The divergent *Caenorhabditis elegans* beta-catenin proteins BAR-1, WRM-1 and HMP-2 make distinct protein interactions but retain functional redundancy in vivo. Genetics *159*, 159–172.

Pettitt, J., Wood, W.B., and Plasterk, R.H. (1996). *cdh-3*, a gene encoding a member of the cadherin superfamily, functions in epithelial cell morphogenesis in *Caenorhabditis elegans*. Development *122*, 4149–4157.

Rocheleau, C.E., Downs, W.D., Lin, R.L., Wittmann, C., Bei, Y.X., Cha, Y.H., Ali, M., Priess, J.R., and Mello, C.C. (1997). Wnt signaling and an APC-related gene specify endoderm in early *C. elegans* embryos. Cell *90*, 707–716.

Rocheleau, C.E., Yasuda, J., Shin, T.H., Lin, R., Sawa, H., Priess, J.R., Davis, R.J., and Mello, C.C. (1999). WRM-1 activates the LIT-1 protein kinase to transduce anterior/posterior polarity signals in *C. elegans*. Cell *97*, 717–726.

Roegiers, F., and Jan, Y.N. (2004). Asymmetric cell division. Curr. Opin. Cell Biol. *16*, 195–205.

Shetty, P., Lo, M.C., Robertson, S.M., and Lin, R.L. (2005). *C. elegans* TCF protein, POP-1, converts from repressor to activator as a result of Wnt-induced lowering of nuclear levels. Dev. Biol. *285*, 584–592.

Siegfried, K.R., and Kimble, J. (2002). POP-1 controls axis formation during early gonadogenesis in *C. elegans*. Development *129*, 443–453.

Siegfried, K.R., Kidd, A.R., III, Chesney, M.A., and Kimble, J. (2004). The *sys-1* and *sys-3* genes cooperate with Wnt signaling to establish the proximal-distal axis of the *Caenorhabditis elegans* gonad. Genetics *166*, 171–186.

Silhankova, M., Jindra, M., and Asahina, M. (2005). Nuclear receptor NHR-25 is required for cell-shape dynamics during epidermal differentiation in *Caenorhabditis elegans*. J. Cell Sci. *118*, 223–232.

Sternberg, P.W., and Horvitz, H.R. (1988). *lin-17* mutations of *Caenorhabditis elegans* disrupt certain asymmetric cell divisions. Dev. Biol. *130*, 67–73.

Tabara, H., Sarkissian, M., Kelly, W.G., Fleenor, J., Grishok, A., Timmons, L., Fire, A., and Mello, C.C. (1999). The *rde-1* gene, RNA interference, and transposon silencing in *C. elegans*. Cell *99*, 123–132.

Takeshita, H., and Sawa, H. (2005). Asymmetric cortical and nuclear localizations of WRM-1/β-catenin during asymmetric cell divisions in *C. elegans*. Genes Dev. *19*, 1743–1748.

Thorpe, C.J., Schlesinger, A., Carter, J.C., and Bowerman, B. (1997). Wnt signaling polarizes an early *C. elegans* blastomere to distinguish endoderm from mesoderm. Cell *90*, 695–705.

Timmons, L., Court, D.L., and Fire, A. (2001). Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in *Caenorhabditis elegans*. Gene *263*, 103–112.

Valenta, T., Lukas, J., and Korinek, V. (2003). HMG box transcription factor TCF-4's interaction with CtBP1 controls the expression of the Wnt target Axin2/Conductin in human embryonic kidney cells. Nucleic Acids Res. *31*, 2369–2380.

Van Gilst, M., Gissendanner, C.R., and Sluder, A.E. (2002). Diversity and function of orphan nuclear receptors in nematodes. Crit. Rev. Eukaryot. Gene Expr. *12*, 65–88.

Supplemental Data

Crosstalk between a Nuclear Receptor

and β-Catenin Signaling Decides Cell Fates

in the *C. elegans* Somatic Gonad

Masako Asahina, Tomas Valenta, Marie Silhankova, Vladimir Korinek,and Marek Jindra

Figure S1. POP-1 Asymmetry in the Somatic Gonad Precursors

Freshly hatched larvae of the JK3437 strain that expresses a GFP::POP-1 fusion protein were fed either control bacteria containing the pPD129.36 empty vector (left panel), or bacteria expressing *nhr-25* dsRNA (right panel). Brackets show pairs of unequally divided daughters of the Z1 and/or Z4 cells. Expected asymmetry of GFP::POP-1 (stronger signal in the nuclei of the proximal daughters) is visible in control (A and B) as well as in RNAi treated L1 worms (E and F). However, in some animals the asymmetry was not apparent regardless whether they were subjected to *nhr-25* RNAi. The experimental cohort of animals showed the typical frequency of the *nhr-25* gonadal defect.

Table S1. *nhr-25* RNAi Affects DTC and AC Numbers Only during Early Gonad Development

hours[1]	Number of DTCs (% of RNAi treated worms)					Number of AC (%)		
	1	2	3	4	n	0	1	n
empty vector **0**	4	96	0	0	160	1	99	382
nhr-25(RNAi)	3	47	39	11	168	34	66	465
empty vector **4**	4	96	0	0	186	1	99	194
nhr-25(RNAi)	3	94	3	0	196	6	94	198
empty vector **7**	6	94	0	0	105	0	100	77
nhr-25(RNAi)	3	97	0	0	88	2	98	98
empty vector **10**	7	93	0	0	107	2	98	101
nhr-25(RNAi)	2	98	0	0	124	3	97	102
empty vector **20**	7	93	0	0	187	1	99	205
nhr-25(RNAi)	5	95	0	0	168	3	97	190

[1]Time of RNAi application since hatching (0 hours). For RNAi applied later than from hatching, newly hatched worms were first fed for 4, 7, 10 or 20 hours, respectively, on control bacteria containing the pPD129.36 empty vector, and then transferred to plates seeded with either the same control bacteria or bacteria expressing *nhr-25* dsRNA.

Table S2. *nhr-25* Genetically Interacts with *pop-1* and *sys-1* during Early Gonad Development

	hours[1]	Fertility[3]		Arm elongation	
		%	n	%	n
pop-1(q645); empty vector[2]	0	0	126	0	28
pop-1(q645); nhr-25(RNAi)	0	16	141	61	44
pop-1(q645); empty vector	10	0	20	0	20
pop-1(q645); nhr-25(RNAi)	10	0	26	0	26
sys-1(q544); empty vector	0	0	30	0	30
sys-1(q544); nhr-25(RNAi)	0	20	30	37	30

[1]Time of RNAi application since hatching (0 hours).
[2]Worms fed on control bacteria containing the empty pPD129.36 vector.
[3]Offspring of fertile *pop-1(q645); nhr-25(RNAi)* and *sys-1(q455); nhr-25(RNAi)* parents all displayed the Sys gonadal defect.

Table S3. Effects of *nhr-25*, *pop-1* and *sys-1* RNAi on DTC Number

RNAi targets[1]	DTC number (% animals)		
	missing (0-1)	extra (3-4)	*n*
nhr-25 + empty vector[2]	3	35	511
pop-1 + empty vector	44	0	220
sys-1 + empty vector	56	0	245
nhr-25 + *pop-1*	10	22	294
nhr-25 + *sys-1*	42	4	262

[1]For double knockdown experiments, equal amounts of bacteria from two cultures were mixed.
[2]To allow comparisons between double and single knock-down experiments, equal amounts of control bacteria containing the empty pPD129.36 vector were added.

3.4 Signalizace Wnt blokuje apoptózu indukovanou ligandem TRAIL v lidských maligních hematopoietických buňkách

Signalizace Wnt je důležitým kontrolním mechanismem, který ovlivňuje proliferaci a přežívání řady buněčných typů, mimo jiné se uplatňuje při regulaci těchto procesů u pre-B buněk a některých typech chronických leukémií [151, 232, 233]. Proliferační stimulace buněk prostřednictvím signalizace Wnt tak může interferovat s jinými buněčnými mechanismy, které řídí osud buňky, jako například s programovanou buněčnou smrtí - apoptózou. Rozhodnutí o tom, zda buňka přežije, či podstoupí apoptózu, je tedy výsledkem integrace apoptotických a proliferačních stimulů. V této práci jsme se zaměřili na studium vlivu signalizace Wnt na apoptózu vyvolanou ligandem TRAIL u hematopoietických buněk. Ligand TRAIL (Tumor necrosis factor- Related Apoptosis-Inducing Ligand) patří do skupiny ligandů příbuzných k TNF (Tumor Necrosis Factor) a tak jako většina těchto ligandů indukuje u senzitivních buněk apoptózu zprostředkovanou tzv. receptory smrti (death receptors). TRAIL interaguje se specifickými receptory DR4 a DR5, tím indukuje vznik intracelulárního proteinového komplexu DISC (Death-Inducing Signaling Complex) a následnou aktivaci iniciační kaspázy 8 (nebo kaspázy 10). Tato iniciační kaspáza jednak aktivuje další tzv. efektorové (označované rovněž jako exekuční) kaspázy, např kaspázu 3, které iniciují degradaci řady buněčných proteinů. Druhou aktivitou iniciační kaspázy 8 je přeměna neaktivního proapoptotického proteinu Bid (člen proteinové rodiny Bcl-2) v jeho aktivní zkrácenou formu. Aktivní Bid je pak translokován do mitochondrií, kde se podílí na aktivaci mitochondriální apoptotické mašinerie [234-237].

Jak je dokumentováno v předkládané práci, ligand TRAIL indukuje apoptózu u řady hematopoiteckých buněčných linií. Jako základní testovací systém, který by umožnil sledovat vliv signalizace Wnt na apotózu indukovanou ligandem TRAIL, jsme zvolili kokultivaci příslušných hematopoietikých buněčných linií s transformovanými fibrobroblasty Rat2, které exprimují Wnt1 (buňky Rat2Wnt1), respektive kontrolní vektor (buňky Rat2MV7). Kokultivace s buňkami produkujícími Wnt1 vedla u některých buněčných linií k částečné blokaci apoptózy indukované ligandem TRAIL (linie T-buněčného původu Jurkat a CEM). U testovaných pre-B buněčných liniích KM3 a REH vedla kokultivace s buňkami Rat2Wnt1 k takřka kompletní inhibici apoptózy, v případě myeloidních buněk nebyla apoptóza nijak ovlivněna. Hlavním mechanismem, jak signalizace Wnt ovlivňuje apoptózu iniciovanou ligandem TRAIL se zdá být vliv na expresi proapoptotických receptorů DR4 a DR5 v cílových buňkách. Kokultivace

s buňkami exprimujícími Wnt1 vede u pre-B buněčné linie KM3 k inhibici exprese DR4 a DR5 na úrovni mRNA i proteinu. Snížení exprese těchto receptorů na povrchu cílových buněk způsobuje, že ligand TRAIL nenachází na cílových buňkách své vazebné partnery, což vede k inhibici apoptózy (mimo jiné nedochází k aktivaci kaspáz). Kokultivace s buňkami Rat2Wnt1 vede u buněk KM3 rovněž ke stabilizaci β-kateninu a změnám v expresi některých cílových genů signalizace Wnt. Zvyšuje se exprese genu *c-myb* a naopak se snižuje exprese genu *p21* a paradoxně se také snižuje exprese genu *c-myc*. Snížená exprese genu *c-myc* ovšem může být v tomto případě důležitá pro inhibici apoptózy. Jak bylo dříve publikováno c-myc může zvýšit intenzitu apoptózy indukované ligandem TRAIL v případě epiteliální linie HA1E [238]. Snížení exprese c-myc spolu s inhibicí transkripce p21 může tedy působit anti-apoptoticky. Aditivním mechanismem, který přispívá k inhibici apoptózy se zdá být aktivace kinázové dráhy MEK1/ERK1 v cílových buňkách způsobená ligandem Wnt. Některé práce ukázaly, že ligandy Wnt mají za jistých podmínek schopnost aktivovovat zmíněnou kinázovou dráhu [239, 240]. Signální dráha MEK1/ERK1 má schopnost inhibovat apoptózu vyvolanou ligandem TRAIL [241].

Stabilizace β-kateninu způsobená ligandem Wnt ovšem není dostačující podmínkou pro inhibici apoptoptózy vyvolané ligandem TRAIL. Experimenty s využitím rekombinantního proteinu Wnt, nebo Wnt-kondiciovaného média, či jiných buněk produkujících ligand Wnt, naznačují, že pro úplnou inhibici apoptózy je nutná kokultivace s buňkami Rat2Wnt1. Je tedy možné, že pro inhibici apoptózy je kromě samotného ligandu Wnt nutný další extracelulární membránový faktor, který je produkovaný buňkami Rat2Wnt1 jako výsledek jejich autostimulace ligandem Wnt.

Antiapoptotické působení signální dráhy Wnt bylo ukázáno rovněž jinými skupinami. Signální dráha Wnt se podílí na inhibici apoptózy u krysích fibroblastů, osteoblastů a některých střevních buněk [242]. Jak ukázala naše práce, signalizace Wnt může inhibovat apoptózu indukovanou některými ligandy ze skupiny TNF. Vzhledem k tomu, že se seriózně pracuje na využití ligandu TRAIL v rámci protinádorové terapie, je potřeba brát v úvahu při volbě správné terapeutické strategie také možnou interferenci apoptózy indukované ligandem TRAIL a signální dráhy Wnt.

Wnt-induced signaling suppresses TRAIL-mediated apoptosis of human malignant hematopoietic cells

Lenka Doubravská[1], Šárka Šímová[1], Lukáš Čermák, Tomáš Valenta, Vladimír Kořínek[2] and Ladislav Andera[2*]

Laboratory of Cell Signaling and Apoptosis, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic

[1] first co-authors, [2] senior co-authors, [*] corresponding author

Running title: Wnt signaling attenuates TRAIL-induced apoptosis

Address correspondence to: Dr. Ladislav Anděra, Laboratory of Cell Signaling and Apoptosis, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vídeňská 1083, 14220 Praha 4, Czech Republic

Fax: +420-241062471

Phone: +420-244472282

E-mail: andera@biomed.cas.cz

1

ABSTRACT

The Wnt signaling pathway is essential for the regulation of proliferation and maintenance of hematopoietic stem cells, progenitors as well cells at various stages of differentiation. During B cell development Wnt-induced signaling is involved in the pre-pro B transition and is apparently important for B cell survival. Wnt1- and Wnt3a-expressing Rat2 fibroblasts efficiently suppressed apoptosis of human pre-B cell-derived cell lines KM3 and REH induced by the cytotoxic ligand TRAIL while apoptosis of more mature Ramos lymphoma or myeloid cells remained unaffected. Wnt-expressing fibroblasts induced in KM3 cells β-catenin stabilization, downregulation of the TRAIL receptors DR4/DR5 and suppression of caspase-8 and Bid processing. The antiapoptotic effect was partly dependent on the activity of MEK1/ERK kinases and was unaffected by the PI3K inhibitor wortmannin. Interestingly, the recombinant Wnt3a and Wnt5a ligands, Wnt3a-producing L cells or GSK3β inhibitor were considerably less effective or completely ineffective in inhibiting apoptosis of KM3 cells. These results imply the existence of an additional antiapoptotic signal mediated by Wnt1- or Wnt3a-transformed Rat2 fibroblasts. This signaling in conjunction with the Wnt-triggered cascade of cellular events suppresses TRAIL-induced apoptosis of pre-B cells. Such composed antiapoptotic signaling could be of importance during B cell differentiation as well as malignant transformation.

2

INTRODUCTION

Regulation of apoptosis is interconnected with cell proliferation and a number of pro-proliferative signals were shown to influence the apoptotic status of the affected cell. A large family of secreted lipid-modified glycoproteins, the Wnt ligands, participate in the regulation of cell proliferation, differentiation and survival (1, 2). Interaction of the Wnt proteins with their receptor complex - transmembrane polypeptides of the Frizzled family together with LPR 5/6 co-receptors - results in the activation of so-called canonical and non-canonical signaling in the target cell (3-5). β-catenin is the key player of the canonical Wnt pathway. In unstimulated cells β-catenin is marked for ubiqutinylation and degradation by action of a large multiprotein complex that includes Ser/Thr kinase GSK3β and two "scaffold" proteins Axin1/2 and APC. Canonical signaling inhibits activity of the GSK3β/Axin1/2/APC complex and stabilized β-catenin accumulates in the cytoplasm and also in the cell nucleus. Nuclear β-catenin associates with the transcription factors of the Tcf/Lef family and activates transcription of their target genes. Non-canonical Wnt signaling leads to the mobilization of intracellular calcium or to activation of kinases of the JNK family and small GTPases of the Rho family (6). In the hematopoietic system the Wnt proteins participate in maintenance and differentiation of hematopoietic stem cells and progenitors (7). Wnt signaling is also required during maturation of the thymic T cells (8, 9) and for the survival of the B cells at the pre-B-cell stage (10, 11). Furthermore, the active Wnt pathway suppresses apoptosis of the serum-deprived hematopoietic CD34+ progenitors. The pro-proliferative and anti-apoptotic function of Wnt signaling was observed not only in the hematopoietic

3

cells but also in other cell types. It was reported that Wnt-activated signaling inhibits serum-withdrawal-induced apoptosis of osteoblasts, preadipocytes, and fibroblasts (12-15). Potential anti-apoptotic function of Wnt signaling was also supported by inhibition of Wnt1 or Wnt2 signaling with monoclonal antibodies or with Wnt antagonist Dickkopf-1. These treatments induced apoptosis of malignant melanoma or mesothelioma cells (16-18).

In contrast to the Wnt ligands, death ligands of the TNF family induce apoptosis mainly of target cells (19-21). Among them TRAIL is known to induce apoptosis namely of transformed cells and thus seems to be a promising anti-tumor agent of a new generation (22-24). TRAIL interacts with its pro-apoptotic receptors TRAIL-R1/DR4 or TRAIL-R2/DR5, induces formation of the intracellular Death-Inducing Signaling Complex (DISC) and subsequent activation of the initiator caspases-8 or -10. These activated caspases cleave Bid, proapoptotic BH3-only member of the Bcl-2 family. Truncated Bid (tBid) then translocates to mitochondria where it co-activates mitochondrial apoptotic signaling (25). TRAIL-induced apoptosis can be affected at a number of regulatory check points at the level of pro- and anti-apoptotic (TRAIL-R3 and TRAIL-R4) expression and cell surface localization, expression of caspase-8 competitor FLIP, postranslational modification of Bid or enhanced expression of anti-apoptotic proteins from the Bcl-2 and IAP families. Receptor-mediated activation of PI3K/Akt, Erk or protein kinase C signaling pathways or tumor elevated activity of casein kinase II can also negatively influence the outcome of TRAIL-induced apoptosis (26-30).

Here we report that Wnt signaling suppresses TRAIL-induced apoptosis of human pre-B leukemia cells. The efficient inhibition of apoptosis requires a direct contact of

4

leukemic cells with the Rat2 fibroblast feeder cells expressing the Wnt1 or Wnt3a ligands. The anti-apoptotic action of the Wtn1/Wnt3a transgenic Rat2 feeders is only partially substituted by either recombinant soluble Wnt3a or Wnt3a-expressing murine L cells. This indicates that an additional stimulus provided specifically by Wnt-transformed Rat2 fibroblasts is required for more efficient suppression of TRAIL-induced apoptosis in attached pre-B leukemia cells.

MATERIALS AND METHODS

Cell lines, reagents and antibodies

Human hematopoietic cell lines KM3, REH (pre-B cells); Ramos (B- cells); ML-1, HL-60, THP-1 (myeloid cells); Jurkat, CEM, MOLT-4 (T cells); NK3 (NK cells) and TF-1 (erythromyeloid cells) were cultured in RPMI medium with 10% FCS. Mock-infected and Wnt1- or Wnt3a-infected immortalized rat fibroblast Rat2, wild-type embryonic mouse fibroblasts L and mouse L fibroblasts with stably transfected Wnt3a (L-Wnt3a) (ATCC) were cultured in DMEM medium with 10% FCS. Following kinase inhibitors were used: inhibitor of GSK-3, BIO and inactive inhibitor of GSK-3, MethylBIO was kindly provided by Dr. Brivanlou, MEK1 inhibitor PD-98059 and PI3kinase inhibitor wortmannin were purchased from Sigma. Recombinant mouse Wnt3a and human Dickkopf-1 were purchased from R&D Systems. Human N-terminally His-tagged recombinant TRAIL (amino acids 95-281) was affinity-purified in our laboratory after its overexpression in E.coli(BL-21) and deprived of contaminating E.coli endotoxins by Endotrap chromatography (Profos AG). AnnexinV-FITC was donated by Apronex Ltd., Czech Republic. Hoechst 33258 was purchased from Molecular Probes. Commercially

5

available antibodies were purchased from indicated suppliers: mouse monoclonal Myc tag (Roche Molecular Biochemicals), mouse monoclonal phospho-ERK (Upstate Biotechnology), mouse monoclonal α-tubulin (Exbio), rabbit polyclonal caspase-8 and caspase-3 (BD Biosciences), rabbit polyclonal Bid (Santa Cruz), rabbit polyclonal polyADP-ribose polymerase (PARP) (Calbiochem), rabbit polyclonal ERK (Cell Signaling). Anti-TRAIL receptors flow cytometry set was purchased from Alexis.

Co-cultivation of hematopoietic cells on a layer of feeder cells

Rat fibroblasts Rat2 [transduced with retroviral constructs expressing mouse Wnt1, Wnt3a (Rat2Wnt1, Rat2Wnt3a) or with empty retrovirus (Rat2MV7)] (31) or mouse fibroblast L cells (wild-type or Wnt3a-expressing) were seeded to form a monolayer at 80% confluency. Next day, hematopoietic cells were spread on the feeder cells and co-cultivated for 8 hours. After this incubation, cells were used for further experiments.

Proliferation assays

KM3 cells (3 x 10^5 cfu) were spread in triplicates onto 90%-confluent cultures of feeder cells (Rat2MV7 or Rat2Wnt1) in 24-well plates and after 8 hours of co-culture were pulsed with 2 μCi of [^{3}H]thymidine (each well). Cells were incubated for another 18 hours before harvesting. Feeder cells without KM3 cells were treated under the same conditions and were used as background of proliferation. KM3 cells were, together with Rat2 feeders, harvested by scraping and after washing, the incorporated radioactivity was measured by liquid scintillation counting.

6

For the CSFE cell proliferation assay KM3 cells were preincubated with CFSE at 37°C for 8 minutes, washed with PBS containing 2% FCS, co-cultured on 90% confluent feeder cells for 24 hours and analyzed by flow cytometry.

Western blotting

Cell lysates were separated by SDS PAGE and transferred onto nitrocellulose membranes (Amersham). Membranes were blocked with 5% nonfat milk in PBS containing 0.05% Tween-20 (PBS/Tween), incubated with specific primary antibodies and then after several washes with appropriate peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies (BioRad). After washing three times with PBS/Tween, the blots were visualized by enhanced chemoluminescence (ECL, Pierce).

Flow cytometry and apoptosis assays

Hematopoietic cells were separated from the layer of the feeder fibroblasts by gentle pipetting, washed with ice-cold PBS and incubated with the blocking solution (PBS containing 20% human serum, 1% gelatin and 0.1% azide) on ice for 15 min. Cells were then washed once with the wash buffer (PBS containing 1% gelatin and 0.1% azide), incubated with appropriate primary monoclonal antibodies, washed twice with ice-cold wash buffer and finally incubated with the secondary goat anti-mouse antibodies coupled to phycoerythrin (IgG1-PE) (SouthernBiotech). After two final washes the surface expression of the receptors on live cells (negatively stained with Hoechst 33258) was analyzed by flow cytometry on LSRII (BD Biosciences).

7

For the apoptosis assays, cells were either mock-treated or treated with TRAIL (200 ng/ml) for indicated times. After the treatment, cells were harvested from the feeder cells, washed with ice-cold PBS and stained with AnnexinV-FITC and Hoechst 33258. Stained cells were analyzed by flow cytometry.

RNA isolation and quantitative real-time PCR

Total RNA was prepared using Trizol Reagent (Invitrogen) according to the manufacturer's protocol and reversely transcribed with SuperScript II reverse transcriptase (Invitrogen) using oligo dT primer. The cDNA was amplified using SYBR-Green PCR Master Mix (Roche) and human specific primers (sequences available upon request) in MX3000® (Stratagene) or LightCycler® 480 System (Roche). Normalizations across samples were performed using geometric average of constitutive gene expression of the *SDHA* or *BACT* genes.

RESULTS

TRAIL-induced apoptosis of several hematopoietic cell lines is suppressed by Wnt1-expressing fibroblasts

The cytotoxic ligand TRAIL can efficiently induce apoptosis of a number of cell lines derived from hematopoietic malignancies and the ligands of Wnt family act as essential factors in T and B cell differentiation and proliferation. We were interested whether these two signaling pathways crosstalk and how they could affect each other. We tested the effect of Wnt1-expressing Rat2 fibroblasts used as cushion/feeder cells on TRAIL-induced apoptosis using a panel of hematopoietic cell lines of various origin (Table 1). Co-cultivation of some cell lines with Rat2Wnt1 feeder cells but not with the mock-transfected cells promoted partial (Jurkat or CEM T-cell lines) or almost complete (KM3 and REH B-cell lines) resistance to TRAIL-induced apoptosis. In contrast, TRAIL-induced cell death of myeloid cell lines was virtually unaffected by Rat2Wnt1 feeders. In follow-up detailed analysis of this phenomenon we analyzed pre-B cell line KM3. First, we examined whether Rat2Wnt1 fibroblasts could possibly enhance proliferation of KM3 cells and in this indirect way "balance" TRAIL-induced apoptosis. Thymidine incorporation assay and CFSE analysis (not shown) revealed that neither Wnt1- nor Wnt3a-expressing Rat2 fibroblasts enhanced proliferation of co-cultivated KM3 cells (Table 2). Thus, we assumed that Rat2Wnt-induced signaling can interfere directly with the cellular mechanisms of TRAIL-induced apoptosis in selected hematopoietic cell lines.

Rat2Wnt1 fibroblasts suppress the proximal events in TRAIL apoptotic signaling in KM3 pre-B cells

9

Direct comparison of Rat2Wnt1-responding KM3 cells with ML-1 cells, i.e. with control cells unaffected by the type of the feeders (Fig. 1A), revealed clear downregulation of the pro-apoptotic TRAIL receptor DR5 from the surface of the   Rat2Wnt1-treated KM3 cells (Fig. 1B). Although the additional pro-apoptotic TRAIL receptor DR4 was only marginally expressed on both ML-1 and KM3 cells, Rat2Wnt1 feeder cells also induced its downregulation in KM3 and not in ML-1 cells (Fig. 1B). This implied that the diminished sensitivity to TRAIL could be at least in part related to the reduced surface expression of the corresponding TRAIL receptors in KM3.

Proximal events in TRAIL-induced apoptosis are DISC-mediated activation of caspase-8 followed up by caspase-8-mediated processing of the proapoptotic BH3-only sentinel Bid to its truncated form (tBid). Caspase-8 activation and Bid processing were almost completely inhibited in KM3 cell cultivated on Rat2Wnt1 fibroblasts (Fig. 1C). Similarly, processing of the effector caspase-3 and cleavage of its target proteins PARP and cFlip was at 6 hr time point significantly attenuated and at the later time point completely suppressed.

Rat2Wnt1-induced downregulation of DR4 and DR5 cell surface expression is possibly regulated at transcriptional and/or posttranscriptional levels. Using quantitative real-time RT PCR (RT-qPCR) we examined Rat2Wnt1-induced changes in transcription of *DR4* and *DR5* as well as several other apoptosis- and proliferation-related genes in KM3 cells (Fig. 2). Indeed, transcription of both *DR4* and *DR5* mRNAs was significantly attenuated by Rat2Wnt1 fibroblasts. Furthermore, expression of *c-myc* and *p21/WAF1/CIP*1 was also reduced in Rat2Wnt1-treated KM3 cells (Fig. 2). In agreement with the RT-qPCR data, Wnt1-mediated downregulation of *c-myc* mRNA was also

10

reflected in a reduced expression of the corresponding protein as evidenced by Western blotting (Fig. 1C, compare the zero time points). The decrease in the c-Myc expression was rather surprising as c-Myc was reported previously as a direct target of canonical Wnt signaling (32). Nevertheless, we detected upregulation of another known target of the Wnt/β-catenin pathway, *c-MYB*, in Rat2Wnt1-stimulated KM3 cells as well as in KM3 cells treated with Rat2Wnt3a feeders or with the recombinant Wnt3a protein (not shown). Expression of additional Wnt-responsive genes *cyclin D, Axin2*, and survivin was unaffected by the type of the feeder cells. Similarly, *bcl-2* mRNA remained unchanged during the experiment (Fig. 2 and data not shown).

Direct Wnt-induced signaling does not provide full protection against TRAIL-induced apoptosis of KM3 cells

Direct Wnt-induced signaling was shown to provide protection against serum withdrawal or drug-induced apoptosis in osteoblasts and fibroblasts (12, 14). These effects were examined either autonomously in Wnt1-transformed cells or using the exogenous recombinant Wnt3a protein. In order to dissect the relation between anti-apoptotic action of Rat2Wnt1 cells and Wnt-induced signaling in KM3 cells we compared anti-apoptotic effects of several different Wnt signaling-triggering systems and reagents. In addition to Rat2Wnt1 fibroblasts we also employed Rat2Wnt3a fibroblasts, murine Wnt3a-expressing L cells, conditioned medium from these cells, recombinant and commercially available Wnt3a and Wnt5a, and shortcut activator of canonical Wnt signaling BIO (an inhibitor of GSK3β) (33). Wnt-induced stabilization of β-catenin is a hallmark of the initiation of the canonical Wnt signaling pathway. The treatment of KM3 cells with all

11

indicated cell lines or reagents (except Wnt5a that is known as the non-canonical pathway activator) induced accumulation of β-catenin in responding KM3 cells (Fig. 3A). As expected, mock-transfected feeder cells and the inactive variant of the GSK3β inhibitor MetBIO were unable to induce an increase in the β-catenin protein levels (Fig. 3A).

Although all the relevant stimuli presumably activated the canonical Wnt signaling in KM3 cells (the most efficient "stabilizer" of β-catenin appeared to be L-Wnt3a cells), the individual stimuli greatly differed in the ability to suppress TRAIL-induced apoptosis. Co-cultivation of KM3 cells on Rat2 fibroblasts expressing Wnt1 or Wnt3a efficiently attenuated their apoptosis (albeit with a weaker effect of Wnt3a), but L-Wnt3a feeders, despite strong accumulation of β-catenin, suppressed apoptosis to a lesser extent (Fig. 3B). Similarly, priming the KM3 cells with recombinant Wnt3a, Wnt5a or with a Wnt3a-conditioned medium attenuated TRAIL-induced apoptosis of KM3 cells either relatively weakly (Wnt3a, Wnt3a-conditioned medium) or not at all (Wnt5a) (Fig. 3B). In agreement with these results, recombinant Dickkopf-1, a direct inhibitor of Wnt signaling, only partially suppressed the anti-apoptotic effect of Rat2Wnt1 fibroblasts (not shown). In a sharp contrast to the natural inducers of Wnt signaling, the synthetic inhibitor of GSK3β activity, BIO, did not protect KM3 cells against TRAIL-induced apoptosis. Moreover,   BIO eliminated the protective effect of Rat2Wnt1 feeders and it even enhanced the overall efficacy of TRAIL-induced apoptosis (Fig. 3B). The inactive analog MetBIO had only a minor effect on the anti-apoptotic signaling of Rat2Wnt1 fibroblasts (Fig. 3B). RT-qPCR analysis of the effect of selected treatments on the expression of Wnt target genes and TRAIL receptors revealed that both LWnt3a medium

12

and BIO affected expression of *c-myb* and *myc* genes in KM3 cells in a similar way as did Rat2Wnt1 feeders (Fig. 3.C). However, in a sharp contrast to Rat2Wnt1 feeders none of these treatments was reflected in suppression of the TRAIL receptor DR4 and DR5 expression. Thus, apparently, the activation of the canonical Wnt signaling pathway provides only a partial protection against TRAIL-induced apoptosis to KM3 cells and additional factor(s) produced specifically by Wnt1- or Wnt3a-transformed fibroblasts are required for a more efficient anti-apoptotic protection of KM3 cells, i.e. for example for the downregulation of the DR4/DR5 receptors. This conclusion was further supported experimentally using TRAIL-sensitive B cell line Ramos (Burkitt lymphoma). Co-cultivation of these cells on Rat2Wnt1 fibroblasts induced accumulation of β-catenin (Fig. 4.A). However, in contrast to KM3, neither Rat2Wnt1 nor Rat2Wnt3a feeder cells protected Ramos cells against TRAIL-induced apoptosis (Fig. 4.B and not shown). Additionally, the downregulation of DR4/DR5 expression was not detected in Ramos cells incubated with Rat2Wnt1 or Rat2Wnt3a feeders (not shown). Taken together, these results indicate that: (1) activation of canonical Wnt signaling *per s*e is not sufficient to inhibit the TRAIL-induced apoptosis; (2) co-stimulatory, anti-apoptotic signals originating from Rat2Wnt1/Wnt3a fibroblasts are not possibly relayed to Ramos cells.

Rat2Wnt1 fibroblasts protect KM3 cells against TRAIL-induced apoptosis via MEK1/ERK-dependent signaling

The Wnt ligands can, under certain conditions, trigger activation of MEK1/ERK1/2 and PI3K/Akt signaling. These signaling pathways are also implicated in inhibiting apoptosis induced by various stimuli (34, 35). Therefore, we examined whether these signaling

pathways could also participate in the Wnt-mediated protection of KM3 cells against TRAIL-induced apoptosis. Co-cultivation of KM3 cells on Rat2Wnt1 feeders did not result in an observable phosphorylation of ERK or Akt kinases (not shown). However, pre-treatment of KM3 cells cultivated on Rat2 or Rat2Wnt1 feeder cells with MEK1 inhibitor PD-98059 strongly suppressed Wnt1-related protection of KM3 cells against TRAIL (Fig. 5) although it did not inhibit Rat2Wnt1-induced stabilization of β-catenin (not shown). In contrast, wortmannin, an inhibitor of PI3-kinase, only marginally attenuated the anti-apoptotic effect of Rat2Wnt1 feeder cells (Fig. 5). Neither PD98059 nor wortmanin had an adversary effect on Rat2Wnt1-induced changes in c-myc or DR5 expression (not shown). This implicates that in addition to Rat2Wnt1-related changes in the expression of the proapoptotic DR4 and DR5 receptors (Figs. 1B and 2), MEK1/ERK-mediated modifications of the TRAIL signaling pathway could be involved in the regulation of TRAIL-induced apoptosis of KM3 cells.

14

DISCUSSION

Wnt signaling is essential for pre-B-cell proliferation and survival and also participates in the augmentation of proliferation and survival of B cell chronic leukemias (10, 36). Initial screening of a panel of human hematopoietic TRAIL-sensitive cell lines revealed an unequal response to the apoptosis-modulating effect of Wnt1-transformed Rat2 fibroblasts. In the co-cultivation experiments the Rat2Wnt1 fibroblasts attenuated TRAIL-induced apoptosis of several T- and B-cell-derived cell lines but not cells of the myeloid or NK origin. This observation is in agreement with the proposed role of Wnt signaling in the regulation of B- a T-cell survival (9, 10).

The canonical, i.e. TCF/β-catenin-dependent, Wnt pathway mediates the anti-apoptotic signaling in Rat-1 fibroblasts, osteoblasts and rat intestinal RIE cells (12, 38, 39). There are partly conflicting data about the Wnt-mediated activation of anti-apoptotic proteins Bcl-2 and Bcl-XL. Wnt1 expression does not stimulate expression of Bcl-2/Bcl-XL in RIE cells, but it was reported that Wnt3a upregulates the Bcl-2 production in osteoblasts (12, 39). Our quantitative real-time PCR analysis of mRNA isolated from Rat2Wnt1-stimulated KM3 cells does not support apparent Wnt-mediated upregulation of Bcl-2 or BclXL expression. Moreover, although c-Myc was described as a direct target gene of the canonical Wnt pathway in colorectal cells (40), we reproducibly observed downregulation of this gene in KM3 cells stimulated with Rat2Wnt1 fibroblasts, GSK3β inhibitor BIO or with LWnt3a-conditioned medium (see Figs. 2 and 3). Nevertheless, expression of another Wnt-responsive gene, *c-myb* (40), was elevated in KM3 cells primed by various Wnt signaling-related stimuli (Rat2Wnt1/Wnt3a, L-Wnt3a cells, recombinant Wnt, BIO, etc.; Fig. 3C and data not shown). Myc expression enhanced

15

TRAIL-induced apoptosis in kidney epithelial cells HA1E via upregulation of the DR5

receptor (41) and, consequently, its downregulation in KM3 cell could be anti-apoptotic.

We further observed suppression of DR4 and DR5 expression at both mRNA and protein

levels in Rat2Wnt1-treated KM3 cells (see Figs. 1C and 2). The decrease in the

expression of the TRAIL receptors suggests that the block of TRAIL-induced apoptosis

occurs at the proximal stage of TRAIL signaling, especially at the DISC level. Indeed, we

detected very weak activation of the DISC caspase-8 and negligible processing of its

downstream effector Bid (Fig. 1B). However, a residual caspase-8 activity led most

probably to direct caspase-3 activation and to the cleavage of its downstream substrates

PARP and cFlip.

Recombinant Wnt3a or Wnt1- and Wnt3a-enriched medium were shown to

suppress serum withdrawal-induced apoptosis of fibroblasts, preadipocytes and

osteoblasts (12-14). Our extensive analysis of Rat2-independent Wnt signaling provided

us with several ambiguous and surprising results. Recombinant Wnt3a, Wnt3a-enriched

medium or mouse L fibroblast-expressing Wnt3a were, despite effective activation of

Wnt signaling in target KM3 cells, approximately 2-3-fold less efficient inhibitors of

TRAIL-induced apoptosis than Rat2 fibroblasts expressing Wnt1 or Wnt3a. In contrast,

a shortcut activator of Wnt signaling, GSK3β inhibitor BIO, completely abrogated the

anti-apoptotic effect of RatWnt1 fibroblasts; thus, presumably, the GSK3β activity is

antiapoptotic in KM3 cells. This conclusion is supported by observations that deletion

of *GSK3β* or inhibition of its function enhances TNFα- or TRAIL-induced apoptosis of

mouse embryonic fibroblasts or prostate cancer cells (42, 43). A comparison of the

Rat2Wnt-1 action on two different B-cell derived cell lines, i.e. KM3 (pre-B ALL) and

16

Ramos (Burkit lymphoma), revealed a further unexpected finding. Although we detected increased levels of the β-catenin protein in both cell lines upon stimulation with the Rat2Wnt-1 feeder cells, only KM3 cells gained the resistance to TRAIL-induced apoptosis. Furthermore, a subsequent RT-qPCR analysis did not show any decrease in transcriptional levels of proapoptotic TRAIL receptors DR4 and DR5 in Ramos cells (Fig. 4.C and data not shown). These results clearly suggest that activation of canonical Wnt signaling is not sufficient to inhibit the TRAIL-induced apoptosis. We further hypothesized that putative co-stimulatory, anti-apoptotic signals originating from Rat2Wnt1 fibroblasts were possibly relayed to KM3 pre-B cells and not to more advanced Ramos cells. Conditioned media harvested from Rat2Wnt1/Wnt3a cells cannot provide the apoptotic resistance to TRAIL in KM3 cells and the presence of the feeder cells in mixed cultures is essential for the full inhibition of TRAIL-induced apoptosis (data not shown). Thus, we presume that Wnt-transformed Rat2 fibroblasts (which respond to the Wnt signals – see ref. 31) express an identified anti-apoptotic, membrane or extracellular matrix-associated factor. One of the potential candidates might be the Wnt1-activated, secreted and extracellular matrix-associated protein WISP-1 (45). As WISP-1 inhibits p53- and myc-induced apoptosis (39, 46), it could also participate by an unknown mechanism in repressing TRAIL-induced apoptosis of KM3 cells.

Interestingly, the Wnt ligands activate antiapoptotic MEK/ERK- and PI3K/Akt-related cascades in fibroblasts and osteoblasts (12, 44). Both ERK and Akt mediated signaling were reported to be inhibitory for TRAIL-induced apoptosis of various tumor cells (27, 29), nevertheless, only PD-98059-mediated inhibition of the ERK signaling pathway but not the suppression of PI3K by wortmannin countered Rat2Wnt1-induced

17

anti-apoptotic signaling in KM3 cells. Thus, apparently, PI3K/Akt signaling is not essential as a provider of anti-apoptotic signaling in KM3 cells.

The results presented in this study indicate that in one cell type, Wnt-signaling can trigger a molecular response that might effectively influence the behavior of the "by-standing" cell. Unraveling the molecular mechanisms of anti-apoptotic action of the Wnt pathway would not only enhance our present knowledge about the way how cells communicate, but could possibly be useful in setting up anti-tumor drug treatment strategies.

CONCLUSION

In this communication we show that Wnt1 or Wnt3a can both directly and indirectly suppress TRAIL-induced apoptosis of several hematopoietic cell lines. This signaling attenuates apoptosis of both pre-T and pre-B-derived cell lines but not cells of myeloid origin. The most efficient anti-apoptotic signaling originates from Wnt1-transformed Rat2 fibroblasts and apparently is composed of direct Wnt-induced signaling in the target hematopoietic cells and of indirect signaling transduced by an unknown signaling mechanism from Wnt-transformed Rat2 fibroblasts but not similarly transformed murine L cells. This combined effect leads to the downregulation of TRAIL receptor expression both at mRNA and protein levels and to inefficient caspase-8 and Bid processing. Rat2Wnt-mediated anti-apoptotic signaling towards responsive cells is partially suppressed through the inhibition of MEK1/ERK signaling but not via the PI3K/Akt pathway. This combined anti-apoptotic effect of certain Wnt1- or Wnt3a-expressing cells might be one of the reasons for an enhanced survival of hematopoietic malignancies.

18

Acknowledgements

TABLES AND FIGURES

Table 1. Rat2Wnt1-mediated suppression of TRAIL-induced apoptosis of selected hematopoietic cell lines.

Hematopoietic cells (10^6/well of 12-well plate) were grown either without feeder cells (plastic) or co-cultivated on the cushion of Rat2MV7 or Rat2Wnt1 fibroblasts for 8 hrs, and then TRAIL was added to the concentration of 200 ng/ml and the cultivation continued for another 15 hrs. Cells were gently released from the feeder fibroblasts by pipetting, stained with propidium iodide and the portion of dead, PI-positive cells was determined by flow cytometry.

Table 2. Co-cultivation of pre-B KM3 cells on feeder cells marginally inhibits their proliferation.

KM3 cells were cultivated without feeder cells (plastic) and on Rat2MV7 or Rat2Wnt1, L_{TK}^- and LWnt3a fibroblasts for 8 hours, then [^{3}H]thymidine was added and cells were cultivated for another 18 hours before harvesting. The incorporation of [^{3}H]thymidine was quantified by liquid scintillation.

Figure 1. Rat2Wnt1 feeder cells suppress cell surface expression of TRAIL receptors and processing of caspase-8 and Bid in KM3 cells.

KM3 and ML-1 cells were cultivated for 8 hours on feeder Rat2MV7 or Rat2Wnt1 fibroblasts and then with TRAIL (200 ng/ml) for additional 15 hrs. Cells were gently harvested by pipetting and analyzed for apoptosis using propidium iodide staining (**A**) or

20

for the cell surface expression of TRAIL receptors DR4 and DR5 (**B**) by flow cytometry.
C, Western blots of total cell lysates prepared from KM3 cells grown on Rat2MV7 or
Rat2Wnt1 fibroblasts for 6 hrs and subsequently incubated with TRAIL as indicated. α-
tubulin: a loading control. Arrows show cleaved forms of c-Flip, caspase-8, Bid, caspase-
3 and polyadenylate ribose polymerase (PARP).

**Figure 2. Real-time quantitative PCR (RT-qPCR) analysis of Rat2Wnt1-induced
changes of gene expression in KM3 cells**

KM3 cells were cultivated on Rat2MV7 or Rat2Wnt1 cells for 8 hrs and TRISOL-
purified RNAs were analyzed by RT-qPCR. Colors indicate the ratio of transcript
abundance according to color bar scale. Normalizations across samples were performed
using geometric average of constitutive gene expression of *SDHA*. Diagram shows
relative expression profiles of selected genes involved in the regulation of apoptosis and
cell cycle (based on SDHA-normalized median ratios of three repeats) in Rat2Wnt1-
versus Rat2MV7-treated KM3 cells.

**Figure 3. Diverse effects of various feeder cells and other reagents on β-catenin
stabilization and TRAIL-induced apoptosis of KM3 cells.**

A, KM3 cells were incubated on different feeder cells (Rat2 or mouse L fibroblasts), with
the conditioned medium (CM), with recombinant Wnt3a (50 ng/ml) or Wnt5a (0.5 μg/ml)
and with BIO (2 μM) and MetBIO (2 μM), respectively. After 8 hrs the cells were
harvested and lysed. The total cell lysates were analyzed by Western blotting using anti-
β-catenin or anti-α-tubulin (loading control) antibody. **B**, KM3 cells were pre-incubated

21

with the feeder cells, recombinant ligands/conditioned media, or GSK3β inhibitors for 8

hrs and then treated with recombinant TRAIL (200 ng/ml) for additional 12 hrs. TRAIL-

induced apoptosis was analyzed by Annexin V-FITC surface staining and flow

cytometry. **C**, KM3 cells were treated as in A with the indicated agents and purified RNA

was analyzed by RT-qPCR as described in Fig. 2A.

Figure 4. B cell-derived cell lines KM3 and Ramos differ in their response to Rat2Wnt1 fibroblasts.

KM3 or Ramos cells were cultivated either on Rat2MV7 or Rat2Wnt1 for 8 hours, and

then were either analyzed for β-catenin levels using Western blotting of the   whole cell

lysates (**A**) or   for TRAIL-induced apoptosis (**B**) (Annexin V-FITC staining/flow

cytometry).

Figure 5. MEK1 inhibitor PD98059 attenuates the antiapoptotic effect of RatWnt1 on KM3 cells.

KM3 cells were treated as indicated in Fig.1. Ninety minutes before TRAIL addition,

PD98059 or wortmannin were added to the final concentration of 50 μM and 1 μM,

respectively. The cells were grown for additional 15 hrs. Cells were stained for Annexin

V-FITC and analyzed by flow cytometry.

Table 1

Cell line	Origin	Propidium iodide-positive cells			
		Untreated cells	*Plastic dish*	*Rat2MV7*	*Rat2Wnt1*
KM3	pre-B cell	3 ± 2	43 ± 3	53 ± 4	4 ± 1
REH	pre-B cell	2 ± 2	42 ± 4	49 ± 3	3 ± 2
ML-1	myeloid	3 ± 1	53 ± 3	48 ± 2	43 ± 3
HL-60	myeloid	5 ± 2	34 ± 3	31 ± 5	35 ± 3
THP-1	myeloid	2 ± 1	25 ± 2	30 ± 3	23 ± 4
Jurkat	T cell	3 ± 1	43 ± 4	41 ± 3	23 ± 2
CEM	T cell	5 ± 2	70 ± 4	73 ± 3	43 ± 3
Molt-4	T cell	4 ± 2	46 ± 4	21 ± 2	7 ± 2
NK 3.3	NK cell	4 ± 1	38 ± 3	54 ± 4	46 ± 3
TF-1	erythromyeloid	3 ± 2	54 ± 4	43 ± 3	39 ± 3

Table 2

KM3 on	Relative proliferation (%)
plast	100±14
Rat2MV7	93,2±8,2
Rat2Wnt1	77,8±4
Rat2Wnt3a	77,4±20,4
L$_{TK-}$	74,2±15,1
LWnt3a	77,3±11,8

24

REFERENCES

1.   Nusse R. Wnt signaling in disease and in development. Cell Res 2005; 15: 28-32.

2.   Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-850.

3.   Moon RT. Wnt/beta-catenin pathway. Sci STKE 2005; 2005: cm1.

4.   Cadigan KM, Liu YI. Wnt signaling: complexity at the surface. J Cell Sci 2006 119: 395-402.

5.   Gordon MD, Nusse R. Wnt signaling: Multiple pathways, multiple receptors and multiple transcription factors. J Biol Chem 2006; 281: 22429-22433.

6.   Kohn AD, Moon RT. Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium 2005; 38: 439-446.

7.   Staal FJ, Clevers HC. WNT signalling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol 2005; 5: 21-30.

8.   Gounari F, Aifantis I, Khazaie K, et al. Somatic activation of beta-catenin bypasses pre-TCR signaling and TCR selection in thymocyte development. Nat Immunol 2001; 2: 863-869.

9.   Ioannidis V, Beermann F, Clevers H, Held, W. The beta-catenin--TCF-1 pathway ensures CD4(+)CD8(+) thymocyte survival. Nat Immunol 2001; 2: 691-697.

10.   Reya T, O'Riordan M, Okamura R, et al. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 2000; 13: 15-24.

11.   Dosen G, Tenstad E, Nygren MK, Stubberud H, Funderud S, Rian E. Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC Immunol 2006; 7: 13.

12.   Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S. Wnt proteins prevent

        apoptosis of both uncommitted osteoblast progenitors and differentiated

        osteoblasts by beta-catenin-dependent and -independent signaling cascades

        involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 2005;

        280: 41342-41351.

13.   Longo KA, Kennell JA, Ochocinska MJ, Ross SE, Wright WS, MacDougald O.

        A. Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction

        of insulin-like growth factors. J Biol Chem 2002; 277: 38239-38244.

14.   Ueda Y, Hijikata M, Takagi S, et al. Wnt/beta-catenin signaling suppresses

        apoptosis in low serum medium and induces morphologic change in rodent

        fibroblasts. Int J Cancer 2002; 99: 681-688.

15.   Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the

        Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005

        24: 2410-2420.

16.   Grotewold L, Ruther U. The Wnt antagonist Dickkopf-1 is regulated by Bmp

        signaling and c-Jun and modulates programmed cell death. EMBO J 2002; 21:

        966-975.

17.   He B, You L, Uematsu K, et al. A monoclonal antibody against Wnt-1 induces

        apoptosis in human cancer cells. Neoplasia 2004; 6: 7-14.

18.   You L, He B, Xu Z, et al. An anti-Wnt-2 monoclonal antibody induces apoptosis

        in malignant melanoma cells and inhibits tumor growth. Cancer Res 2004; 64:

        5385-5389.

19. Fas SC, Fritzsching B, Suri-Payer E, Krammer PH. Death receptor signaling and its function in the immune system. Curr Dir Autoimmun 2006 9: 1-17.

20. Shakibaei M, Schulze-Tanzil G, Takada Y, Aggarwal BB. Redox regulation of apoptosis by members of the TNF superfamily. Antioxid Redox Signal 2005; 7: 482-496.

21. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004; 16: 139-144.

22. Bouralexis S, Findlay DM, Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 2005; 10: 35-51.

23. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004; 14: 359-372.

24. Duiker EW, Mom CH, de Jong S, et al. The clinical trail of TRAIL. Eur J Cancer 2006; 2: 2233-2240.

25. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490.

26. Harper N, Hughes MA, Farrow SN, Cohen GM, MacFarlane M. Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling. J Biol Chem 2003; 278: 44338-44347.

27. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001; 276: 10767-10774.

28. Ortiz-Ferron G, Tait SW, Robledo G, de Vries E, Borst J, Lopez-Rivas A. The mitogen-activated protein kinase pathway can inhibit TRAIL-induced apoptosis by prohibiting association of truncated Bid with mitochondria. Cell Death Differ 2006; 13:1857-1865.

29. Soderstrom TS, Poukkula M, Holmstrom TH, Heiskanen KM, Eriksson JE. Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8. J Immunol 2002; 169: 2851-2860.

30. Wang G, Ahmad KA, Ahmed K. Modulation of death receptor-mediated apoptosis by CK2. Mol Cell Biochem 2005; 274: 201-205.

31. Jue SF, Bradley RS, Rudnicki JA, Varmus HE, and Brown AM. The mouse Wnt-1 gene can act via a paracrine mechanism in transformation of mammary epithelial cells. Mol Cell Biol 1992; 12: 321-328.

32. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.

33. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004; 10: 55-63.

34. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005; 24: 7482-7492.

35.   Panka DJ, Atkins MB, Mier JW. Targeting the mitogen-activated protein kinase

       pathway in the treatment of malignant melanoma. Clin Cancer Res 2006; 12:

       2371s-2375s.

36.   Lu D, Zhao Y, Tawatao R, et al. Activation of the Wnt signaling pathway in

       chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2004; 101: 3118-3123.

37.   Qiang YW, Endo Y, Rubin JS, Rudikoff S. Wnt signaling in B-cell neoplasia.

       Oncogene 2003; 22: 1536-1545.

38.   Chen S, Guttridge DC, You Z, et al. Wnt-1 signaling inhibits apoptosis by

       activating beta-catenin/T cell factor-mediated transcription. J Cell Biol 2001; 152:

       87-96.

39.   You Z, Saims D, Chen S, et al. Wnt signaling promotes oncogenic transformation

       by inhibiting c-Myc-induced apoptosis. J Cell Biol 2002; 157: 429-440.

40.   van de Wetering M, Sancho E, Verweij C, et al. The beta-catenin/TCF-4 complex

       imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111:

       241-250.

41.   Rottmann S, Wang Y, Nasoff M, Deveraux QL, Quon KC. A TRAIL receptor-

       dependent synthetic lethal relationship between MYC activation and

       GSK3beta/FBW7 loss of function. Proc Natl Acad Sci U S A 2005; 102: 15195-

       15200.

42.   Liao X, Zhang L, Thrasher JB, Du J, Li B. Glycogen synthase kinase-3beta

       suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand

       resistance in prostate cancer. Mol Cancer Ther 2003; 2: 1215-1222.

43. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 2004; 279: 39541-39554.

44. Yun MS, Kim SE, Jeon SH, Lee JS, Choi KY. Both ERK and Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferation. J Cell Sci 2005; 118: 313-322.

45. Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ. WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev 2000; 14: 585-595.

46. Su F, Overholtzer M, Besser D, Levine AJ. WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev 2002; 16: 46-57.

Table 1

Cell line	Origin	Propidium iodide-positive cells			
		Untreated cells	*Plastic dish*	*Rat2MV7*	*Rat2Wnt1*
KM3	pre-B cell	3 ± 2	43 ± 3	53 ± 4	4 ± 1
REH	pre-B cell	2 ± 2	42 ± 4	49 ± 3	3 ± 2
ML-1	myeloid	3 ± 1	53 ± 3	48 ± 2	43 ± 3
HL-60	myeloid	5 ± 2	34 ± 3	31 ± 5	35 ± 3
THP-1	myeloid	2 ± 1	25 ± 2	30 ± 3	23 ± 4
Jurkat	T cell	3 ± 1	43 ± 4	41 ± 3	23 ± 2
CEM	T cell	5 ± 2	70 ± 4	73 ± 3	43 ± 3
Molt-4	T cell	4 ± 2	46 ± 4	21 ± 2	7 ± 2
NK 3.3	NK cell	4 ± 1	38 ± 3	54 ± 4	46 ± 3
TF-1	erythromyeloid	3 ± 2	54 ± 4	43 ± 3	39 ± 3

Table 2

KM3 on	Relative proliferation (%)
plast	100±14
Rat2MV7	93,2±8,2
Rat2Wnt1	77,8±4
Rat2Wnt3a	77,4±20,4
L_{TK-}	74,2±15,1
LWnt3a	77,3±11,8

Figure 1A

ML-1

KM3

PI fluorescence

— Untreated
— Cells on Rat2MV7 + TRAIL
— Cells on Rat2Wnt1 + TRAIL

1B

ML-1   KM3

DR4

DR5

Phycoerythrin fluorescence

— GAM-PE   — Cells on Rat2MV7
— Cells on plast   — Cells on Rat2Wnt1

1C

	KM3 on Rat2MV7	KM3 on Rat2Wnt1
TRAIL	0' 6h 15h	0' 6h 15h

cFlip-L

Caspase-8

Bid

Caspase-3

PARP

c-myc

α-tubulin

Figure 2

Figure 3A

β-catenin

α-tubulin

Lanes: Rat2MV7, Rat2Wnt1, Rat2Wnt3a, L$_{TK-}$, L Wnt3a, L$_{TK-}$ CM, L Wnt3a CM, Wnt3a, Wnt5a, MetBIO, BIO

3B

KM3 on Rat2MV7 | KM3 on Rat2Wnt1 | KM3 on Rat2Wnt3a | KM3 on L | KM3 on LWnt3a

untreated: 15.4% | 5.49% | 11.7% | 10.9% | 10.7%

TRAIL: 41% | 19.2% | 24% | 46.4% | 34.7%

KM3 on Rat2MV7 +L medium | KM3 on Rat2MV7 +LWnt3a medium | KM3 +Wnt3a (rec.) | KM3 +Wnt5a (rec.)

untreated: 9.19% | 8.98% | 9.38% | 8.02%

TRAIL: 55.4% | 48.5% | 43.5% | 57%

KM3 on Rat2MV7+BIO | KM3 on Rat2Wnt1+BIO | KM3 on Rat2MV7+MetBIO | KM3 on Rat2Wnt1+MetBIO

untreated: 15.6% | 14.4% | 6.49% | 4.3%

TRAIL: 57.3% | 75.8% | 57.4% | 30.2%

3C

0.1   1.0   10.0

Columns: C-MYB, MYC, DR4, DR5

KM3/Rat2MV7
KM3/Rat2Wnt1
KM3/Rat2MV7 +MetBIO
KM3/Rat2MV7 +BIO
KM3/Rat2MV7 + LWnt3a medium

Figure 4A

4B

KM3   Ramos

Rat2MV7   Rat2Wnt1   Rat2MV7   Rat2Wnt1

β-catenin

α-tubulin

Untreated   TRAIL 15 hours

KM3 on Rat2MV7 — 14.1% / 47.9%

KM3 on Rat2Wnt1 — 5.98% / 9.96%

Ramos on Rat2MV7 — 5.25% / 73.3%

Ramos on Rat2Wnt1 — 3.3% / 70.1%

Cell number

Annexin V FITC

Figure 5

4 ZÁVĚR

Cílem předkládané práce bylo přispět k poznání mechanismů, které ovlivňují aktivitu signalizace Wnt v buněčném jádře. Hlavní výsledky lze shrnout do následujících bodů:

1. Zjistili jsme, že transkripční korepresor CtBP1 má schopnost blokovat signalizaci Wnt, a to prostřednictvím inhibice transkripce cílových genů této signalizace. Represivní působení proteinu CtBP je podmíněno aktivitou s ním asociovaných histon deacetyláz.

2. Identifikovali jsme nádorový supresor HIC1 jako nový inhibitor signální dráhy Wnt. HIC1 přímo interaguje s klíčovým proteinem signalizace Wnt transkripčním faktorem TCF-4 a tato interakce je základem pro inhibičního působení proteinu HIC1. HIC1 relokuje transkripční komplexy TCF-4/β-katenin do specifických jaderných struktur a brání tak jejich vazbě na specifické cílové promotory, čímž dochází k zablokování transkripce. Pro efektivní relokaci komplexů TCF-4/β-katenin je důležitá strukturní funkce proteinu CtBP.

3. Nukleární recetor NHR-25 je shopen v buňkách prekurzorů gonády hlístice *Caenorhabditis elegans* interagovat s β-kateniny WRM-1 a SYS-1. Interakce s těmito β-kateniny moduluje transkripci cílových genů signalizace Wnt. Vzájemná interference mezi aktivitou signální dráhy Wnt a proteinem NHR-25 je rozhodujícím dějem, který determinuje osud somatických buněčných prekurzorů gonády. Zatímco signalizace Wnt je klíčová pro určení distálního vývoje buněk, tak NHR-25 řídí osud buněk proximálních.

4. Signální dráha Wnt má potenciál blokovat u některých hematopoietických buněčných linií apoptózu indukovanou ligandem TRAIL, zástupcem ligandů příbuzných TNF. Inhibiční působení signalizace Wnt je založeno především na snížení exprese specifických proaptotických receptorů DR4 a DR5, aditivní efekt pro inhibici apoptózy má indukce kinázové kaskády MEK1/ERK1, která rovněž blokuje apoptózu indukovanou ligandem TRAIL.

SEZNAM POUŽITÉ LITERATURY

1.   Cadigan, K.M. and R. Nusse, *Wnt signaling: a common theme in animal development.* Genes Dev, 1997. **11**(24): p. 3286-305.

2.   Logan, C.Y. and R. Nusse, *The Wnt signaling pathway in development and disease.* Annu Rev Cell Dev Biol, 2004. **20**: p. 781-810.

3.   Moon, R.T., et al., *The promise and perils of Wnt signaling through beta-catenin.* Science, 2002. **296**(5573): p. 1644-6.

4.   Kuhl, M., *Non-canonical Wnt signaling in Xenopus: regulation of axis formation and gastrulation.* Semin Cell Dev Biol, 2002. **13**(3): p. 243-9.

5.   Ciruna, B., et al., *Planar cell polarity signalling couples cell division and morphogenesis during neurulation.* Nature, 2006. **439**(7073): p. 220-4.

6.   Kohn, A.D. and R.T. Moon, *Wnt and calcium signaling: beta-catenin-independent pathways.* Cell Calcium, 2005. **38**(3-4): p. 439-46.

7.   Saburi, S. and H. McNeill, *Organising cells into tissues: new roles for cell adhesion molecules in planar cell polarity.* Curr Opin Cell Biol, 2005. **17**(5): p. 482-8.

8.   Kusserow, A., et al., *Unexpected complexity of the Wnt gene family in a sea anemone.* Nature, 2005. **433**(7022): p. 156-60.

9.   Cox, R.T. and M. Peifer, *Wingless signaling: the inconvenient complexities of life.* Curr Biol, 1998. **8**(4): p. R140-4.

10.   Packard, M., D. Mathew, and V. Budnik, *Wnts and TGF beta in synaptogenesis: old friends signalling at new places.* Nat Rev Neurosci, 2003. **4**(2): p. 113-20.

11.   Wang, J. and A. Wynshaw-Boris, *The canonical Wnt pathway in early mammalian embryogenesis and stem cell maintenance/differentiation.* Curr Opin Genet Dev, 2004. **14**(5): p. 533-9.

12.   Weaver, C. and D. Kimelman, *Move it or lose it: axis specification in Xenopus.* Development, 2004. **131**(15): p. 3491-9.

13.   Reya, T. and H. Clevers, *Wnt signalling in stem cells and cancer.* Nature, 2005. **434**(7035): p. 843-50.

14.   Radtke, F., H. Clevers, and O. Riccio, *From gut homeostasis to cancer.* Curr Mol Med, 2006. **6**(3): p. 275-89.

15.   Reya, T., et al., *A role for Wnt signalling in self-renewal of haematopoietic stem cells.* Nature, 2003. **423**(6938): p. 409-14.

16.   Moon, R.T., et al., *WNT and beta-catenin signalling: diseases and therapies.* Nat Rev Genet, 2004. **5**(9): p. 691-701.

17.   Gregorieff, A. and H. Clevers, *Wnt signaling in the intestinal epithelium: from endoderm to cancer.* Genes Dev, 2005. **19**(8): p. 877-90.

18.   Bienz, M., *beta-Catenin: a pivot between cell adhesion and Wnt signalling.* Curr Biol, 2005. **15**(2): p. R64-7.

19.   Brembeck, F.H., M. Rosario, and W. Birchmeier, *Balancing cell adhesion and Wnt signaling, the key role of beta-catenin.* Curr Opin Genet Dev, 2006. **16**(1): p. 51-9.

20.   Xing, Y., et al., *Crystal structure of a beta-catenin/axin complex suggests a mechanism for the beta-catenin destruction complex.* Genes Dev, 2003. **17**(22): p. 2753-64.

21.   Lee, E., et al., *The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway.* PLoS Biol, 2003. **1**(1): p. E10.

22.   Salic, A., et al., *Control of beta-catenin stability: reconstitution of the cytoplasmic steps of the wnt pathway in Xenopus egg extracts.* Mol Cell, 2000. **5**(3): p. 523-32.

23. Hart, M.J., et al., *Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta.* Curr Biol, 1998. **8**(10): p. 573-81.

24. Doble, B.W. and J.R. Woodgett, *GSK-3: tricks of the trade for a multi-tasking kinase.* J Cell Sci, 2003. **116**(Pt 7): p. 1175-86.

25. Marikawa, Y. and R.P. Elinson, *beta-TrCP is a negative regulator of Wnt/beta-catenin signaling pathway and dorsal axis formation in Xenopus embryos.* Mech Dev, 1998. **77**(1): p. 75-80.

26. Hart, M., et al., *The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell.* Curr Biol, 1999. **9**(4): p. 207-10.

27. Fuchs, S.Y., V.S. Spiegelman, and K.G. Kumar, *The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer.* Oncogene, 2004. **23**(11): p. 2028-36.

28. Huang, H.C. and P.S. Klein, *The Frizzled family: receptors for multiple signal transduction pathways.* Genome Biol, 2004. **5**(7): p. 234.

29. Pinson, K.I., et al., *An LDL-receptor-related protein mediates Wnt signalling in mice.* Nature, 2000. **407**(6803): p. 535-8.

30. Bhanot, P., et al., *A new member of the frizzled family from Drosophila functions as a Wingless receptor.* Nature, 1996. **382**(6588): p. 225-30.

31. Tamai, K., et al., *LDL-receptor-related proteins in Wnt signal transduction.* Nature, 2000. **407**(6803): p. 530-5.

32. Lee, J.S., A. Ishimoto, and S. Yanagawa, *Characterization of mouse dishevelled (Dvl) proteins in Wnt/Wingless signaling pathway.* J Biol Chem, 1999. **274**(30): p. 21464-70.

33. Wallingford, J.B. and R. Habas, *The developmental biology of Dishevelled: an enigmatic protein governing cell fate and cell polarity.* Development, 2005. **132**(20): p. 4421-36.

34. Mao, J., et al., *Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway.* Mol Cell, 2001. **7**(4): p. 801-9.

35. Brannon, M., et al., *A beta-catenin/XTcf-3 complex binds to the siamois promoter to regulate dorsal axis specification in Xenopus.* Genes Dev, 1997. **11**(18): p. 2359-70.

36. Behrens, J., et al., *Functional interaction of beta-catenin with the transcription factor LEF-1.* Nature, 1996. **382**(6592): p. 638-42.

37. Korinek, V., et al., *Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.* Science, 1997. **275**(5307): p. 1784-7.

38. Tetsu, O. and F. McCormick, *Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.* Nature, 1999. **398**(6726): p. 422-6.

39. Shtutman, M., et al., *The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.* Proc Natl Acad Sci U S A, 1999. **96**(10): p. 5522-7.

40. Mann, B., et al., *Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas.* Proc Natl Acad Sci U S A, 1999. **96**(4): p. 1603-8.

41. Willert, J., et al., *A transcriptional response to Wnt protein in human embryonic carcinoma cells.* BMC Dev Biol, 2002. **2**: p. 8.

42. Baker, N.E., *Molecular cloning of sequences from wingless, a segment polarity gene in Drosophila: the spatial distribution of a transcript in embryos.* Embo J, 1987. **6**(6): p. 1765-1773.

43. Cabrera, C.V., et al., *Phenocopies induced with antisense RNA identify the wingless gene.* Cell, 1987. **50**(4): p. 659-63.

44. Nusse, R. and H.E. Varmus, *Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome.* Cell, 1982. **31**(1): p. 99-109.

45. van Ooyen, A. and R. Nusse, *Structure and nucleotide sequence of the putative mammary oncogene int-1; proviral insertions leave the protein-encoding domain intact.* Cell, 1984. **39**(1): p. 233-40.

46. Nusse, R., et al., *The Wnt-1 (int-1) oncogene promoter and its mechanism of activation by insertion of proviral DNA of the mouse mammary tumor virus.* Mol Cell Biol, 1990. **10**(8): p. 4170-9.

47. Nusse, R., et al., *A new nomenclature for int-1 and related genes: the Wnt gene family.* Cell, 1991. **64**(2): p. 231.

48. Nichols, S.A., et al., *Early evolution of animal cell signaling and adhesion genes.* Proc Natl Acad Sci U S A, 2006.

49. Miller, J.R., *The Wnts.* Genome Biol, 2002. **3**(1): p. REVIEWS3001.

50. Miller, D.J., E.E. Ball, and U. Technau, *Cnidarians and ancestral genetic complexity in the animal kingdom.* Trends Genet, 2005. **21**(10): p. 536-9.

51. Nusse, R. and H.E. Varmus, *Wnt genes.* Cell, 1992. **69**(7): p. 1073-87.

52. Zecca, M., K. Basler, and G. Struhl, *Direct and long-range action of a wingless morphogen gradient.* Cell, 1996. **87**(5): p. 833-44.

53. Smolich, B.D., et al., *Wnt family proteins are secreted and associated with the cell surface.* Mol Biol Cell, 1993. **4**(12): p. 1267-75.

54. Willert, K., et al., *Wnt proteins are lipid-modified and can act as stem cell growth factors.* Nature, 2003. **423**(6938): p. 448-52.

55. Linder, M.E. and R.J. Deschenes, *Model organisms lead the way to protein palmitoyltransferases.* J Cell Sci, 2004. **117**(Pt 4): p. 521-6.

56. Zhai, L., D. Chaturvedi, and S. Cumberledge, *Drosophila wnt-1 undergoes a hydrophobic modification and is targeted to lipid rafts, a process that requires porcupine.* J Biol Chem, 2004. **279**(32): p. 33220-7.

57. Bartscherer, K., et al., *Secretion of Wnt ligands requires Evi, a conserved transmembrane protein.* Cell, 2006. **125**(3): p. 523-33.

58. Banziger, C., et al., *Wntless, a conserved membrane protein dedicated to the secretion of Wnt proteins from signaling cells.* Cell, 2006. **125**(3): p. 509-22.

59. Coudreuse, D.Y., et al., *Wnt gradient formation requires retromer function in Wnt-producing cells.* Science, 2006. **312**(5775): p. 921-4.

60. Prasad, B.C. and S.G. Clark, *Wnt signaling establishes anteroposterior neuronal polarity and requires retromer in C. elegans.* Development, 2006. **133**(9): p. 1757-66.

61. Goodman, R.M., et al., *Sprinter: a novel transmembrane protein required for Wg secretion and signaling.* Development, 2006. **133**(24): p. 4901-11.

62. Panakova, D., et al., *Lipoprotein particles are required for Hedgehog and Wingless signalling.* Nature, 2005. **435**(7038): p. 58-65.

63. Eaton, S., *Release and trafficking of lipid-linked morphogens.* Curr Opin Genet Dev, 2006. **16**(1): p. 17-22.

64. Cadigan, K.M., *Regulating morphogen gradients in the Drosophila wing.* Semin Cell Dev Biol, 2002. **13**(2): p. 83-90.

65. Tsuda, M., et al., *The cell-surface proteoglycan Dally regulates Wingless signalling in Drosophila.* Nature, 1999. **400**(6741): p. 276-80.

66. Lin, X., *Functions of heparan sulfate proteoglycans in cell signaling during development.* Development, 2004. **131**(24): p. 6009-21.

67. Franch-Marro, X., et al., *Glypicans shunt the Wingless signal between local signalling and further transport.* Development, 2005. **132**(4): p. 659-66.

68. Han, C., et al., *Drosophila glypicans Dally and Dally-like shape the extracellular Wingless morphogen gradient in the wing disc.* Development, 2005. **132**(4): p. 667-79.

69. Giraldez, A.J., R.R. Copley, and S.M. Cohen, *HSPG modification by the secreted enzyme Notum shapes the Wingless morphogen gradient.* Dev Cell, 2002. **2**(5): p. 667-76.

70. Gerlitz, O. and K. Basler, *Wingful, an extracellular feedback inhibitor of Wingless.* Genes Dev, 2002. **16**(9): p. 1055-9.

71. De Cat, B., et al., *Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements.* J Cell Biol, 2003. **163**(3): p. 625-35.

72. Capurro, M.I., et al., *Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.* Cancer Res, 2005. **65**(14): p. 6245-54.

73. Song, H.H., et al., *The loss of glypican-3 induces alterations in Wnt signaling.* J Biol Chem, 2005. **280**(3): p. 2116-25.

74. Nusse, R., *Wnts and Hedgehogs: lipid-modified proteins and similarities in signaling mechanisms at the cell surface.* Development, 2003. **130**(22): p. 5297-305.

75. Miura, G.I. and J.E. Treisman, *Lipid modification of secreted signaling proteins.* Cell Cycle, 2006. **5**(11): p. 1184-8.

76. Kuhl, M., et al., *Antagonistic regulation of convergent extension movements in Xenopus by Wnt/beta-catenin and Wnt/Ca2+ signaling.* Mech Dev, 2001. **106**(1-2): p. 61-76.

77. Mikels, A.J. and R. Nusse, *Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context.* PLoS Biol, 2006. **4**(4): p. e115.

78. Hsieh, J.C., *Specificity of WNT-receptor interactions.* Front Biosci, 2004. **9**: p. 1333-8.

79. Wang, H.Y., T. Liu, and C.C. Malbon, *Structure-function analysis of Frizzleds.* Cell Signal, 2006. **18**(7): p. 934-41.

80. Bhanot, P., et al., *Frizzled and Dfrizzled-2 function as redundant receptors for Wingless during Drosophila embryonic development.* Development, 1999. **126**(18): p. 4175-86.

81. He, X., et al., *LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way.* Development, 2004. **131**(8): p. 1663-77.

82. Tamai, K., et al., *A mechanism for Wnt coreceptor activation.* Mol Cell, 2004. **13**(1): p. 149-56.

83. Hoang, B., et al., *Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis.* J Biol Chem, 1996. **271**(42): p. 26131-7.

84. Kawano, Y. and R. Kypta, *Secreted antagonists of the Wnt signalling pathway.* J Cell Sci, 2003. **116**(Pt 13): p. 2627-34.

85. Glinka, A., et al., *Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction.* Nature, 1998. **391**(6665): p. 357-62.

86. Mao, B., et al., *Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling.* Nature, 2002. **417**(6889): p. 664-7.

87. Itasaki, N., et al., *Wise, a context-dependent activator and inhibitor of Wnt signalling.* Development, 2003. **130**(18): p. 4295-305.

88. Semenov, M., K. Tamai, and X. He, *SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.* J Biol Chem, 2005. **280**(29): p. 26770-5.

89. Hsieh, J.C., et al., *A new secreted protein that binds to Wnt proteins and inhibits their activities.* Nature, 1999. **398**(6726): p. 431-6.

90. Lu, W., et al., *Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth.* Cell, 2004. **119**(1): p. 97-108.

91. Xu, Q., et al., *Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair.* Cell, 2004. **116**(6): p. 883-95.

92. Kazanskaya, O., et al., *R-Spondin2 is a secreted activator of Wnt/beta-catenin signaling and is required for Xenopus myogenesis.* Dev Cell, 2004. **7**(4): p. 525-34.

93. Kim, K.A., et al., *Mitogenic influence of human R-spondin1 on the intestinal epithelium.* Science, 2005. **309**(5738): p. 1256-9.

94. Nam, J.S., et al., *Mouse cristin/R-spondin family proteins are novel ligands for the Frizzled 8 and LRP6 receptors and activate beta-catenin-dependent gene expression.* J Biol Chem, 2006. **281**(19): p. 13247-57.

95. Kemler, R., *From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion.* Trends Genet, 1993. **9**(9): p. 317-21.

96. Drees, F., et al., *Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly.* Cell, 2005. **123**(5): p. 903-15.

97. Yamada, S., et al., *Deconstructing the cadherin-catenin-actin complex.* Cell, 2005. **123**(5): p. 889-901.

98. Birchmeier, W., *Cell adhesion and signal transduction in cancer. Conference on cadherins, catenins and cancer.* EMBO Rep, 2005. **6**(5): p. 413-7.

99. Peifer, M. and E. Wieschaus, *The segment polarity gene armadillo encodes a functionally modular protein that is the Drosophila homolog of human plakoglobin.* Cell, 1990. **63**(6): p. 1167-76.

100. Peifer, M., et al., *The segment polarity gene armadillo interacts with the wingless signaling pathway in both embryonic and adult pattern formation.* Development, 1991. **111**(4): p. 1029-43.

101. Molenaar, M., et al., *XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos.* Cell, 1996. **86**(3): p. 391-9.

102. Huber, A.H., W.J. Nelson, and W.I. Weis, *Three-dimensional structure of the armadillo repeat region of beta-catenin.* Cell, 1997. **90**(5): p. 871-82.

103. Orsulic, S. and M. Peifer, *An in vivo structure-function study of armadillo, the beta-catenin homologue, reveals both separate and overlapping regions of the protein required for cell adhesion and for wingless signaling.* J Cell Biol, 1996. **134**(5): p. 1283-300.

104. Hoffmans, R. and K. Basler, *Identification and in vivo role of the Armadillo-Legless interaction.* Development, 2004. **131**(17): p. 4393-400.

105. Korswagen, H.C., M.A. Herman, and H.C. Clevers, *Distinct beta-catenins mediate adhesion and signalling functions in C. elegans.* Nature, 2000. **406**(6795): p. 527-32.

106. Korswagen, H.C., *Canonical and non-canonical Wnt signaling pathways in Caenorhabditis elegans: variations on a common signaling theme.* Bioessays, 2002. **24**(9): p. 801-10.

107. Kidd, A.R., 3rd, et al., *A beta-catenin identified by functional rather than sequence criteria and its role in Wnt/MAPK signaling.* Cell, 2005. **121**(5): p. 761-72.

108. Zeng, X., et al., *A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation.* Nature, 2005. **438**(7069): p. 873-7.

109. Liu, C., et al., *Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism.* Cell, 2002. **108**(6): p. 837-47.

110. Park, T.J., et al., *Subcellular localization and signaling properties of dishevelled in developing vertebrate embryos.* Curr Biol, 2005. **15**(11): p. 1039-44.

111. Yamamoto, H., et al., *Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability.* J Biol Chem, 1999. **274**(16): p. 10681-4.

112. Willert, K., et al., *A Drosophila Axin homolog, Daxin, inhibits Wnt signaling.* Development, 1999. **126**(18): p. 4165-73.

113. Chia, I.V. and F. Costantini, *Mouse axin and axin2/conductin proteins are functionally equivalent in vivo.* Mol Cell Biol, 2005. **25**(11): p. 4371-6.

114. Huang, J., et al., *APC mutations in colorectal tumors with mismatch repair deficiency.* Proc Natl Acad Sci U S A, 1996. **93**(17): p. 9049-54.

115. Kinzler, K.W. and B. Vogelstein, *Lessons from hereditary colorectal cancer.* Cell, 1996. **87**(2): p. 159-70.

116. Brocardo, M., I.S. Nathke, and B.R. Henderson, *Redefining the subcellular location and transport of APC: new insights using a panel of antibodies.* EMBO Rep, 2005. **6**(2): p. 184-90.

117. Xing, Y., et al., *Crystal structure of a beta-catenin/APC complex reveals a critical role for APC phosphorylation in APC function.* Mol Cell, 2004. **15**(4): p. 523-33.

118. Harris, T.J. and M. Peifer, *Decisions, decisions: beta-catenin chooses between adhesion and transcription.* Trends Cell Biol, 2005. **15**(5): p. 234-7.

119. Li, X., et al., *Protein phosphatase 2A and its B56 regulatory subunit inhibit Wnt signaling in Xenopus.* Embo J, 2001. **20**(15): p. 4122-31.

120. Seeling, J.M., et al., *Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A.* Science, 1999. **283**(5410): p. 2089-91.

121. Ikeda, S., et al., *GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin.* Oncogene, 2000. **19**(4): p. 537-45.

122. Cong, F., L. Schweizer, and H. Varmus, *Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP.* Development, 2004. **131**(20): p. 5103-15.

123. Holmen, S.L., et al., *Wnt-independent activation of beta-catenin mediated by a Dkk1-Fz5 fusion protein.* Biochem Biophys Res Commun, 2005. **328**(2): p. 533-9.

124. Yamamoto, H., H. Komekado, and A. Kikuchi, *Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin.* Dev Cell, 2006. **11**(2): p. 213-23.

125. Blitzer, J.T. and R. Nusse, *A critical role for endocytosis in Wnt signaling.* BMC Cell Biol, 2006. **7**: p. 28.

126. Davidson, G., et al., *Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction.* Nature, 2005. **438**(7069): p. 867-72.

127. van Amerongen, R. and A. Berns, *Re-evaluating the role of Frat in Wnt-signal transduction.* Cell Cycle, 2005. **4**(8): p. 1065-72.

128. Katanaev, V.L., et al., *Trimeric G protein-dependent frizzled signaling in Drosophila.* Cell, 2005. **120**(1): p. 111-22.

129. Liu, X., J.S. Rubin, and A.R. Kimmel, *Rapid, Wnt-induced changes in GSK3beta associations that regulate beta-catenin stabilization are mediated by Galpha proteins.* Curr Biol, 2005. **15**(22): p. 1989-97.

130. Ossipova, O., et al., *Distinct PAR-1 proteins function in different branches of Wnt signaling during vertebrate development.* Dev Cell, 2005. **8**(6): p. 829-41.

131.   Cong, F., L. Schweizer, and H. Varmus, *Casein kinase Iepsilon modulates the signaling specificities of dishevelled.* Mol Cell Biol, 2004. **24**(5): p. 2000-11.

132.   Hino, S., et al., *Casein kinase I epsilon enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of beta-catenin.* J Biol Chem, 2003. **278**(16): p. 14066-73.

133.   van de Wetering, M., et al., *Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF.* Cell, 1997. **88**(6): p. 789-99.

134.   Polakis, P., *Wnt signaling and cancer.* Genes Dev, 2000. **14**(15): p. 1837-51.

135.   Park, J.Y., et al., *Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis.* Liver Int, 2005. **25**(1): p. 70-6.

136.   Satoh, S., et al., *AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.* Nat Genet, 2000. **24**(3): p. 245-50.

137.   Behrens, J., *Control of beta-catenin signaling in tumor development.* Ann N Y Acad Sci, 2000. **910**: p. 21-33; discussion 33-5.

138.   Pinto, D. and H. Clevers, *Wnt, stem cells and cancer in the intestine.* Biol Cell, 2005. **97**(3): p. 185-96.

139.   Yokoya, F., et al., *beta-catenin can be transported into the nucleus in a Ran-unassisted manner.* Mol Biol Cell, 1999. **10**(4): p. 1119-31.

140.   Fagotto, F., U. Gluck, and B.M. Gumbiner, *Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of beta-catenin.* Curr Biol, 1998. **8**(4): p. 181-90.

141.   Koike, M., et al., *beta-Catenin shows an overlapping sequence requirement but distinct molecular interactions for its bidirectional passage through nuclear pores.* J Biol Chem, 2004. **279**(32): p. 34038-47.

142.   Stadeli, R., R. Hoffmans, and K. Basler, *Transcription under the control of nuclear Arm/beta-catenin.* Curr Biol, 2006. **16**(10): p. R378-85.

143.   Wiechens, N. and F. Fagotto, *CRM1- and Ran-independent nuclear export of beta-catenin.* Curr Biol, 2001. **11**(1): p. 18-27.

144.   Cong, F. and H. Varmus, *Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of beta-catenin.* Proc Natl Acad Sci U S A, 2004. **101**(9): p. 2882-7.

145.   Krieghoff, E., J. Behrens, and B. Mayr, *Nucleo-cytoplasmic distribution of beta-catenin is regulated by retention.* J Cell Sci, 2006. **119**(Pt 7): p. 1453-63.

146.   Xiong, Y. and Y. Kotake, *No exit strategy? No problem: APC inhibits beta-catenin inside the nucleus.* Genes Dev, 2006. **20**(6): p. 637-42.

147.   van Noort, M. and H. Clevers, *TCF transcription factors, mediators of Wnt-signaling in development and cancer.* Dev Biol, 2002. **244**(1): p. 1-8.

148.   Galceran, J., et al., *Wnt3a-/--like phenotype and limb deficiency in Lef1(-/-)Tcf1(-/-) mice.* Genes Dev, 1999. **13**(6): p. 709-17.

149.   Verbeek, S., et al., *An HMG-box-containing T-cell factor required for thymocyte differentiation.* Nature, 1995. **374**(6517): p. 70-4.

150.   Huang, Z., et al., *Transcriptional regulation of CD4 gene expression by T cell factor-1/beta-catenin pathway.* J Immunol, 2006. **176**(8): p. 4880-7.

151.   Reya, T., et al., *Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism.* Immunity, 2000. **13**(1): p. 15-24.

152.   Korinek, V., et al., *Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4.* Nat Genet, 1998. **19**(4): p. 379-83.

153. Barker, N., et al., *Restricted high level expression of Tcf-4 protein in intestinal and mammary gland epithelium.* Am J Pathol, 1999. **154**(1): p. 29-35.

154. Korinek, V., et al., *Two members of the Tcf family implicated in Wnt/beta-catenin signaling during embryogenesis in the mouse.* Mol Cell Biol, 1998. **18**(3): p. 1248-56.

155. Merrill, B.J., et al., *Tcf3: a transcriptional regulator of axis induction in the early embryo.* Development, 2004. **131**(2): p. 263-74.

156. Clevers, H. and M. van de Wetering, *TCF/LEF factor earn their wings.* Trends Genet, 1997. **13**(12): p. 485-9.

157. Van de Wetering, M., et al., *Extensive alternative splicing and dual promoter usage generate Tcf-1 protein isoforms with differential transcription control properties.* Mol Cell Biol, 1996. **16**(3): p. 745-52.

158. Duval, A., et al., *The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines.* Cancer Res, 2000. **60**(14): p. 3872-9.

159. Roose, J., et al., *The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors.* Nature, 1998. **395**(6702): p. 608-12.

160. Cavallo, R.A., et al., *Drosophila Tcf and Groucho interact to repress Wingless signalling activity.* Nature, 1998. **395**(6702): p. 604-8.

161. Gasperowicz, M. and F. Otto, *Mammalian Groucho homologs: redundancy or specificity?* J Cell Biochem, 2005. **95**(4): p. 670-87.

162. Barker, N., et al., *The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation.* Embo J, 2001. **20**(17): p. 4935-43.

163. Hecht, A., et al., *The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates.* Embo J, 2000. **19**(8): p. 1839-50.

164. Takemaru, K.I. and R.T. Moon, *The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression.* J Cell Biol, 2000. **149**(2): p. 249-54.

165. Teo, J.L., et al., *Specific inhibition of CBP/beta-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation.* Proc Natl Acad Sci U S A, 2005. **102**(34): p. 12171-6.

166. Sierra, J., et al., *The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes.* Genes Dev, 2006. **20**(5): p. 586-600.

167. Hecht, A., et al., *Functional characterization of multiple transactivating elements in beta-catenin, some of which interact with the TATA-binding protein in vitro.* J Biol Chem, 1999. **274**(25): p. 18017-25.

168. Mosimann, C., G. Hausmann, and K. Basler, *Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo.* Cell, 2006. **125**(2): p. 327-41.

169. Kim, S., et al., *Mediator is a transducer of Wnt/beta-catenin signaling.* J Biol Chem, 2006. **281**(20): p. 14066-75.

170. Malik, S. and R.G. Roeder, *Dynamic regulation of pol II transcription by the mammalian Mediator complex.* Trends Biochem Sci, 2005. **30**(5): p. 256-63.

171. Conaway, R.C., et al., *The mammalian Mediator complex and its role in transcriptional regulation.* Trends Biochem Sci, 2005. **30**(5): p. 250-5.

172. Daniels, D.L. and W.I. Weis, *Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation.* Nat Struct Mol Biol, 2005. **12**(4): p. 364-71.

173. Parker, D.S., J. Jemison, and K.M. Cadigan, *Pygopus, a nuclear PHD-finger protein required for Wingless signaling in Drosophila.* Development, 2002. **129**(11): p. 2565-76.

174. Belenkaya, T.Y., et al., *pygopus Encodes a nuclear protein essential for wingless/Wnt signaling.* Development, 2002. **129**(17): p. 4089-101.

175. Hoffmans, R., R. Stadeli, and K. Basler, *Pygopus and legless provide essential transcriptional coactivator functions to armadillo/beta-catenin.* Curr Biol, 2005. **15**(13): p. 1207-11.

176. Townsley, F.M., B. Thompson, and M. Bienz, *Pygopus residues required for its binding to Legless are critical for transcription and development.* J Biol Chem, 2004. **279**(7): p. 5177-83.

177. Takemaru, K., et al., *Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway.* Nature, 2003. **422**(6934): p. 905-9.

178. Tago, K., et al., *Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein.* Genes Dev, 2000. **14**(14): p. 1741-9.

179. Ishitani, T., J. Ninomiya-Tsuji, and K. Matsumoto, *Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase-related Nemo-like kinase-dependent phosphorylation in Wnt/beta-catenin signaling.* Mol Cell Biol, 2003. **23**(4): p. 1379-89.

180. Smit, L., et al., *Wnt activates the Tak1/Nemo-like kinase pathway.* J Biol Chem, 2004. **279**(17): p. 17232-40.

181. Wang, S. and K.A. Jones, *CK2 controls the recruitment of Wnt regulators to target genes in vivo.* Curr Biol, 2006. **16**(22): p. 2239-44.

182. Sachdev, S., et al., *PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies.* Genes Dev, 2001. **15**(23): p. 3088-103.

183. Yamamoto, H., et al., *Sumoylation is involved in beta-catenin-dependent activation of Tcf-4.* Embo J, 2003. **22**(9): p. 2047-59.

184. Spiegelman, V.S., et al., *Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor.* Mol Cell, 2000. **5**(5): p. 877-82.

185. He, T.C., et al., *Identification of c-MYC as a target of the APC pathway.* Science, 1998. **281**(5382): p. 1509-12.

186. Sansom, O.J., et al., *Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine.* J Biol Chem, 2005. **280**(31): p. 28463-7.

187. Lustig, B., et al., *Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors.* Mol Cell Biol, 2002. **22**(4): p. 1184-93.

188. Jho, E.H., et al., *Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway.* Mol Cell Biol, 2002. **22**(4): p. 1172-83.

189. Gregorieff, A., R. Grosschedl, and H. Clevers, *Hindgut defects and transformation of the gastro-intestinal tract in Tcf4(-/-)/Tcf1(-/-) embryos.* Embo J, 2004. **23**(8): p. 1825-33.

190. Hecht, A. and M.P. Stemmler, *Identification of a promoter-specific transcriptional activation domain at the C terminus of the Wnt effector protein T-cell factor 4.* J Biol Chem, 2003. **278**(6): p. 3776-85.

191. Schaeper, U., et al., *Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation.* Proc Natl Acad Sci U S A, 1995. **92**(23): p. 10467-71.

192. Katsanis, N. and E.M. Fisher, *A novel C-terminal binding protein (CTBP2) is closely related to CTBP1, an adenovirus E1A-binding protein, and maps to human chromosome 21q21.3.* Genomics, 1998. **47**(2): p. 294-9.

193. Chinnadurai, G., *CtBP family proteins: more than transcriptional corepressors.* Bioessays, 2003. **25**(1): p. 9-12.

194. Sundqvist, A., K. Sollerbrant, and C. Svensson, *The carboxy-terminal region of adenovirus E1A activates transcription through targeting of a C-terminal binding protein-histone deacetylase complex.* FEBS Lett, 1998. **429**(2): p. 183-8.

195. Subramanian, T. and G. Chinnadurai, *Association of class I histone deacetylases with transcriptional corepressor CtBP.* FEBS Lett, 2003. **540**(1-3): p. 255-8.

196. Srinivasan, L. and M.L. Atchison, *YY1 DNA binding and PcG recruitment requires CtBP.* Genes Dev, 2004. **18**(21): p. 2596-601.

197. Kim, J.H., et al., *CtBP represses p300-mediated transcriptional activation by direct association with its bromodomain.* Nat Struct Mol Biol, 2005. **12**(5): p. 423-8.

198. Furusawa, T., et al., *Identification of CtBP1 and CtBP2 as corepressors of zinc finger-homeodomain factor deltaEF1.* Mol Cell Biol, 1999. **19**(12): p. 8581-90.

199. Brannon, M., et al., *XCtBP is a XTcf-3 co-repressor with roles throughout Xenopus development.* Development, 1999. **126**(14): p. 3159-70.

200. Houston, D.W., et al., *Repression of organizer genes in dorsal and ventral Xenopus cells mediated by maternal XTcf3.* Development, 2002. **129**(17): p. 4015-25.

201. Merrill, B.J., et al., *Tcf3 and Lef1 regulate lineage differentiation of multipotent stem cells in skin.* Genes Dev, 2001. **15**(13): p. 1688-705.

202. Hamada, F. and M. Bienz, *The APC tumor suppressor binds to C-terminal binding protein to divert nuclear beta-catenin from TCF.* Dev Cell, 2004. **7**(5): p. 677-85.

203. Cuilliere-Dartigues, P., et al., *TCF-4 isoforms absent in TCF-4 mutated MSI-H colorectal cancer cells colocalize with nuclear CtBP and repress TCF-4-mediated transcription.* Oncogene, 2006. **25**(32): p. 4441-8.

204. Fang, M., et al., *C-terminal-binding protein directly activates and represses Wnt transcriptional targets in Drosophila.* Embo J, 2006. **25**(12): p. 2735-45.

205. Barnes, C.J., et al., *Functional inactivation of a transcriptional corepressor by a signaling kinase.* Nat Struct Biol, 2003. **10**(8): p. 622-8.

206. Lin, X., et al., *Opposed regulation of corepressor CtBP by SUMOylation and PDZ binding.* Mol Cell, 2003. **11**(5): p. 1389-96.

207. Kagey, M.H., T.A. Melhuish, and D. Wotton, *The polycomb protein Pc2 is a SUMO E3.* Cell, 2003. **113**(1): p. 127-37.

208. Riefler, G.M. and B.L. Firestein, *Binding of neuronal nitric-oxide synthase (nNOS) to carboxyl-terminal-binding protein (CtBP) changes the localization of CtBP from the nucleus to the cytosol: a novel function for targeting by the PDZ domain of nNOS.* J Biol Chem, 2001. **276**(51): p. 48262-8.

209. Deltour, S., et al., *The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif.* Mol Cell Biol, 2002. **22**(13): p. 4890-901.

210. Fujii, H., et al., *Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer.* Oncogene, 1998. **16**(16): p. 2159-64.

211. Deltour, S., et al., *The carboxy-terminal end of the candidate tumor suppressor gene HIC-1 is phylogenetically conserved.* Biochim Biophys Acta, 1998. **1443**(1-2): p. 230-2.

212. Pinte, S., et al., *The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties.* J Biol Chem, 2004. **279**(37): p. 38313-24.

213. Chen, W.Y., et al., *Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors.* Nat Genet, 2003. **33**(2): p. 197-202.

214. Carter, M.G., et al., *Mice deficient in the candidate tumor suppressor gene Hic1 exhibit developmental defects of structures affected in the Miller-Dieker syndrome.* Hum Mol Genet, 2000. **9**(3): p. 413-9.

215. Chen, W., et al., *Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis.* Cancer Cell, 2004. **6**(4): p. 387-98.

216. Chen, W.Y., et al., *Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses.* Cell, 2005. **123**(3): p. 437-48.

217. Wales, M.M., et al., *p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3.* Nat Med, 1995. **1**(6): p. 570-7.

218. Britschgi, C., et al., *Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1.* Oncogene, 2006. **25**(14): p. 2030-9.

219. Roegiers, F. and Y.N. Jan, *Asymmetric cell division.* Curr Opin Cell Biol, 2004. **16**(2): p. 195-205.

220. Morrison, S.J. and J. Kimble, *Asymmetric and symmetric stem-cell divisions in development and cancer.* Nature, 2006. **441**(7097): p. 1068-74.

221. Kimble, J.E. and J.G. White, *On the control of germ cell development in Caenorhabditis elegans.* Dev Biol, 1981. **81**(2): p. 208-19.

222. Hubbard, E.J. and D. Greenstein, *The Caenorhabditis elegans gonad: a test tube for cell and developmental biology.* Dev Dyn, 2000. **218**(1): p. 2-22.

223. Siegfried, K.R., et al., *The sys-1 and sys-3 genes cooperate with Wnt signaling to establish the proximal-distal axis of the Caenorhabditis elegans gonad.* Genetics, 2004. **166**(1): p. 171-86.

224. Lo, M.C., et al., *Phosphorylation by the beta-catenin/MAPK complex promotes 14-3-3-mediated nuclear export of TCF/POP-1 in signal-responsive cells in C. elegans.* Cell, 2004. **117**(1): p. 95-106.

225. Botrugno, O.A., et al., *Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation.* Mol Cell, 2004. **15**(4): p. 499-509.

226. Hossain, A. and G.F. Saunders, *Synergistic cooperation between the beta-catenin signaling pathway and steroidogenic factor 1 in the activation of the Mullerian inhibiting substance type II receptor.* J Biol Chem, 2003. **278**(29): p. 26511-6.

227. Gummow, B.M., J.N. Winnay, and G.D. Hammer, *Convergence of Wnt signaling and steroidogenic factor-1 (SF-1) on transcription of the rat inhibin alpha gene.* J Biol Chem, 2003. **278**(29): p. 26572-9.

228. Mizusaki, H., et al., *Dax-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome, gene 1) gene transcription is regulated by wnt4 in the female developing gonad.* Mol Endocrinol, 2003. **17**(4): p. 507-19.

229. Mulholland, D.J., et al., *Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.* Oncogene, 2003. **22**(36): p. 5602-13.

230. Yang, X., et al., *Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells.* Oncogene, 2006. **25**(24): p. 3436-44.

231. Terry, S., et al., *Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.* J Cell Biochem, 2006. **99**(2): p. 402-10.

232. Lu, D., et al., *Activation of the Wnt signaling pathway in chronic lymphocytic leukemia.* Proc Natl Acad Sci U S A, 2004. **101**(9): p. 3118-23.

233. Staal, F.J. and H.C. Clevers, *WNT signalling and haematopoiesis: a WNT-WNT situation.* Nat Rev Immunol, 2005. **5**(1): p. 21-30.

234. Bouralexis, S., D.M. Findlay, and A. Evdokiou, *Death to the bad guys: targeting cancer via Apo2L/TRAIL.* Apoptosis, 2005. **10**(1): p. 35-51.

235. Fas, S.C., et al., *Death receptor signaling and its function in the immune system.* Curr Dir Autoimmun, 2006. **9**: p. 1-17.

236. Thorburn, A., *Death receptor-induced cell killing.* Cell Signal, 2004. **16**(2): p. 139-44.

237. Duiker, E.W., et al., *The clinical trail of TRAIL.* Eur J Cancer, 2006. **42**(14): p. 2233-40.

238. Rottmann, S., et al., *A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function.* Proc Natl Acad Sci U S A, 2005. **102**(42): p. 15195-200.

239. Cheng, J.Q., et al., *The Akt/PKB pathway: molecular target for cancer drug discovery.* Oncogene, 2005. **24**(50): p. 7482-92.

240. Yun, M.S., et al., *Both ERK and Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferation.* J Cell Sci, 2005. **118**(Pt 2): p. 313-22.

241. Soderstrom, T.S., et al., *Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8.* J Immunol, 2002. **169**(6): p. 2851-60.

242. Almeida, M., et al., *Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT.* J Biol Chem, 2005. **280**(50): p. 41342-51.